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Antecedentes: En la infección persistente por virus de la hepatitis C (VHC), 
la reactividad de los linfocitos T citotóxicos (LTC) se encuentra alterada y esto 
afecta al control del VHC. La expresión del receptor de la interleuquina-7 
(CD127) en estas células podría regular la reactividad de los LTC a través de 
la modulación del equilibrio entre Bim/Mcl-1. Bim es una molécula pro-
apotótica bloqueada por la acción de Mcl-1. La expresión de Bim/Mcl-1 y la 
reactividad de los LTC VHC-específicos se compararon en relación al 
fenotipo CD127. 
 
Material y Métodos: Se obtuvieron linfocitos de sangre periférica (LSP) de 
pacientes HLA-A2+ VHC+. Los LTC VHC-específicos se visualizaron mediante 
tinción de los LSP con Ac-anti CD8 y complejos pentaméricos HLA-
A2/péptido (pentámeros).  El fenotipo Mcl-1/Bim/CD127/IFN-! en los LTC 
VHC-específicos se analizó mediante tinción de las células CD8+/pentámero+ 
detectables con Ac anti Mcl-1/Bim/CD127/IFN-!. La capacidad proliferativa in-
vitro tras estimulación específica de los LTC VHC específicos se evalúo en 
presencia y ausencia del inhibidor z-VAD-fmk. Todas las células marcadas se 
analizaron mediante citometría de flujo. 
 
Resultados: Los LTC VHC-específicos con fenotipo CD127bajo se asociaron 
a elevada viremia del VHC, mientras que las células fenotipo CD127alto se 
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correlacionaron con carga viral indetectable (P < 0.001). Directamente ex 
vivo, la frecuencia de células pentámero+ fue similar en los grupos con 
expresión alta y baja de CD127. Sin embargo, la capacidad prolierativa tras 
estimulación antígeno-específica se encontraba alterada en el grupo con 
expresión CD127bajo (P<0.05), aunque esto se corrigió mediante tratamiento 
con z-VAD-fmk (P<0.05). La expresión de Mcl-1 directamente ex vivo fue baja 
(P<0.01) y la expresión de Bim aumentó tras el encuentro antigénico en las 
células con fenotipo CD127bajo (P<0.05). La diferencia ex vivo entre la 
expresión de Mcl-1 y Bim en las células pentámero+ se correlacionó 
directamente con la expresión de CD127 (P<0.001) y con la reactividad de 
las células pentámero+ (P<0.05). La frecuencia de células productoras de 
IFN-! directamente ex vivo fue menor en las células CD127bajo que en las 
CD127alto (P<0.05). 
 
Conclusiones: Un expresión baja ex vivo de Mcl-1 y una sobre-expresión de 
Bim tras el encuentro antigénico se encuentran involucradas en la 
hiporeactividad de los LTC-VHC-específicos con baja expresión de CD127 
durante la infección crónica, aunque esto puede ser superado mediante el 













Background: In persistent hepatitis C virus (HCV) infection, HCV-specific 
cytotoxic T lymphocyte (CTL) reactivity is impaired and this affects HCV 
control. Interleukin-7 receptor (CD127) expression on these cells could 
regulate CTL reactivity through Mcl-1/Bim balance modulation. Bim is a pro-
apoptotic molecule blocked by the action of Mcl-1. Mcl-1/Bim expression and 
T cell reactivity on HCV-specific CTLs were compared according to CD127 
phenotype. 
 
Materials and Methods: Peripheral blood lymphocytes (PBL) from HLA-A2+ 
HCV+ patients were obtained. HCV-specific CTLs were visualized by staining 
PBL with anti-CD8 and HLA-A2/peptide pentameric complexes (pentamer). 
Mcl-1/Bim/CD127/IFN-! phenotype of HCV-specific CTLs was tested by 
staining detectable CD8+/pentamer+ cells with anti-Mcl-1/Bim/CD127/IFN-! 
antibodies. HCV-specific CTL proliferation ability after specific in vitro 
challenge was tested in the presence and absence of pancaspase inhibitor z-
VAD-fmk. All stained cells were analyzed by flow cytometry.  
 
Results: CD127low-expressing HCV-specific CTLs associated with high HCV 
viraemia, while CD127high correlated with undetectable viral loads (P < 0.001). 
Directly ex vivo, pentamer+ cell frequency was similar according to CD127 
expression level. Nevertheless, CD127low pentamer+ cell proliferation after 
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specific in vitro challenge was impaired (P < 0.05), although this was 
corrected by z-VAD-fmk treatment (P < 0.05). Mcl-1 expression was low 
directly ex vivo (P < 0.01), and Bim was up regulated after antigen encounter 
(P < 0.05) of CD127low pentamer+ cells. The ex vivo difference between Mcl-1 
and Bim expression on pentamer+ cells correlated positively with CD127 
expression level (P < 0.001) and with pentamer+ cell reactivity (P < 0.05). The 
frequency directly ex vivo of IFN-!-producing pentamer+ cells was lower in 
CD127low group than in CD127high group (P<0.05).    
 
Conclusion: A low ex vivo Mcl-1 expression and Bim up-regulation after 
antigen encounter are involved in CD127low HCV-specific CTL hyporeactivity 














 Hepatitis C virus (HCV) is hepatotropic, non-cytopathic virus able to 
evade immune system efficiently as mechanism to persist in infected hosts. It 
has been estimated that more than 170 million people are infected with HCV. 
This virus is spread by contact with infected blood and body fluids. 
Approximately 80% of infections succeed in establishing a chronic infection 
with the potential for developing severe liver diseases such as cirrhosis and 
hepatocellular carcinoma (HCC) [1, 2]. 
 
 No effective vaccine against HCV is available till date. Therapy for HCV 
infection as peg-interferon-alpha and ribavirin [3], has limited efficacy, in 
particular against the genotype 1 virus [4, 5]. The standard care for HCV 
genotype 1 is currently protease inhibitor (Boceprevir or Telaprevir), peg-
Interferon-alpha and ribavirin while for other genotypes double therapy with 
peg-interferon alpha plus ribavirin is still the standard of care. An extended 
search for new therapy is progressing, already in phase III studies ready to 
come in the market in the next two years, but still many chronic HCV patients 
are not cured with these combinations. For these reasons it is necessary to 
look for new strategies to control HCV infection. Due to the lack of adequate 
cell culture systems, HCV studies have been slowed down for a long time, but 
continuous progress in the last few years it has overcome this obstacle. In-
vivo model to study the biology of HCV have been significantly restricted due 
to the limited experimental availability of chimpanzees, the primary model for 
HCV [6, 7], and difficulties encountered in reproducing true infection in small 
animals. Two breakthroughs has been an important contribution to the field: 
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firstly, subgenomic replicons (i.e. without structural genes) [8-10], which are 
highly permissive for HCV replication [11] and secondly, HCV complete 
replication in cell culture [12-14]. However, it has long been recognized that 
these models are complicated by the particularly high error rate of the HCV 
RNA replicase [15]. 
 
 Moreover, it is widely accepted that immune-mediated host-virus 
interactions are responsible for the outcome of HCV and pathogenesis of 
further severe diseases. Hence, it is interesting to deep in the knowledge of 
these interactions to find new potential theraputical targets. To be familiar with 
HCV infection, a brief outline of HCV structure and its life cycle is provided 
below. 
 
II.1 HCV structure:  
 
The hepatitis C virus (HCV) is an enveloped; positive stranded RNA 
virus and represents the Hepacivirus genus in the Flaviviridae family. HCV is 
a small, enveloped, positive sense single-stranded RNA-virus. Spherically 
shaped with a diameter of between 55–65 nm HCV virion consists of the HCV 
RNA genome, core and the envelope glycoproteins, E1 and E2.  The HCV 
genetic material (RNA) surrounds by an icosahedral capsid of core proteins, 
which encased in a lipid membrane, called the viral envelope, in which are 





HCV Genome:  
 
The positive sense single stranded RNA genome contains two highly 
conserved non-coding regions (UTR, un-translated region) in the region 5' 
and 3' which flank a coding region (ORF, open reading frame) that is 9600 
base pair long [17]. At the 5' and 3' ends of the RNA are important to 
translation and replication of the viral RNA instead of translating into proteins. 
The 5' UTR site that is ribosome-binding site called IRES —Internal ribosome 
entry site, starts the translation of a very long protein containing about 3,000 
amino acids [18]. Structural proteins of the HCV include Core protein, E1 and 
E2; whereas, NS2, NS3, NS4, NS4A, NS4B, NS5, NS5A, and NS5B as non-
structural proteins are located at 3’ end and function as protease, helicase 














Table II.1: Functions of genetic elements of HCV.  
     T. Jake Liang etal Ann Intern Med. 2000. 
 
HCV is very heterogeneous in their genome. This is due to the rapid 
viral replication, ranging between 1010 to 1012 virions per day (and a 
predicated viral half-life of 2 to 3 hours) [20] and high error rate of viral RNA 
polymerase (10-5 errors / nucleotide) without proofreading activity of RNA 
polymerase [21]. These all reasons are responsible to generate different 
genotypes, refers to the heterogeneity among different HCV strains isolated in 
different geographical areas and reflects the accumulation of mutations over a 
long period of evolution of the virus, and quasispecies, which are the 
translation of the heterogeneity arising during viral replication in the infected 
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person [22, 23]. There are six known genotypes (numbered 1 through 6) and 
more than 50 subtypes (e.g., 1a, 1b, 2a etc) [24]. 
 
II.2 Life cycle of HCV 
 
The full replication cycle of HCV can be done by using isolation and 
engineering of infectious HCV, which have been relatively recent realization in 
the field, as has the description and characterization of animal models for 
infection. The development of HCV replicons [8-10, 25], HCV pseudo typed 
particles (HCVpp) [26] and most recently the infectious HCV cell culture 
system [12-14] have advanced our understanding of the viral life cycle. 
Hepatocytes are the primary site of HCV infections. HCV life cycle begins with 
binding of the virus to cell surface receptors. The putative receptors, the 
tetraspanin protein CD81 [26-29], the scavenger receptor class B member I 
(SR-B1) [26, 30-32] and the tight junction proteins claudin-1 [33] and 
occluding, [34-36] have all been shown to enable HCV entry. In addition, the 
low-density lipoprotein receptor [28, 37-39], asialoglycoprotein receptor [40], 
and glycosaminoglycans (heparin sulfate) are also involved, but their exact 
roles have not been determined. By clathrinmediated endocytosis [41, 42], 
HCV enters the cell. The virus undergoes an uncoating process by fusion 
between the viral envelope and endosomal membrane in the acidified 
endosomal compartment [9, 29, 43-46] via E1/E2-mediated class II fusion [47, 
48], to expose the viral genomic RNA to host-cell machinery. About ~9.6 kb 
viral RNA genome is released into the host cell cytoplasm, to serve as 
template for the translation of the viral proteins. IRES-mediated translation of 
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the HCV genome produces a single ~3,000 amino-acid polyprotein [49], which 
is processed by cellular and viral proteases into at least 10 different protein 
products. These products include the structural proteins, which form the viral 
particle (the virus core and the envelope proteins E1 and E2), and the 
nonstructural proteins P7, NS3, NS4A, NS4B, NS5A and NS5B [50]. Viral 
replication is driven by minus strand intermediate. HCV double stranded RNA 
(dsRNA) is freely exposed in the cytoplasm of infected cell [49], which is 
recognizable for host innate immune system.  
 
 Nucleocapsid is formed by assembling capsid proteins, genomic RNA. 
The nucleocapsid bud through intracellular membranes into cytoplasmic 
vesicles. Finally, by secretory pathway, mature enveloped virions release from 
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II.3 Natural history of HCV:  
 
Acute HCV infection is difficult to diagnose because of asymptomatic 
behavior of 70%-80% of infected individuals. Most infected persons do not get 
diagnosed until many years later, due to unaware of their exposure to HCV. 
Chronic hepatitis C infection is marked by the persistence of HCV RNA in the 
blood for at least 6 months after onset of acute infection. Self-limiting infection 
in 15%-25% of patients have been observed. Approximately 75%-85% of 
infected patients fail to clear the virus by 6 months, and develop chronic 
hepatitis. Many factors affect the rate of chronic HCV infection, including the 
age at time of infection, gender, ethnicity, and the development of jaundice 
during the acute infection. 
 
Therefore, a large proportion of HCV-infected persons, are at risk for 
advanced liver fibrosis, HCV- related extrahepatic complications, cirrhosis and 
HCC (Fig II.3). Moreover, a highly variable rates of liver fibrosis progression is 
the result of the amount of alcohol consumption, age of initial HCV infection, 
degree of inflammation, HIV or HBV co-infection, and co-mordid conditions. 
An estimated 10%- 20% of chronic HCV infections develop end-stage liver 
disease over one or two decades. During chronic HCV infection or cirrhosis, 
extrahepatic manifestations can appear and HCC can occur only after 




 Stephen etal, Int. J. Med. Sci. 2006  
Figure II.3: Natural history of HCV infection 
 
II.4 Immune response:  
 
To fight against a viral infection the host displays two kinds of immune 
responses: the innate and adaptive responses. The innate response is the 
first immunological barrier and it is essential in cytopathic viruses. This 
response limits viral spreading but also acts as adaptive response activator 
through antigen presentation to viral specific cells. Adaptive response is the 
second line in the immunological defense. It plays a major role in non-
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cytopathic viral infections because this type of viruses behaves as an 
intracellular parasite and they remain occult to the innate system.  
 
But, highly productive and replicative viruses such as, HCV is 
associated with ineffective antiviral immunity during persistent viral infections. 
The complex ineffective immune response involves the functional 
deterioration of antiviral responses and contraction of the size of this response 
(Fig II.3). 
 
II.4.1. Innate immune response during acute HCV infection 
  
 The first response to HCV protein is thought to be IFN-# production by 
infected hepatocytes, which are able to secrete type I IFN. The infected cells 
are sensed with pathogen associated molecular patterns (PAMP), Toll like 
receptor-3 (TLR3) [51] and retinoic acid–inducible gene I (RIG-I) [52, 53] by 
endosomal dsRNA and cytosolic dsRNA respectively, which is an essential 
intermediate in the HCV replication cycle, and thus, they may be important in 
the pathogenesis of hepatitis C [54]. RIG-I recruits IFN- # promoter stimulator 
protein 1 (IPS-1; also called CARD adaptor inducing IFN-# CARDIF), virus-
induced signaling adapter (VISA), and mitochondrial antiviral signaling protein 
(MAVS) [55-57], after ATP-driven activity dependant on recognition of viral 
proteins [58]. On other hand, TLR3 dimerization, due to leucine-rich repeats 
[59], recruits the adapter protein, Toll–IL-1 receptor domain– containing 
adaptor inducing IFN-# (TRIF). Both processes result in downstream 
signaling, nuclear translocation of IFN regulatory factor 3 (IRF3) and leads to 
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stimulation of the transcription of a set of genes including IFN-# [60]. Antiviral 
state, induced by secreted IFN #, gives an alert to uninfected cells by 
activation of effector molecules. Binding of IFN -# to cognate receptor 
complex leads to the activation of JAK/STAT pathway, which results in the 
induction of IFN-stimulated genes (ISGs) and leads to enhance the IFN 
response [61] (Fig. II.4). 
 
However, HCV has organized a number of countermeasures not only 
to inhibit the induction phase, but also interfere with the effector phase of the 
IFN system (Fig. II.4). It has been confirmed, by in-vitro studies, that HCV 
serine protease, NS3/4A is enable to cleave MAVS [62], TRIF [63], IPS-1 [64] 
and oligomerization of MAVS, which is part of signaling process [51, 55, 62, 
63, 65, 66]. Disruption of IRF-3 activation occurred by NS3 protein action [67] 
and it has been shown with different cell lines in-vitro studies [51, 66]. Another 
key player, HCV core, when over expressed in cell culture, disturbs antiviral 
activity via interfering in JAK/STAT signaling and ISG expression by inhibition 
of STAT1 activation. Simultaneously it induces its degradation [68, 69] by 
induction of inhibitor of the JAK/STAT pathway SOCS3 [70], protein 
phosphatase 2A (PP2A), which ultimately reduces the transcriptional activity 
of ISG factor 3 (ISGF3) [71]; and inhibition of ISGF3 interaction to IFN-
stimulated response elements [61]. HCV NS5A interferes with the function of 
ISGs by inhibiting 2"-5" oligoadenylate synthetase (2"-5" OAS) and leads to 
overall ISG expression impairment [72]. Protein kinase R (PKR) can 
negatively regulate HCV replication noncytolytically in cell cultures [73, 74], 
which can interacts with HCV NS5A and lost its function. Interestingly, HCV 
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E2 acts as distraction target to PKR [75]. To sum up, the main targets of HCV 
proteins to evade immune response are interference with the induction of IFN 
synthesis, IFN-induced intracellular signaling and IFN-induced effector 
mechanisms (Fig.II.4). 
 
 Dendritic cells (DC) are professional antigen presenting cells with 
important functions in antiviral immunity through activation of adaptive 
immune responses. Type-I IFNs are also produced by plasmocytoid (p) DCs, 
which derive from the lymphoid lineage. Although, production of IFN 
alpha/beta, in early phase of infection occurs after recognition of ssRNA and 
dsRNA by TLR7 and TLR9 respectively, the mechanism is still not clear [76]. 
The frequency of pDCs in the blood [77] and their production of IFN-$ in HCV 
infection are reduced after in vitro stimulation [78]. The possible mechanism 
has been demonstrated in in-vitro studies. First, HCV core and NS3 activate 
monocytes by TLR2 signaling to produce TNF-$ [79], which in turn inhibits 
IFN-$ production and induces pDC apoptosis [78]. Second, HCV itself inhibits 
IFN-$ production of pDCs [80]. However, other studies revealed regular 
response to TLR stimulation by circulating pDCs of chronically infected 
individuals [81, 82] and they have high levels of endogenous type I IFNs 
without immuno-dysfuction [76]. Although this defense mechanism is 
significant, the host rarely overcomes HCV infection, which suggests several 
other viral evasion mechanisms that are poorly or not understood yet. 
 
 Another group of DCs, myeloid DCs (mDCs) derive from the 
myeloid lineage [83, 84]. Due to its tolerogenic and stimulatory role [83, 84], 
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mDCs have been broadly studied in HCV infection. mDCs have not been 
observed to be decreased in peripheral blood or dysfunctional in HCV chronic 
infected individuals in in-vitro studies [85, 86]. Nevertheless, HCV proteins 
can interact with monocytes/macrophages through TLR2, inducing the IL-10 
production, which hampers IL-12 production by mDC and IFN-$ by pDC, or 
they directly inhibit DC differentiation [87]. IL-12 cytokine production by mDC 
is decreased in HCV patients in response to stimuli like CD40 L or poly (I:C) 
[88], which can explain clearly the shift from Th1 to Th2 response in HCV 
patients. In-vitro studies indicate that DC expressing core and E1 proteins 
have lower stimulatory ability, which is associated to the lack of maturation 




Figure II.4: Evasion of Innate immune response by HCV: (A) Interference in IFN synthesis: Blocking of TLR 3 and RIG-1 signaling respectively, by 
cleavage of the adaptor molecule TRIF and IPS-1 via HCV NS3/4A; (B) Interference in IFN-induced Effector mechanisms: Binding of IFN ! and its 
receptor with TYK2 and JAK1 kinase activation lead to form ISGF3 complex, where this complex interact with IFN stimulated response elements 
(ISREs) within the promoter and enhancer region of ISGs to induces ISGs (such as 2’, 5’ OAS, PKR, IRF7) production in nucleus. HCV core 
induce SOCS1/3, which is the inhibitor of the JAK/STAT pathway and inhibits STAT1 phosphorylation, which inhibits assembly of trimeric ISGFs 
complex. Function of ISGs inhibited by HCVE2 and HCV NS3/4A. 
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 Other cells involved in the innate response are the NK cells. Functions of 
these cells include generating a cytotoxic response, regulatory cytokines 
production and control on DC maturation and amplitude of DC response, 
which may deeply impact on type of down- stream adaptive immune 
responses. Response to HCV infection by NK cell is direct apoptosis induction 
of infected cells with production of antiviral cytokines [90, 91]. Moreover, NK 
cell depletion or dysfunction favor HCV persistence [90]. The role of 
interactions between HLA class I and killer cell–Ig-like receptors (KIR) during 
HCV infection has been shown. KIR can regulate NK cell activities. However 
puzzling contradictions for this topic in different studies have been revealed 
[92-94]. The importance of NK cells in the resolution of HCV infection is 
illustrated by the influence of genetic polymorphisms of KIR and their HLA 
ligands on the outcome of HCV infection, which was dependent on a 
homozygous HLA class I ligand background [95-97]. There is need to focus 
on clear understanding of functional and molecular HLA-KIR interactions to 
know about the possible way for NK cell- mediated protection in animal 
models of HCV infection.  
 However, an increased proportion of NK cells expressing activating 
receptors, enhanced cytotoxicity and defective cytokine production have 
revealed in chronic HCV infection [98]. Megan et al revealed that IL28A 
cytokine could significantly inhibit IFN-! production lead to NK cell inactivation 
[99], which would be important to attenuate chronically activated NK cells. 
Consequently, the analysis of functional scene between NK cells and type 3 
IFN in the immune response to virus will be required to understand the role of 
the NK in disease progression during HCV infection. 
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II.4.2. Adaptive immune response 
 
 The second barrier to control HCV infection is the adaptive immunity. 
This response has two arms to fight against pathogens; humoral and cellular 
immune response. Humoral immune response, that means neutralizing and 
non-neutralizing antibodies can endorse antiviral activity and pathogenesis 
[50]. Cellular immune response shows antiviral immunity by means of virus 
specific CD8 cytotoxic T lymphocytes (CTLs) and CD4 T helper cells, which 
play key effector and regulatory roles respectively. These T cells take part in 
viral pathogenesis of HCV by direct killing of infected cells or producing 
soluble factors able to clear the virus in a non-cytolytic manner, but also can 
lead to HCV pathogenic events, favoring direct liver damage and attracting 
non-specific inflammatory cells to perpetuate the liver inflammation [50]. 
 
II.4.3. Humoral immune response 
 Neutralizing antibodies (nAbs) generally play a critical role for controlling 
initial viremia and protecting from re-infection in viral infections. However, the 
role of the humoral immune response in the clearance of HCV infection has 
been in the dark for a long time due to difficulties to determine relative role of 
antibodies to neutralize HCV. It can exclusively be evaluated by relevant 
model systems. It is thought that HCV clearance could occur in the absence 
of nAbs. If they are present alone, these antibodies are inadequate to 
eradicate HCV in most of the cases in early studies [100-104]. It has been 
proved that HCV specific T cells may compensate for lack of neutralizing 
antibodies to obtain HCV clearance [105]. However, due to the development 
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of novel model systems [12-14, 26, 106], it is possible to focus on HCV entry 
into host cells and neutralization process which demonstrated that nAbs are 
induced by patients who subsequently control [107] or resolve [108] viral 
infection in the early phase of infection and contrary in chronic infection. This 
suggests that a strong, early, broad nAbs response may contribute to 
resolution of HCV in the acute phase of infection while delayed induction of 
nAbs may contribute to development of chronic HCV infection. 
 
  Instead of the rapid, vigorous and multi-specific antiviral host 
immune responses, chronic patients have been shown to develop a delayed 
and inefficient neutralizing antibody response [108] due to HCV escape 
mechanism [109]. Recent studies make evident that entry of HCV can be 
hampered or modulated by nAbs of chronic HCV patients [110-112], while it is 
controversial in cell culture study [113]. In addition, although nAbs are 
incapable to clear the virus in chronic infection, due to selection pressure 
exerting on viral variants, they contribute to the evolution of the HCV envelope 
sequences to escape [114, 115]. It has been proposed that HCV stimulates B 
cells in a B cell receptor-independent manner in chronic infection [116] and 
may favor the development of lymphoproliferative and autoimmune diseases 
[50]. Although, in vitro studies make evident that the neutralization ability of 
HCV-specific nAbs is enhanced by complement activation against 
pseudotyped viruses [116], there is absence of direct experimental evidence 
about the presence of any of these Ab- mediated functions during natural 
HCV infection. However, immune complexes are believed to play a 
pathogenetic role in the development of manifestations such as 
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cryoglobulinemia, glomerulonephritis, porphyria cutanea tarda, and 
necrotizing cutaneous vasculitis during chronic HCV infection [117-119]. 
 
II.4.4. Cellular immune response 
 
 Cytotoxic T lymphocyte (CTL) responses are essential to control HCV 
infection. Efficiency of antiviral CTL responses depends on where these cells 
are primed. Efficient antiviral CTL response is observed when it is primed in 
lymphoid organs, whereas within the liver, priming is more tend to induce T 
cell inactivation, tolerance or apoptosis [50]. A strong, multispecific and long-
lasting T-cell immune response emerge to be important for control of viral 
infection [104, 120]. Persistent HCV unsuccessfully control by T effector cells 
is due to multiple causes, such as: HCV escape mutant generation, 
immunosuppressive effects exertion, Tregs induction, or effector T cell 
exhaustion or apoptosis [121-124]. 
 
II.4.5 Adaptive cellular response during acute HCV infection 
 
 Vigorous CD4+ and CD8+ T cell responses targeting multiple HCV 
regions with intrahepatic production of IFN-! emerged in acute hepatitis C 
infection [101, 123, 125]. Decreasing viral titer correlates precisely with the 
appearance of HCV-specific T cells and IFN-! expression in the liver [126]. 
The appearance of HCV-specific T cells can be detectable in the peripheral 
blood or in the liver compartment several weeks after infection in humans or 
experimental chimpanzee models [61, 104], respective with primary peak of 
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transaminases and irrespective of clinical outcome (resolution or chronicity). 
Delayed emerging of antigen-specific responses are also essential for the 
HCV control [61]. 
 
 The protective function of CD4+ T cells appear to be due to the 
production of antiviral cytokines, but also their helping nature to antiviral B 
cells and in CD8+ T cell response. The HCV clearance has been observed 
and correlated with vigorous proliferation of specific CD4+ T cells [80, 127] 
with concurrent IL-2 and IFN-! production [128, 129]. The early sustained 
development of CD4+ T cell response needs to be successful for viral 
clearance [128], whereas HCV- specific CD4+ T cell responses are not 
observed in chronic HCV infection. Moreover, the recurrent viremia has been 
correlated with loss of previous strong CD4+ T cell responses after several 
months of viral clearance [130, 131]. Studies on the relative importance of 
CD4 help in spontaneous recovery in acute HCV infection demonstrated that 
fact [132]. CTL priming in presence of CD4 help is critical factor in protective 
function [128].  
 
 Similarly, Antigen-dependent reactivity of HCV-specific CD8+ T cells has 
been proved by a rapid decay of CD8+ T cell responses during antiviral 
therapy [133]. It is evident that, CD8 T cells play a direct role in terminating 
hepatitis C as shown by prospective studies of acute infection in chimpanzees 
[134], in which it is revealed that a vigorous, multispecific, and polyclonal 
intrahepatic CD8 CTL response during early infection correlated with HCV-1 
clearance. Furthermore, it is concluded after monitoring the course of HBV 
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infection in CD8-depleted in chimpanzees that CD8+ cells are the main 
effector cells responsible for viral clearance and disease pathogenesis during 
acute HBV infection, and this study suggests that viral clearance is mediated 
by both noncytolytic and cytolytic effector functions of the CD8+-T-cell 
response [135]. In addition, after accidental needlestick exposure, subjects 
who develop acute HCV infection, the vigor and quality of the antiviral T cell 
response determines the outcome of acute HCV infection. The subjects who 
cleared the virus experience a prolonged episode of acute hepatitis that 
coincided with a CD8+ T cell response to HCV, while chronic infection 
develops in subjects who fail to produce a significant T cell response [123]. 
Therefore, significant, broader, multi-specific HCV specific CTLs are important 
in acute HCV infection control. 
 
 The appearance of self-sustaining memory T cells (CD127+ memory 
HCV-specific CD8+ T cells and CD4+ T cells) are necessary to control HCV 
infection [101, 123, 128]. In fact, years after HCV control due to anti-HCV 
treatment it is possible to find HCV traces in association with HCV-specific T 
cell reactivity. These data suggest that HCV-specific memory T cells are 
essential to clear HCV infection completely after the initial acute clearing 
[136].  
 
II.4.6 Adaptive cellular response during chronic HCV infection 
  
 Therefore, complete resolved HCV patients exhibit broader CTL 
responses with higher functional avidity and wider cross-recognition ability 
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than patients with persistent HCV infection [137]. There are evidences that 
demonstrate rapid mutation in HCV genome, T cell exhaustion because of 
expression of inhibitory molecules, immune regulatory cytokine induction and 
immune modulatory T reg cell activation, which are the main reasons for HCV 
persistence in chronically infected patients [121, 138-141]. Like Retrovirus, 
HCV polymerase has high replication rate and lack of proofreading capacity, 
which permit a rapid virus escape from emerging humoral and cellular 
immune responses and lead to persistent infection [139, 142]. Mutation study 
in early HCV infection in HLA class I restricted epitopes targeted by CD8+ T 
cells are associated with persistence [143, 144], which proved indirectly that 
HLA-restricted CD8+ T cells exert selection pressure. Furthermore, the HLA 
alleles can influence infection outcome [145]. 
 
 The secretion of certain immuno-regulatory cytokines is also related with 
HCV persistence. IL-10 cytokine is found to increase during chronic HCV 
infection [146]. In chronic HCV patients, the suppression of IFN-! production 
and proliferation of virus- specific CD4+ and CD8+ T cells have been observed 
in livers with IL-10 –producing HCV- specific CD8+ T cells [147]. IL-10 
produced by monocytes or NK cells down-regulates effector T cell responses. 
For instance, monocytes secrete IL-10 in response to HCV core–mediated 
TLR2 stimulation in vitro [148]. IL-10 producing HCV-specific CD8+ T cells 
inhibits IFN-" production [149], but also promotes apoptosis of pDCs [148], 
and induces liver infiltration of chronically infected individuals, suggesting that 
they modulate liver immunopathology to favor HCV persistence [147]. In 
addition, intrahepatic HCV-specific IL-10 producing CD8+ T cells prevent liver 
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damage during chronic disease [150]. Moreover, TGF-! is also involved in 
antiviral immune suppression and chronic HCV infection evolution [151]. To 
sum up these data, regulatory cytokines such as IL-10 or TGF-beta decrease 
liver inflammation, after affecting the protective immune response, developing 
a dual task. First of all, they impair T cell responses to allow viral persistence 
but also decrease liver damage to extend host survival. 
 
Regulatory T cells (Tregs) are important to control the balance between 
host damage and viral control produced by specific immune response. In 
cases of excessive immune response, that could be harmful for the host, 
these cells can induce immune-tolerance to the viral epitopes. Tregs are 
derived from natural or induced T cell populations, in which natural CD4+ 
Tregs are generated during normal T cell development in the thymus, 
whereas induced Tregs are generated from mature T cells [152]. T cell subset 
with suppressive function, CD4+ CD25+ FoxP3+ regulatory T (Treg) cells, 
engages in the control of auto-immunity and immune responses, through 
various mechanisms including the inhibition of APC maturation and T-cell 
activation [153]. No difference has been found in the frequency of Treg cells 
and the extent of suppression irrespective of the outcome of the infection 
[154]. However, higher Tregs frequency has been observed in chronic HCV 
infected patients than in resolved patients [155-158]. Interestingly, depletion of 
CD25+ cells could enhance responsiveness of the remaining HCV-specific 
effector cells in vitro [155-157], which suggests a fundamental role of Tregs in 
the establishment of chronic HCV infection. Moreover, Treg cells are induced 
and proliferate in chronic HCV infection and appeared to alter liver 
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inflammation [159]. Conversely, Programmed Death ligand-1 (PDL-1) 
mediated inhibition limits the expansion of Tregs by controlling STAT-5 
phosphorylation (pSTAT-5) [160], which can diminish suppressive function of 
Tregs, lead to viral load control and ultimately ensure long-lasting survival of 
the host. 
 
HCV is able to induce the up-regulation of different negative co-
stimulatory molecules in order to provoke an anergic status on HCV-specific T 
cells. Expression of the inhibitory receptor PD-1 is one of these molecules 
involved in the generation of a state of exhaustion on HCV-specific CD8+ T 
cells during chronic HCV infection [161, 162]. Importance of expression of PD-
1 in HCV-specific T cell failure mechanism has been observed [163, 164], 
which can hinder by mutation in T cell epitopes [165]. In addition, blocking of 
PD-1 signaling resulted in the functional restoration of blood-derived HCV-
specific CD8+ T cell responses in chronic infection [164, 166]. However, the 
PD-1 alone is not sufficient in defining exhausted HCV-specific CD8+ T cells 
during HCV infection. To restore function of HCV-specific T cells isolated from 
liver biopsies of infected patients, there is need of CTLA4 blockade in addition 
to PD-1 blockade [167]. In addition, the co-expression of other inhibitory 
receptors such as 2B4, CD160, Tim-3 and KLRG1 occurred in about half of 
HCV-specific CD8+ T cell responses and correlate with low or intermediate 
level of CD127 expression, impaired proliferative capacity, and an 
intermediate T cell differentiation stage [168]. These data indicates that HCV 
infection modulates different negative co-stimulatory molecules to favor the 




T cell stimulation in the liver encourages tolerance by using 
mechanisms such as, immune divergence [169], generation of regulatory T 
cells [170], T cell anergy [171] and T cell death [172]. Undeniably, hepatic 
tolerance can explain the elevated frequency of viral persistence during 
hepatotropic virus infections [172]. Although there are evidences showing that 
most infectious microorganisms are promptly removed from the liver by 
inflammation, a favorable situation for evading immune responses occurs in 
some viruses, leading to the triumph of certain pathogens such as HBV and 
HCV. The Fig I.5 depicted inflammatory and tolerance activity in liver by 
stimulation of different molecules or receptors.  Till date, there are two main 
mechanisms by which HBV and HCV could successfully escape from CTL 
action: escape mutant generation, and immunosuppressive effects exertion 





Figure II.5: Collective illustration of the hepatic cells with inflammatory and tolerance 
activities by stimulation of different molecules or receptors. LSEC: Liver sinusoidal 
endothelial cells; KC: Kuffer cells; DC: Dendritic cells; HSC: Hepatic stellate cells; 
TNF: Tumor necrosis factor; IL: Interleukin; mDC: Myeloid dendratic cell; pDC: 
Plasmacytoid dendritic cell; PD-L1: Programmed death ligand-1; Bim: BCL-2 
interacting mediator; Tim-3: T cell immunoglobulin mucin-3; CTLA-4: Cytotoxic T-




Fig II.6: Apoptosis-programmed cell death. 
 
Among these mechanisms involved in viral hepatitis persistence, new 
advances on the role of T cell death induction have been obtained recently 




 A normal cellular process involving physiologically relevant cell death 
and deletion of unwanted cells is called apoptosis. Apoptosis is essential for 
cell selection, tissue homeostasis, morphogenesis, and host defense in multi- 
cellular organisms. A cell that undergoes apoptosis dies neatly, without 
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damaging its neighbors. The apoptotic signals give rise to activate various 
proteins and follow a specific classical caspase chain reaction set activation 
[175]. Quickly and neatly dismantlement process includes membrane blebbing 
with shrinking of the cytoplasm and condensation of the nucleus. Phagocytic 
cells begin to pick up the apoptotic bodies, preventing the release of cellular 
content and ultimately avoiding inflammation [176] (Fig II.6). Apoptosis occurs 
by two mechanisms: active and passive mechanism. No presence of antigen 
gives a signal for termination of immune response by passive apoptotic 
mechanism (intrinsic pathway). On the other hand, the ligation of Fas (CD95) 
and TNF receptors-“death receptors” triggered apoptosis lead to active 
mechanism of apoptosis (extrinsic pathway). Briefly, apoptosis mechanisms 
involve a family of cysteine proteases, called caspases. These molecules are 
synthesized in the cell as inactive precursors, or pro-caspases for self-
protection against accidental death, which are usually activated after receiving 
proper trigger by cleavage (Fig II.7).  
 
 Structurally, pro-caspases contain three domains: N terminal prodomain, 
a large subunit and a small subunit. After activation, the active caspase 
enzyme is formed by heterodimerization of small and large subunits [177]. 
Moreover, active caspase molecules are ready to cleave target proteins such 
as structural or signaling proteins and other effector caspases, preventing 









Figure II.7: Caspase activation: Inactive proenzyme (procaspase) activated by 
proteolytic cleavage by another member of caspase family and cleaved two 




Figure II.8: Apoptosis: Extrinsic pathway. A: Mitochondria-independent extrinsic 
pathway: Fas-FasL ligation strikes to recruit pro-caspase 8 activation and induction 
of caspase cascade by caspase 3 leading to apoptosis; B: Mitochondria-dependent 
extrinsic pathway: Fas-FasL ligation trigger to activate the pro-caspase 8, which 
cleave Bid (pro-apoptotic Bcl-2 family molecule) to form truncated Bid (tBid). Then, 
mitochondrial dependent cell death begins with tBid. 
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 II.5.1. Extrinsic pathway 
 
 The extrinsic pathway initiates from outside the cell through triggering 
the activation of transmembrane “death receptors” that are members of the 
TNF receptor gene superfamily. Members of this receptor family bind to 
extrinsic ligands known as pro-apoptotic ligands [178] and transduce 
intracellular signals that ultimately result in the destruction of the cell [179, 
180]. To date the best characterized ligands of these receptors are FasL, 
TNF-!, Apo3L and Apo2L and corresponding receptors are FasR, TNFR1, 
DR3 and DR4/DR5, respectively [184-186]. The signal transduction of active 
cell death process involves several caspases. Activated caspases have an 
effect on several cellular functions as part of the process that results in the 
death of the cells [178]. 
 The signal transduction of mitochondrial-independent active cell death 
process involves binding of a pro-apoptotic ligand (such as FasL) with its 
receptors (Fas) on the surface of a target cell. The cytosolic tail of receptors 
contains a death domain, which when activated, binds to an adaptor protein, 
which in turn recruits the specific procaspase-8 and -10 and activates them by 
proteolytic cleavage [181] that finally initiates the proteolytic caspase cascade 
leading to apoptosis. Activated caspase 8 triggers the caspase cascade via 
two different pathways, leading to cell death. In type 1 apoptosis, such as in 
lymphocytes, caspase 8 activates caspase 3 whereas in type 2 apoptosis, like 
in hepatocytes and pancreatic cells, caspase 8 activate the pro-apoptotic 
molecule Bid and go ahead for apoptosis via the disruption of mitochondrial 
membrane and cytochrome C release [182] (Fig II.8). The T cell death by type 
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1 and type 2 Fas induced apoptosis fate is decided by the ratio between 
proteolytically activated effector caspases, X-chromosome linked inhibitor of 
apoptosis protein and proto-typical effector caspase substrate inhibitor of 
caspase-activated DNase. Interestingly, HCV specific intrahepatic 
lymphocytes contribute to bystander killing via Fas-FasL interaction [183], 
which support the fact that the liver facilitates liver-trapped activated T cell 
apoptosis [190]. 
 
II.5.2. Intrinsic pathway 
 
 The intrinsic or mitochondrial pathway is initiated within the cell, involving 
non-receptor-mediated intracellular signals and inducing activities in the 
mitochondria that initiate apoptosis. DNA damage, loss of cell-survival factors 
or other types of severe cell stress causes the induction signal for the intrinsic 
pathway. This passive death process pivots on the balance of activity 
between pro- and anti- apoptotic signals of the B cell lymphoma 2 (Bcl-2) 
family proteins [184]. This balance is maintained by regulation of the 
permeability of the mitochondrial membrane and by the pro- or anti-apoptotic 
signal that will be released inside the cell [185]. Following mitochondrial 
permeabilization, the intrinsic pathway divides into two pathways: Apoptosis 
protease-activating factor-1 (Apaf-1) dependent and Apaf-1 independent 
pathway. In Apaf-1 dependent pathway, release of cytochrome c from 
mitochondria, by triggering the pro-apoptotic Bcl-2 family member [186], and 
ATP activate monomer inactive Apaf-1 proteins by a conformational change, 





Figure II.9: Apoptosis: Intrinsic pathway. Death stimulation up regulates Bcl-2 
interacting mediator leading to the separation from Bcl-2, favoring the activation of 
Bax, Bak, which form pores in the mitochondrial membrane leading to release of 
cytochrome c. Cytochrome c with Apaf-1 and procaspase 9 participate in the 
formation of apoptosome, which activate caspase 9. Caspase-9 activates caspase 3 
after cleavage of pro-caspase-3. That caspase-3 triggers to induction of caspase 




 Apoptosome allows activation of pro-caspase 9, which consequently 
triggers the caspase cascade [188]. On the other hand, in Apaf-1 independent 
pathway, permeabilization of mitochondrial membrane release DIABLO like 
proteins, which activates effector caspases by provoking inhibitors of 
apoptosis proteins [189] and triggers caspase cascade [190, 191] (Fig II.9). 
 
  The balance of pro- and anti-apoptotic proteins maintains the 
apoptotic activity [191]. The Bcl-2 family members regulate mostly neglect or 
intrinsic pathway. This family is subdivided into three groups of proteins on the 
basis of their functions and the number of Bcl-2 homology (BH) motifs 
included in their primary structure; first group: “anti-apoptotic multidomain” 
members, such as Bcl- xL, have four BH domains (BH1 to BH4) which inhibits 
apoptotic process. Other two groups of “pro-apoptotic multidomain” members, 
which are Bax-like proteins and “BH3-only” proteins [192]. Bax-like proteins 
possess three BH domains (BH1 to BH3), including Bax, Bak, and Bok, which 
are referred as death effector members. BH3-only members contain BH3 
domain, including Bim, Bad, Bik, Puma, Noxa and Bid and are known as 
messengers of death. In addition, C-terminal transmembrane fragment is 
thought to confer anchorage to mitochondrial membranes, which is also 
possessed by most multi-BH members and several BH3-only proteins. 
   
 Three models (Fig II.10) have been postulated by which the BH3 family 
promotes passive cell death in which Bax and Bak bind directly or indirectly 
with cell death sensitizer (e.g., Bad, Bik) and activators of cell death (e.g., 
Bim, tBid). The direct activation model proposes that sensitizer BH3-only 
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proteins displace the activator BH3-only proteins from the anti-apoptotic 
proteins to promote apoptosis. Anti-apoptotic proteins inhibit the activator 




Figure II.10: Models for intrinsic cell death. A: Direct activation model postulates Bcl-
2 inter- acting mediator (Bim) is required for activating Bax and Bak. Anti-apoptotic 
proteins inhibit BH3-only proteins to suppress apoptosis, but not Bax or Bak. 
Replacement of Bim to sensitizer BH3-proteins from the anti-apoptotic proteins 
occurs to promote apoptosis; B: The displacement model proposes that anti-
apoptotic proteins for cell survival must sequester constitutively active Bax and Bak 
in cells. Bim inhibits their respective anti-apoptotic proteins by playing sensitizer role 
to promote apoptosis; C: Embedded together model highlights the active role of the 
membrane, which is not defined in direct activation model and displacement model. 
Bcl-2 family proteins insert into and change their conformations that dictate their 
functions at the membrane. Sensitizer BH3-only proteins relocate the activator BH3-
only proteins and Bax/Bak from the anti-apoptotic proteins to endorse apoptosis. 
Activator BH3-only proteins recruit Bax to the membrane to induce mitochondrial 
outer membrane permeabilization and apoptosis. These reversible interactions are 
directed by equilibrium constants that are depended on the concentrations and 
interactions of the proteins with each other and with membranes. 
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 In the displacement model, Bax and Bak are sequestered by anti-
apoptotic proteins for cell survival and constitutively active in cells. BH3-only 
proteins play the sensitizer role and inhibit their respective anti-apoptotic 
proteins to promote apoptosis. The third model, called embedded together 
model, highlights the interactions occurring in and on membranes, which were 
not explained by direct activation and displacement model. In embedded 
together model, Bcl-2 family proteins insert into and change their 
conformations according to their functions in membrane [193]. The 
predominantly studied messenger death molecule, Bcl-2 interacting protein 




Bim/Bod is a pro-apoptotic protein belonging to the BH3-only group of 
Bcl-2 family members and is being called the “ghost” molecule or “suicide” 
molecule, which enables cells to expire gracefully. Two independent studies 
discovered Bim as a Bcl-2 binding protein and Mcl1- binding protein in 1998 
[201, 202]. Bim induces apoptosis by binding to and antagonizing anti-
apoptotic members of the Bcl-2 family. The Bim interactions have been ob- 
served with Bcl-2 family members, such as Bcl-2, Bcl-xL, Mcl-1, Bcl-w, etc 
[194, 195]. 
 
 Bim is well known pivotal initiator of apoptosis in thymocyte-negative 
selection. Bim has 19 Bim isoforms including three major isoforms, which 
have distinct sizes and pro-apoptotic activities in the mammals, caused by 
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alternative splicing: BimEL (extra long), BimL (long) and BimS (small) [73]. 
The shortest form, BimS, is the most potent and is generally only transiently 
expressed during apoptosis [196]. The other two isoforms are sequestered to 
the dynein motor complex, and apoptotic activity of these longer isoforms is 
regulated by phosphorylation [197, 198], which is triggered by environmental 
stress, resulting in its dissociation from the dynein complex and increasing 
apoptotic activity. 
 
 Expression of Bim is up regulated in human T cells in response to TCR-
triggering by protein kinase C and calcineurin pathways [199]. Nevertheless, 
there are other mechanisms involved in Bim up-regulation during chronic 
infection, such as the effect of certain cytokines. In fact, in a persistent viral 
infection animal model, Bim-mediated apoptosis correlates with low IL-7 
receptor expression on specific T cells [200]. 
 
 The regulation of Bim expression at transcriptional level in growth factor 
deprivation and in endoplasmic reticulum stress has observed by the class O 
fork-head box transcription factor (FOX03A) and transcriptional factor CEPB-! 
respectively [201, 202]. Post-transcriptional phosphorylation of Bim can also 
regulate its function. Phosphorylated Bim is targeted for proteasomal 
degradation and avoid its interaction with Bax, thus maintaining cell existence 
[203, 204]. The signaling adaptor TNFR-associated factor 1 (TRAF1) 
negatively correlates with Bim and it contributes to CD8 T cell-mediated 
control of chronic viral infections. In addition, linking between survival effects 
of TRAF1 and TRAF1-dependent Bim down-modulation has been shown in 
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CD8 T cells [205-207]. TRAF1 is particularly vanished from virus-specific CD8 
T cells during the chronic human immunodeficiency virus and lymphocytic 
chorio-meningitis virus (LCMV) infection [208]. 
 
 Bim plays a vital role in the immune system, in bone biology and in 
tumor-genesis by inducing apoptosis[209]. Bim in T cells, B cells, neurons and 
many other cell types can trigger apoptosis [209]. Gene targeting in mice for 
the important region for apoptosis, BH3 region, uncovered the important 
physiological role in Bim [210]. In fact, in the absence of Bim, leukocytes in 
blood as well as in LNs, thymus, and spleen were high in number [210]. The 
role of Bim in apoptosis has been revealed in Bim-/- thymocytes, which were 
more resistant to apoptosis after different apoptotic treatment such as 
ionomycin, taxol and !- irradiation [210]. 
 
II.6.1 Death of activated T cells by Bim: 
 
 The liver is having a property that might explain its role in inducing 
tolerance due to its recognition as an alternative primary activation of CD8 T 
cells site. The phenotype of activated CD8 cells in the liver was the same as 
in lymph nodes. However, liver-activated CD8 T cells displayed poor effector 
functions and a unique CD25low CD54low phenotype, which was associated 
with increased expression of the Bim and caspase-3, demonstrating that 
these cells are programmed to apoptosis following intrahepatic activation. 
Strikingly, Bim deficient T cells survived following intrahepatic activation [172]. 
Therefore, the phenotype and fate of naïve CD8 T cells activated by 
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hepatocytes in vivo could explain the death penalty role of Bim in chronic 
hepatotropic viral infection [172]. The distinct phenotype can be due to the 
lack of co-stimulatory molecule expression on hepatocytes [177]; however the 
treatment with IL-2 or anti-CD28 antibodies could rescue hepatocyte-activated 
cells from death [211]. 
 
 Lymphocyte fate deciding pathways synergize to kill activated T cells in 
chronic herpes simplex viral immune responses, whereas death of activated T 
cells in acute immune responses relies only on the mitochondrial pathway 
involved only Bim with no contribution by Fas, which showed critical 
overlapping roles for Fas and Bim in T cell death during immune response 
shutdown, leading to immune tolerance [212]. 
 
II.6.2. BIM in Hepatitis:  
 
 Bim has been shown to be important for CD8 T cell viability during 
chronic LCMV infection in mice [213]. In this study, in Bim mutated mice, Bim 
mutation almost completely blocked the deletion of cognate antigen specific 
CD8 T cells in liver during chronic viral infection. Bim has a critical role in 
maintaining naive and memory T cells in LCMV infection [214]. In another 
study, it has been shown that a defect in apoptosis dramatically not only 
enhances the antigen-specific memory T cells but also increased the number 
of virus-specific CD4+ T cells in the lymph nodes following acute LCMV 
infection, compared to the parental genotypes or wild type mice [215]. 
Therefore, the loss of both Bim and Fas caused the increase in memory T 
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cells in acute LCMV infection [215]. The Bim role has been demonstrated in 
the development of LCMV-induced, T cell-mediated hepatitis by controlling 
the apoptosis of both T cells and hepatocytes [216]. 
 
 Bim attrition of virus specific CTLs during HBV infection has also been 
confirmed [217, 218]. The gene expression profile in HBV infection showed 
different patterns of gene expression on HBV-specific CD8+ T cells according 
to viral control. Bim was one of the up-regulated genes in HBV-specific CD8+ 
T cells from patients with chronic HBV infection. Blocking Bim-mediated 
apoptosis improved recovery of HBV-specific CD8+ T cell function [217]. 
Furthermore, the elevated apoptosis has been observed not only with Bim 
tolerogenic phenotype, but also with co-inhibitory signals through CTLA-4 







Figure II.11: Balance between co-stimulatory/ apoptotic molecules and viral-specific 
cyto- toxic T lymphocytes reactivity according to infection outcome. Neg.: Negative; 
Pos.: Positive; CTLs: Cytotoxic T lymphocytes; (+): Possible molecules induced by 
viral infection; (-): Possible molecules down-regulated by viral infection; BIM: Bcl-2 
interacting mediator; Mcl-1: Myeloid cell leukemia sequence-1. 
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 In HCV chronic infection, HCV specific CD8 cells are depleted by Bim 
mediated attrition, and remaining cells are functionally exhausted. The cell 
survival factor CD127 counteracts the induction of apoptosis after antigen 
encounter through myeloid cell leukemia sequence-1 (Mcl-1) expression and 
Bim down-regulation [220] after the cognate antigen recognition by TCR. In 
addition, cleavage of Mcl-1 by caspases modifies its subcellular localization, 
increases its association with Bim and inhibits its anti-apoptotic function [221]. 
Therefore, Mcl-1 will be discussed further.  
 
II.7 Myeloid cell leukemia-1 (Mcl-1):  
 
 Mcl-1 was originally identified as a gene up-regulated early in the 
differentiation program of the human myeloid leukemia cell line, ML-1 [222]. 
Mcl-1 is an anti-apoptotic molecule of Bcl-2 family, which promotes cell 
viability as anti-apoptotic member of this family [223]. The expression of Mcl-1 
affects the programming of differentiation or development and cell viability or 
death. Moreover, according to the data, Mcl-1 may function by providing 
short-term enhancement of cell viability [221]. In addition, Mcl-1 deficiency 
results in periimplantation lethality [220] and genetic studies have 
demonstrated that Mcl-1 functions as an important anti-apoptotic protein in 
several different cell types. Deletion of Mcl-1 in mice leads to embryonic 
lethality owing to a failure of implantation of the blastocyst in the uterus [224]. 
Mcl-1 also promotes the survival of neutrophils and hematopoietic stem cells 
[225, 226]. Mcl-1 is a highly regulated protein, suggesting that the ability to 
closely control Mcl-1 gene expression and protein level is critical for the fine 
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tuning of cell fate decisions, more particularly cell death and survival, but also 
differentiation. 
 Mcl-1 is Bcl-2 family member and therefore, shows sequence similarity, 
particularly in the carboxyl portion, to Bcl-2 [222]. But, it is distinct from Bcl-2 
and Bcl-xL because it lacks a true BH4 domain and is a larger protein that 
encodes an additional internal PEST domain. Mcl-1 is regulated at the 
transcriptional, post-transcriptional and translational levels. Full-length Mcl-1 
consists of three coding exons, a splice variant; Mcl-1S arises by the 
juxtaposition of exons 1 and 3. Full-length Mcl-1 contains the BH1–BH4 Bcl-2 
homology domains while Mcl-1S contains only the BH3 domain [221]. 
 
II.7.1 T cell survival by Mcl-1  
 
 Bcl-2 family members including Mcl-1 are expressed in T lymphocytes. It 
was recently uncovered that among signal transduction pathways 
downstream of TAK1, JNK mediates a survival program through Mcl-1 
stabilization downstream of IL-2R in activated T cells and that blockade of 
TAK1-JNK pathway can eliminate activated T cells by apoptosis [227]. 
Moreover, IL-7 up-regulates Mcl-1 mRNA expression in T cells and hence, 
Mcl-1 plays an important role protection of T-cell survival by IL-7, which 
strongly promotes Mcl-1 stability, possible by controlling lysine-directed 
ubiquitination [228]. In addition, Mcl-1 is required for survival in developing 
thymocytes, primary, and mature T lymphocytes [220, 229]. Furthermore, 
peripheral T cells die upon drug-induced deletion of Mcl-1 in vivo and under 
different in vitro conditions [220, 230]. 
 
51 
II.7.2 Mcl-1 in Hepatitis  
 
 Although it is clear that Mcl-1 is an important molecule for T cell survival, 
aspects of its role in hepatitis remain to be addressed. Mcl-1 as an anti-
apoptotic molecule has a pivotal role in impairment of T cell.  Hepatitis B virus 
X protein, which is implicated in pathogenesis of HBV, enhances cisplatin-
induced hepatotoxicity via a mechanism involving degradation of Mcl-1 [231], 
which could lead to the T cell apoptosis. In HCV infection, the core protein is a 
novel BH3-only viral homologue that contributes to the induction of apoptosis 
and the over expression of Mcl-1 protects against core-induced apoptosis 
[232]. During LCMV infection, over expression of Mcl-1 protected activated T 
cells from death, whereas deletion of Mcl-1 during the course of infection 
leads to a massive loss of LCMV-specific CD4+ and CD8+ T cells [233]. In 
contrast, additional loss of Bax and Bak completely rescued Mcl-1-deficient 
effector T-cell number and function, without enhancing T-cell proliferation. 
Therefore, Mcl-1 is critical for promoting effector T-cell responses, but does so 
by combating pro-apoptotic molecules (beyond Bim) [233]. 
 
 The process of T cell death during chronic viral infection is determined 
by a carefully balanced and complex group of pro- and anti-apoptotic proteins 
of the Bcl-2 family, such as Bim and Mcl-1 [234] (Fig I11). Interestingly, 
persistent hepatotropic viral infection is characterized by continuous TCR 
triggering and CD127 down-regulation on viral-specific CTLs [235], which 
could favor Bim up-regulation. CD127 plays an essential role in mature 
lymphocyte survival by counteracting the induction of apoptosis after antigen 
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encounter through regulation of some of the B cell lymphoma 2 (Bcl-2) 
proteins, enhancing IL-2 secretion and life span [236]. Therefore, HCV could 
modulate CD127 expression on HCV-specific CTLs to impair the quality of the 
adaptive immune response by IL-7 deprivation, as a survival strategy [121, 
166]. Passive T cell death, or death by cytokine deprivation, is controlled by 
members of the Bcl-2 family, such as Bim and Mcl-1. In addition, it is well 
known that Bim is clearly involved in intrahepatic specific-CTL apoptosis in 
animal models [172, 200, 237]. Furthermore, Bim pro-apoptotic effect is 
blocked by the action of Bcl-2 family anti-apoptotic proteins such as Mcl-1 and 
Bcl-2 [200, 237]. Interestingly, the co-deletion of Bim fails to prevent the loss 
of Mcl-1-deficient T cells during LCMV infection [233], clearly pointing out that 






Figure II.12: Cell survival marker CD127 modulates Bim and myeloid cell leukemia 
sequence-1 expression on hepatitis C virus-specific cytotoxic T lymphocytes after 
cognate antigen stimulation. Misbalance of Mcl-1/Bcl-2 interacting mediator (Bim) 
triggers to apoptosis of hepatitis C virus specific cytotoxic T lymphocytes. TCR: T cell 
receptor; Mcl-1: Myeloid cell leukemia sequence-1. 
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 Bearing in mind all these previous facts, this study tries to test a 
theoretical model to explain specific CTL deletion during persistent 
hepatotropic viral infection (Fig I.12). This model hypothesizes that CD127 
phenotype modulates Bim and Mcl-1 expression on virus-specific CTLs, 
leading to Mcl-1/Bim imbalance during persistent infection, which impairs T 
cell reactivity through apotosis induction and suggesting that restoration of T 
cell function could occur by correcting the levels of Mcl-1 and Bim expression. 
Therefore, in this study, the correlation between CD127 expression on HCV- 





















III. Hypothesis and Objectives:  
 
Based on the rationale about apoptotic molecules and the impairment of HCV-
specific CTL response during chronic hepatitis C infection discussed in 










HCV could modulate CD127 expression on HCV-specific CTLs in 
order to promote a pro-apoptotic state due to a misbalance between pro- 
(Bim) and anti-apoptotic (Mcl-1) molecules that could alter the ability of T 
cell response to control viral infection. Modulation of these pathways could 
restore the HCV-specific cytotoxic response in chronic patients 
characterized by low CD127 expression. 
 
To correlate the functional features and the apoptotic phenotype 
(Bim/Mcl-1) of specific cytotoxic response against HCV depending on the 







- To correlate CD127 expression level with viral replication and liver 
damage on HCV specific T cells  
- To study the phenotypic and functional characteristics of HCV-specific 
cytotoxic T cells in peripheral blood according to CD127 expression 
level: 
 
- Comparison of the proliferation capacity after specific stimulation 
with presence or absence of apoptosis inhibitor according to the 
CD127 expression level.  
 
- Production of interferon gamma according to CD127 expression 
level. 
 
- Bim and Mcl-1 phenotype, directly ex vivo and after specific in vitro 
stimulation in presence or absence of apoptosis inhibitor, according 
to CD127 expression level, and correlation of Bim/Mcl-1 balance 
with HCV-specific T cells reactivity. 
 
- To analyze the frequency of HCV-specific cytotoxic T cells in peripheral 













IV. Design, Material and Methods 
 
IV.1 Study Design:  
 
IV.1.1 Type of study 
 
 To test the hypothesis, we designed a non-experimental, analytical, 
cross-sectional study, which analyzed various characteristics of the HCV-
specific cytotoxic cellular response such as frequency, clonal expansion 
capability, ability to produce IFN-!, phenotype associated with apoptosis 
(Bim/Mcl-1), depending on the expression level of the survival marker CD127. 
Previously we have shown that in subjects with resolved HCV infection, 
CD127high expressing HCV-specific T cells are predominant while in chronic 
patients these cells show a CD127low phenotype [174]. 
 
IV.1.2 Selection of study subjects:  
 
The study was conducted within the health area of Guadalajara 
University Hospital, University of Alcalá, Spain. Samples were collected from 
subjects with HCV infection who referred to the Translational Hepatology Unit, 
Gastroenterology Department of the Guadalajara University Hospital, 
(University of Alcalá, Spain). The study was carried out between January 






1. Admission criteria in the study: 
 
 During the study period, the patients diagnosed with HCV infection, were 
included by consecutive sampling after being referred to the Department of 
Gastroenterology and if they met the following inclusion and exclusion criteria: 
 
1.1  Inclusion criteria: 
  
! Age between 18 and 65. 
 
! Positive serology for HCV infection. 
 
! HCV patient with HLA-A2 positive haplotype. The study was 
restricted to this group only because the method used to detect HCV 
specific CD8 lymphocytes was able to visualize HLA-A2 restricted 
HCV-epitopes.  
 
! Genotype 1: HLA-A2+ HCV infected patients with genotype 1, 
because the immunodominant HCV epitopes analyzed in the study 
belong to HCV genotype 1. 
 
! HLA-A2+ HCV infected patients with detectable HCV specific CTLs 
directly ex vivo: HCV infected cases, who have detectable HCV 
specific CTLs against HCV specific epitopes NS31406–1415 and NS31073–




! Signed an informed consent with the agreement to participate in 
the study. 
 
1.2  Exclusion criteria: 
 
! HCV genotype other than genotype 1. 
 
! Consumption more than 40 grams of ethanol per day for men and 
20 grams for women. 
 
! Presence of other causes of chronic liver diseases such as 
hemochromatosis, autoimmune hepatitis, Wilson's disease, primary 
biliary cirrhosis, porphyria cutanea tarda, non alchoholic steatohepatitis 
and HBV co-infection. 
 
! Primary or secondary immuno-suppression: The subjects with 
primary and secondary immuno-suppression were excluded from the 
study to avoid the possible consequences of immuno-suppression on 
the cytotoxic response against the virus. Therefore, HIV-infected 
subjects and patients with immunosuppressive treatments were 
excluded. 
 
! HLA-A2+ HCV infected patients with no detectable HCV specific 
CTLs directly ex vivo: HCV infected cases, who do not have detectable 
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HCV specific CTLs against HCV specific epitopes NS31406–1415 and 
NS31073–1081 were excluded in this study. 
 
! Patients, who were not ready for signing an informed consent with 
the agreement to participate in the study, were excluded.  
 
IV.1.4 Study Variables:  
 To carry out our objectives previously described, we defined two 
different studies, one analytical cross-sectional study and another quasi 
experimental type pre-post study. In the following lines are presented the 
variables included in both studies: 
 
IV.1.4.1 Analytical cross sectional study.  
 
1. Independent variable:  
 
 The IL-7 receptor (IL-7R) CD127 as a survival marker is important for the 
establishment and maintenance of the cytotoxic T lymphocytes in viral 
infection. Therefore, it is supposed that there could be certain molecules in 
HCV infection that could change in cytotoxic T cells according to CD127 
expression and lead to death of the HCV-specific T cells. We have previously 
shown that CD127 expression on HCV specific CTLs could decide outcome of 
HCV infection [174]. CD127+ expression was found in most sustained 





 Therefore, in this study, the independent variable is dichotomous 
categorical variable with two groups depending upon CD127 expression level 
(CD127low and CD127high) and considered CD127 high or CD127 low according 
to our previous work. Level of CD127 expression was decided by the Mean 
fluorescence intensity (MFI) after anti-CD127-FITC staining of HCV specific 
CTLs. 
 
! CD127low: HLA-A2+ HCV cases with directly ex vivo 
detectable HCV specific CTLs, which were showing less than 20 
MFI for CD127-FITC on pentamer+/CD8+ cells.  
 
! CD127high: CD127high expression level was considered, within 
HLA-A2+ HCV cases with directly ex vivo detectable HCV 
specific CTLs with more than 20 MFI for CD127-FITC on 
pentamer+/CD8+ cells.  
 
2. Dependent Variables:  
 
 To analyze the quantitative and qualitative (function and apoptotic 
phenotype) characteristics of the HCV-specific cytotoxic response according 
to CD127 expression, the cytotoxic response against two immunodominant 
HLA-A2 restricted HCV-epitopes were chosen (NS31406-1415, and NS31073-1081). 




! Frequency of HCV specific CD8+ T cells out of total CD8+ T 
cells: The frequency of HCV specific CTLs was analyzed out of 
total CD8+ T cells from selected HCV populations and recorded 
as percentage after staining with anti-CD8-mAbs and pentamer. 
It is a continuous quantitative variable with a range between 0-
100%. 
 
! Proliferation of HCV specific CD8+ T cells after specific 
stimulation in presence or absence of z-VAD-fmk: The ability of 
HCV specific CTLs to proliferate was analyzed after 10 days 
specific stimulation with or without pan-caspase inhibitor z-VAD-
fmk. It is a categorical variable with two categories in each kind 
of experiment (proliferation positive or negative). 
 
! Serum Alanine amino-transferase (ALT) in international units 
per liter (IU/L): ALT was used as an index of the degree of liver 
inflammation. It is a continuous quantitative variable with a 
range from 0 to 170 IU/ml. ALT>40 IU/mL was considered high 
while ALT<40 IU/mL was considered low.  
 
! Virological status: Serum HCV RNA measured in IU/mL and 
used as an index of degree of viral control. It is a continuous 
quantitative variable with a range between 1.6 x 101 to 6.06 x 




 Diagnosis of HCV infected cases was carried out and grouped 
in sustained virologic responder (SVR) and chronic HCV 
infection (CHC). Subjects, who have persistent HCV RNA 
positive in serum for more than 6 months are called as CHC, 
while subjects who have negative HCV RNA in serum 6 months 
after finishing HCV treatment are considered as SVR. This 
outcome of HCV infection correlates with CD127 expression 
level and is also related to the ALT and viral load levels [174]. 
Most of the CD127high expressing cases were diagnosed as 
SVR, in which ALT and HCV RNA level were low, while 
CD127low expressing HCV specific CTLs were observed in CHC, 
where ALT and HCV RNA level were high, as it was previously 
shown in our work [174]. However, there were some cases, 
which were showing CD127high expression level with diagnosis 
of CHC. It probably was because of the presence of epitope 
mutations at TCR interaction sites i.e. escape mutation as it was 
shown in our previous work [174].  
 
! Production of type I cytokines by HCV specific CD8+ T cells: 
The HCV-specific CTLs were analyzed for IFN-! production 
directly ex vivo as percentage of IFN-! producing HCV specific 
cells according to CD127 expression level out of total HCV-
specific CTLs. It is a continuous quantitative variable with a 




! Expression of Mcl-1 and Bim on HCV specific CD8+ T cells: 
This variable was recorded as MFI after staining with respective 
fluorescence labeled antibodies. It is a continuous quantitative 
variable with a range from 0 to 10,000 fluorescence units. 
 
3. Covariates:  
 
 The following variables were collected to control possible bias according 
to the result of the independent variables. 
 
! Age in years: It is a continuous quantitative variable with 
range from 18 to 65 years. Age can correlate to the evolution time 
of chronic hepatitis infection. Furthermore, aged patients show 
alterations in quality and intensity of the immune system that can 
affect the study's conclusions. 
 
! Sex: It is a dichotomous categorical variable. Male gender is 
associated with a worse prognosis of HCV infection. 
 
! Time of evolution: It is a continuous quantitative variable with 
range from 25 to 30 years. Time of evolution was generated by 
estimating the date on which the person became infected. It is 
considered that subjects with a longer history of the disease may 





! HCV genotype (1a and 1b): In this study, to visualize HCV-
specific CTLs, we used labeled HLA-class I/HCV-peptide 
multimers (pentamers). These pentamers were loaded with HCV 
genotype 1 specific epitope. Therefore, to study the HCV specific 
CTLs, HCV genotype 1 cases were selected.  
 
! HLA-A2+ Haplotype in HCV infected patients: The molecules 
used to visualize HCV specific CTLs called pentamers, were 
capable to recognize those cells in only HLA-A2 restricted HCV 
subjects. Therefore, this variable was used to select the HLA-A2 
restricted patients.  
 
IV.1.4.2 Quasi experimental Study: 
 
 In this quasi-experimental type of study type pre-post testing dynamics 
of Bim/Mcl-1/CD127 (dependent variable) after treatment with or without 
blocking of apoptosis with z-VAD-fmk (independent variable) were analyzed.  
 
1. Independent variable:  
 
 The independent variable is a dichotomous categorical one with two 
possible values depending upon the treatment or not with pancaspase 
inhibitor z-VAD-fmk to inhibit apoptosis on HCV-specific CTLs after specific in 
vitro challenge. It was considered positive when z-VAD-fmk was added or 




2. Dependent Variables:  
 
 The quantitative and qualitative (apoptotic phenotype) characteristics of 
the HCV-specific cytotoxic response, directly ex-vivo and after specific 
antigenic stimulation for 10 days, in presence or absence of pan-caspase 
inhibitor (z-VAD-fmk) were analyzed. To test these features the following 
variables were recorded: 
 
! Expression of Mcl-1 on HCV specific CD8+ T cells directly ex-
vivo and after HCV specific CD8+ T cells specific stimulation in 
presence or absence of z-VAD-fmk. This variable was recorded 
as MFI after staining with respective fluorescence labeled 
antibodies. It is a continuous quantitative variable with a range 
from 0 to 10,000 fluorescence units 
 
! Expression of Bim on HCV specific CD8+ T cells directly ex-
vivo and after HCV specific CD8+ T cells specific stimulation in 
presence or absence of z-VAD-fmk. This variable was recorded 
as MFI after staining with respective fluorescence labeled 
antibodies. It is a continuous quantitative variable with a range 
from 0 to 10,000 fluorescence units. 
 
! Expression of CD127 on HCV specific CD8+ T cells directly 
ex-vivo and after HCV specific CD8+ T cells specific stimulation 
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in presence or absence of z-VAD-fmk. This variable was 
recorded as MFI after staining with respective fluorescence 
labeled antibodies. It is a continuous quantitative variable with a 
range from 0 to 10,000 fluorescence units. 
 
IV.3 Subjects, Material And Experimental Methods  
 
 Between January 2007 and August 2011, 24 subjects with HLA-A2+ 
HCV infection were enrolled in the Translational Hepatology Unit, from the 
University Hospital of Guadalajara, Spain. 
 
IV.3.1 Samples selected for the study: 
 
 The HLA-A2+ HCV infected subjects, who could fulfill the inclusion and 
exclusion criteria were analyzed for HCV specific CTLs. In this cross-sectional 
study, peripheral blood mononuclear cells (PBMC) from 24 consecutive HLA-
A2+ HCV+ genotype-1 subjects, who have directly ex vivo HCV- specific CTLs 
against one or two different HCV-NS3 immunodominant epitopes, were 
obtained. From these cases, 33 different HCV-specific CTL populations were 
isolated, 20 of them specific against NS31406–1415 and another 13 specific 
against NS31073–1081. These samples were split into two groups according to 
CD127 expression level on HCV-specific CTLs. The patients’ clinical and 
virological features, regarding these two CD127 groups, are shown in Table 
IV.1. CD127 expression levels were analyzed on positive HCV specific CTLs 
and CD127 expression was considered high when MFI was higher than 20 
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units.   
IV.3.2 Sample and clinical data collection:  
 
 All subjects included in this study were subjected to a standardized 
questionnaire to collect clinical data of interest as described in the study 
variables section.  
 
1. Virological assessment:  
 
 The collected patients went through the virological assessment to fulfill 
the criteria to include or exclude in the study. Anti-HCV antibodies were 
determined by enzyme-linked immunosorbent assay performed as per the 
manufacturer’s instructions on the Ortho HCV Version 3.0 ELISA Test (Ortho 
Diagnostic System, Raritan, NJ). The viral load of HCV was measured by 
quantitative real-time PCR assay using a Roche kit (Cobas Amplicor HCV 
Monitor 2.0 Roche, Indianapolis, IN, USA), which has lower detection limit 
about 40 IU/mL. The HCV genotype was determined by reverse hybridization 
method and with Inno-LiPPA HCV II, assay kit (Innogentics Inc, Alpharetta, 
GA, USA). ALT level of patients’ serum was determined by using standard 
biochemical procedures. These tests were conducted in the Laboratory of 







Table IV.1. Clinical and virological features of the HCV-specific CTL 







Age (years old) 43 (4) 46 (15) 0.014 











Time of evolution (years) 24 (6) 29 (24) NS 
ALT (IU/mL) 40 (31) 72 (82) <0.001 
HCV viral load (IU/mL) (log scale) 1.6 (0.8) 6.06 (0.96) <0.001 
Genotype 1a/1b (%) 30/70 55/45 NS 
Epitopes tested 
(NS31406/NS31073) (%) 
73/26 54/46 NS 
 
CHC: chronic hepatitis C, CTL: cytotoxic T lymphocyte, F: female, HCV: hepatitis C 
virus, M: male, N: number of samples, NS: non-significant, SVR: sustained virologic 










2. Synthetic peptides and Pentamers:  
 
 A2-restricted peptides corresponding to the genotype-1 NS31406–1415 
region (KLVALGINAV), NS31073–1081 region (CINGVCWTV) and Phycoerithrin-
conjugated (PE-conjugated) HLA-A2 pentameric complexes (pentamer) 
loaded with the same two NS3 peptides were purchased from ProImmune 
(Oxford, UK). 
 
3. Tissue typing:  
 
 To assess the HLA-A2 haplotype of the HCV infected subjects to include 
in the study, the following protocol was used. In brief, 100uL of peripheral 
blood was stained with mouse anti-human-HLA-A2 monoclonal antibody 
labeled with Fluorescein isothiocyanate (FITC) (BD Biosciences, San Diego, 
CA), mixed properly by vortexing and incubated for 20 minutes at room 
temperature (RT). At the end of the incubation period, 2 mL of lysis solution 
was added (BD Biosciences, San Diego, CA) and incubated for another 10 
minutes. Finally, the stained blood was centrifuged at 2,000 rpm after 
vortexing. The obtained pellet was washed twice with wash buffer (PBS + 
0.01% FCS) and subsequently analyzed by flow cytometry i.e. FACS calibur 
cytometer with CELLQuest software (Becton Dickinson, CA). The haplotype 
HLA-A2 positive was set to a value greater than MFI calculated as the mean 




Figure IV.1. Histogram of a HLA-A2 negative and positive sample: The latter peak 
shows a fluorescence intensity of PBMCs stained with anti-HLA-A2 FITC antibody. 
More than 10 units of fluorescence in PBMC is HLA-A2+. (-) Negative. (+) Positive. 
 
IV.4 Processing of peripheral blood samples: 
 
 For the study, 60 ml of heparinized blood was drawn with anti-coagulant 
using standard venipuncture technique. The separation of PBMC from the 
collected blood was done by Ficoll-hypaque method i.e density gradient 
centrifugation technique. Briefly in a 50 mL Falcon tube, 1/3 of Ficoll-hypaque 
(Amersham Pharmacia Biotech AB, Uppsala, Sweden) was taken and 2/3 of 
heparinized blood was gently added from the sidewall of the tube in order to 
prevent mixing of two layers. The tube was centrifuged at 2,000 rpm for 30 
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minutes without break. Then, the PBMCs were collected from the interphase 
of PBS/ficoll with a transfer pipette in a new 15 ml Falcon tube. The collected 
PBMCs were washed 2 times with Roswell Park Memorial Institute 1640 
(RPMI 1640) (Sigma-Aldrich Inc., St. Louis, MO, USA), which was 
supplemented with 10% fetal calf serum (FCS) (Biochrom AG, Berlin, 
Germany). Cells were counted in a Neubauer chamber under an optical 
microscope after staining with Trypan blue for viability of the cells. 
 
On an average, from 60 ml of blood, between 30-40x106 PBMCs were 
obtained. The cells were re-suspended in culture medium i.e. RPMI plus 10% 
FCS to be used further for analysis of the frequency and phenotype of HCV-




1. Pentamer +/CD8+ cell quantification: 
 
 For the detection of HCV-specific CD8+ T cells, a technology that 
enables its count directly ex-vivo without functional assays was used [100, 
238, 239]. This technology involves the use of a pentameric molecule 
(pentamer) which is formed by the union of five HLA molecules of class I 
loaded with HCV specific peptide linked to a fluorescent molecule, 
phycoerythrin (PE). This molecule allows specific binding to HCV specific 
cytotoxic cells and these cells were consequently detected by the 
fluorescence emission through Flow Cytometry (Fig.IV.2). This technique is 
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exceptionally antigen-specific and highly sensitive, since it allows recognizing 
about one antigen specific CD8+ T cell out of 5,000 CD8+ lymphocytes. 
 
 To carry out this test, PBMC were purified from heparinized blood 
samples according to the method described previously. To quantify HCV-
specific CD8+ cells, 0.5-1x106 PBMC were incubated for 10 min at 37oC with 1 
!g of PE-labeled pentamers in RPMI 1640 plus 10% FCS. Cells were washed 
in PBS and then incubated at 4oC for 20 min with saturating concentrations of 
directly conjugated anti-CD8-Pe-Cy5 (Cy) mAbs, (Sigma-Aldrich Inc, St. 
Louis, MO). Subsequently, stained cells were analyzed after washing on a 
Becton Dickinson FACS® using CELLQuestTM software. The cut-off for 
pentamer assay was determined by staining peripheral blood mononuclear 
cells from 10 HLA-A2- chronically infected HCV patients. Using the mean plus 
2 standard deviations as the cut-off point, the lowest percentage at which 
pentamer-binding CD8+ cells could be detect as a separate cell population 
was 0.018% out of total CD8+ cells. At least 250,000 PBMCs were analyzed 
for each staining to achieve a minimum of 50,000 number of CD8 + T cells. 
 
 In this study, we worked with two-pentameric complexes whose structure 
includes two HLA-A2 restricted immunodominant HCV specific peptides. Both 








Figure IV.2: Outline of HLA-A2 / peptide pentameric complex NS31406-1415.  
PE: Phycoerythrin.  
 
 
2. Production of T cell lines 
 
 To assess the ability of clonal expansion of HCV specific CD8+ T cells in 
presence of HCV-specific antigen, in vitro PBMCs were stimulated with 
specific epitopes corresponding to the same peptide regions loaded on 
pentamers (NS31406-1415, and NS31073-1081) (Proimmune Limited, Oxford, UK). 
Peripheral blood lymphocytes were re-suspended at a concentration of 1 X 
106/mL in complete medium plus 10% FCS (Table IV.2). To carry out the 
stimulation, specific peptides were added at a final concentration of 1!M with 
25 IU/ml of IL-2 (RD systems) along with tetanus toxoid to a final 
concentration of 0.5µM. The suspension was distributed carefully without 
vigorous handling in 96 round bottom well plate and incubated for 10 days at 
37oC and atmosphere of 5% CO2. Here, the tetanus toxoid is used to activate 
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T helper cells in order to enhance an environment of type-1 cytokines to help 
in the HCV specific CD8+ T cell proliferation. The recombinant IL-2 (25 IU/mL) 
(RD Systems) was added at the beginning and the day 3, 5, 7, 9 of culture to 
allow the cell proliferation. The IL-2 is the third signal necessary for T cell 
activation, in addition to TCR triggering and positive co-stimulation. These two 
last signals induce IL-2 receptor expression (CD25) about 48 hours after the 
interaction between the TCR and the HLA-I/epitope complex. PBMCs were 
also cultured in the presence of either the pancaspase inhibitor zVAD-fmk (50 
ml) (BD Bioscience, San Jose, CA, USA), or !-galactosidase (2 ug/mL) 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) as control. All cultured 
cells were harvested after ten days and were analyzed by flow cytometry for 
















Table IV.2. Mediums and Buffers used in Experiments:  
 
 
PBMCs: peripheral blood mononuclear cells. FCS: fetal calf serum. PBS: phosphate 










Washing medium for 
separation of PBMCs 
 
!  RPMI 1640 medium  
! 10 % FCS 
 
Washing buffer for PBMCs 
staining with pentameric 
complexes 
 
! 0.1% Sodium Azide 
! 0.1% FCS 
! PBS 
 
Cell Culture Media 
 
! RPMI 1640 Medium: 500 mL 
! Hepes 20 Mm 
! Sodium pyruvate 0.5 mM 
! Penicillium100 U/mL  
! Streptomycin 100 µg/mL  
! 2 Mercaptoethanol 50 µM 
! L-glutamine 
! Essencial amino acids solution 
50 X (1/50) 
! Non-essential amino acids 
solutions 100 X (1/100) 
! 10% FCS 
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3. CD127 phenotypic analysis on CD8+/Pentamer+ cells:  
 
 Approximately 1 to 1.5x106 PBMCs or a variable number of cells were 
incubated for 10 minutes with 1!M of HLA-A2/peptide pentameric complexes 
(PE) in RPMI with 10% FCS (Table 2.2) at room temperature and 
subsequently washed with PBS (phosphate buffer saline) with 0.01% FCS at 
2000 RPM for 5 minutes. After washing, cells were incubated with saturating 
concentrations of anti-CD8-phycoerythrin Cyanine-5 (Pe-Cy5) labeled Abs (R 
& D Systems Inc., Minneapolis, MN) for 20 minutes at 4oC. Phenotypic 
analysis was performed only in cases in which more than 10 cells out of 
50,000 specific CD8+ T cells were detected directly ex vivo or 20 cells out of 
50,000 specific CD8+ T cells were visualized after specific in vitro proliferation. 
The positive pentameric staining tubes further proceed for the CD127 staining 
with 2µL of anti-CD127 antibody (BD Pharmingen, San Jose, CA). After 
further washing, the stained cell suspension was analyzed by the flow 
cytometer. Isotype matched control mAbs were used to set the markers. 
 
4. Intracellular Bim/Mcl-1 staining:  
 
 To evaluate the expression of the pro-apoptotic molecule Bim and anti-
apoptotic molecule Mcl-1 directly ex vivo and after antigenic expansion in the 
presence of z-VAD-fmk or "-galactosidase, HCV specific CD8+ T cells were 
labeled with pentameric complex-PE and anti-CD8-Cy5 antibody, as 
described above. Then, the cells were fixed and permeabilized for 20 minutes 
with Citofix / Cytoperm (BD Bioscience, San Jose, CA). Then the cells stained 
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with Bim unconjugated rabbit anti-human polyclonal antibody (Cell Signalling 
Technology, Beverly, MA), Mcl-1 unconjugated rabbit anti-human mAbs 
(Epitomics, Burlingame, CA, USA) and its isotype-matched control for 45 
minutes in respective tubes and goat anti-rabbit IgG2 Alexa Fluor 488 
secondary antibody (Invitrogen, Carlsbad, CA) for 30 minutes. Finally, the 
cells were washed twice with perm wash buffer and analyzed by flow 
cytometry. Data were expressed as Alexa-Fluor 488 MFI on gated 
pentamer+/CD8+ cells. The absolute value of Alexa-Fluor 488 MFI for Mcl-1 
and Bim staining and the difference between these two values were 
compared according to CD127 expression level, and correlated with 
pentamer+/CD8+ cell reactivity. The cut-off for Mcl-1/Bim positive staining was 
set according to the mean plus 2 standard deviations of the MFI observed 
with the matched control staining. 
 
5. Production of interferon-!: 
 
 To test the ability of IFN-! production, 1x106/ml PBMCs in RPMI 1640 
supplemented with 10% FCS, were stimulated with 2"M HCV specific peptide 
(eg. NS31406-1415) for 6 hours at 37°C, in the presence of 10 "g/ml Brefeldin A 
(Sigma-Aldrich Inc., St. Louis, MO) for the last 4 hours. After washing, cells 
were labeled with pentameric complex (HLA-A2 / NS31406-1415) and anti-CD8-
PeCy5 antibody as discussed above. After incubation and washing again, the 
cells were fixed and permeabilized with 250µL of Cytofix / Cytoperm (BD 
Biosciences, San Diego, CA) for 20 minutes at 4°C. After washing, the cell 
suspension was added 7µL of anti-IFN-! conjugated with FITC (BD 
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Pharmingen, San Jose, CA) and its isotype-matched control (Pharmingen BD, 
San Jose, CA) and incubated for 45 minutes at RT. Finally, the cells were 
washed twice and analyzed by Flow Cytometry. 
 
6. Statistical Analysis:  
 
Non-parametric statistical analysis was carried out. Continuous and 
categorical variables were summarized as median plus interquartile range 
(IQR) and as frequency distribution respectively. Mann-Whitney-U, Wilconxon 
and Spearman tests were employed where appropriate. All the tests were two 

















 V. Results 
 
In persistent HCV infection, HCV specific CTL reactivity is impaired and 
thus leading to chronic HCV infection. The regulation of CTL reactivity could 
be affected by CD127 (IL-7-R) expression on CTLs through Mcl-1/Bim 
balance modulation. Bim, as a pro-apoptotic molecule, is blocked by the 
action of anti-apoptotic molecule- Mcl-1. Correlation of Mcl-1 and Bim 
expression ratio with T-cell reactivity on HCV specific CTLs can help for better 
understanding of the mechanism involved on HCV-specific CTL hyporeactivity 
during chronic HCV infection. Therefore, the aim of this study was to analyze 
the correlation of the Mcl-1/Bim phenotype with their effect on T cell reactivity 
according to CD127 expression on HCV-specific CTLs. As previously 
commented, it has been already shown a negative correlation between 
CD127 expression level and HCV control [174]. 
 
In this study, we obtained blood from HCV+ HLA-A2+ genotype 1 
patients. Peripheral blood lymphocytes were isolated from these patients and 
HCV-specific CTLs were visualized by staining with anti-CD8 and HLA-
A2/peptide pentameric complexes (Pentamer). Furthermore, Mcl-
1/Bim/CD127 phenotype of HCV-specific CTLs were tested by staining of 
detectable CD8+ /pentamer+ cells with anti Mcl-1/Bim/CD127 antibodies. The 
HCV specific CTL proliferation ability after specific in vitro challenge was 
tested in the presence and absence of pancaspase inhibitor z-VAD-fmk. 
Gamma-interferon production after specific in vitro challenge according to 
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CD127 expression level was also tested in these cells. All the stained cells 
were analyzed by flow cytometry.  
 
As per the aim of this study, analysis of the pentameric cells in HCV 
infected patients was done. For this analysis the minimum sensitivity of the 
pentameric complexes to detect HCV specific CTLs was carried out. A group 
of 10 subjects with HLA-A2- chronic HCV infection was used as negative 
control. The cut-off was considered as the average frequencies of the HCV-
specific CD8+ T cells (Pent+) detected in those cases plus two times standard 
error of the mean. By this definition, the discrimination point was 10 CD8+/ 
Pent-NS31406-1415 or Pent-NS31073-1081 positive T cells out of 50,000 CD8+ T 
cells (0.02%). Therefore, it is considered that a subject had detectable cells 
with this technique, when the count of CD8+/Pent-NS31406-1415 or Pent-
NS31073-1081 had more than 10 Pent+ /CD8+ T cells per 50,000 CD8+ T cells. 
This technique is extremely specific as indicated in Figure V.1, where the 
staining with HLA-A2/peptide pentameric complex detecting specific cytotoxic 
cells against HCV NS3 1406-1415 epitope after specific stimulation in a chronic 
HCV HLA-A2+ patient is shown, while this staining did not detect cells after 





Figure. V.1: Dot plots showing the specificity of NS31406-1415 pentameric 
complexes to detect NS31406-1415-specific cytotoxic T cells. In PBMC 
stimulated with NS31406-1415 peptide a double positive cell population CD8+/ 
pent-NS31406-1415+ is detected while after stimulating these cells with an HLA-
A2 immunodominant CMV epitope no pent-NS31406-1415+ cells are detected. 





V.1 Study Variables:  
  
V.1.1 Clinical Characteristics of the Groups:  
 
In this study 24 HLA-A2+ HCV+ genotype 1 patients were included. 
HCV-specific CTLs against two different HCV immunodominant epitopes were 
directly ex vivo observed in those patients. Thirty-three different pentamer+ 
populations from these 24 HLA-A2+ HCV genotype-1 patients with directly ex 
vivo detectable pentamer+ cells were recruited for this study. Of these 33 
different HCV- specific CTL populations, 20 of them had CTLs specific against 
NS31406–1415 and another 13 had CTLs specific against NS31073–10. To study 
the functional characteristic of pent+/CD8+ T cells with respect to CD127 
expression level, study’s samples were split into two groups according to 
CD127 expression. On the basis of our previous work, 20 MFI units for 
CD127-phenotype staining was chosen as cut-off to differentiate high and low 
expressing CD127 cells. CD127high expression level was considered more 
than 20 MFI for CD127-expression on pentamer+/CD8+ cells and CD127 low 
group was showing less than 20 MFI for CD127 expression on 
pentamer+/CD8+ cells. In that work, we showed that during persistent infection 
a CD127low population was observed in peripheral blood, while CD127high 
expressing cells were present predominantly in patients controlling infection. 
In some chronic HCV cases, unexpected CD127high expressing HCV specific 
CTLs were observed but after HCV-epitope sequencing we realize that this 
high CD127 expression was due to absence of immunological pressure. In 
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this study from the 33 HCV-specific CTL populations, 14 cases were 
CD127high phenotype while 19 cases were CD127low.  
 
Table V.1: Clinical and virological features of the groups of the study. 





Age (years old) 43 (4) 46 (15) 0.014 











Time of evolution (years) 24 (6) 29 (24) NS 
ALT (IU/mL) 40 (31) 72 (82) <0.001 
HCV viral load (IU/mL) (log 
scale) 
1.6 (0.8) 6.06 (0.96) <0.001 
Genotype 1a/1b (%) 30/70 55/45 NS 
Epitopes tested 
(NS31406/NS31073) (%) 
73/26 54/46 NS 
 
CHC: chronic hepatitis C, CTL: cytotoxic T lymphocyte, F: female, HCV: 
hepatitis C virus, M: male, N: number of samples, NS: non-significant, SVR: 
sustained virologic response, *Mann-Whitney U test. 
 
Both CD127 groups were similar with respect to principle demographic 
characteristics for example patients’ age, disease evolution time and sex 
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distribution (Table V.1). The average age of the study subjects stood at the 
end of fourth decade in two groups, ranging from 43 years to 46 years. The 
percentage of males was higher than female in both groups, namely for 
CD127high expressing group, 78% were male and 77% in CD127low expressing 
group. Furthermore, the evolution time of disease was similar in studied 
groups, ranging from 20 to 30 years. In summary, these data showed that 
there was consistency in clinical variables between the compared groups. In 
addition, the selected HLA-A2+ HCV+ populations were having specifically the 
same genotype 1a/1b distribution. 
 
V.2 Viral replication and liver damage according to CD127 expression on 
pentamer+ cells:  
 
In the viral infection, CD127 expression, as a survival marker, could 
decide the fate of viral specific CD8+ T cells. In addition, CD127 expression 
could affect to viral load and effectivity of viral specific T cells on destroying 
targeted liver cells. CD127 expression level on HCV specific CD8+ T cells was 
analyzed by studying mononuclear cells from the patients’ peripheral blood 
samples. PBMCs were double stained directly ex-vivo with anti-CD8-PeCy5 
mAbs and PE-pentamers to test the presence of HCV-specific CD8+ cells 
against the two different HCV specific epitopes. The pentameric positive cells 
were further stained with anti-CD127-FITC mAbs. Depending upon the CD127 
expression level, these samples were split into two groups and viral load and 
ALT level were compared to check viral control and liver damage according to 







Figure. V.2: Liver damage and viral control according to CD127 expression on HCV-
specific cytotoxic T cells: Box plots showing serum ALT (IU/mL) and viral load 
(IU/mL) levels according to the CD127 expression on HCV-specific cytotoxic T cells 
(pentamer+/CD8+ cells). §Mann–Whitney U test; MFI, mean fluorescence intensity; n, 
number of cases. 
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HCV individuals with high expression of CD127 were having undetectable or 
low viral load, while HCV specific CTLs from CD127low expressing group 
associated with high viral load. The average HCV viral load of CD127low group 
population was more than 106 IU/ml, whereas for CD127high group was less 
than 102 IU/ml, which is almost three times lower than in CD127low-expressing 
individual group, which showed significant P value about <0.001!. In case of 
liver damage according to CD127 expression level, CD127high group had low 
ALT (about 40 IU/ml), while CD127low group was showing high ALT (about 70 







Figure. V.3:  Representative FACS dot plots and MFI histograms of peripheral T 
cells stained with labeled mAb against CD8 and CD127 and with pentameric HLA-
A2/peptide PE-labeled complexes against NS31406 and NS31073 HCV epitopes 
from cases with different degrees of liver damage and viral control. The figure on the 
upper left corner of the FACS dot plots for pentamer/CD8 staining shows the 
frequency of pentamer+ cells out of the total CD8+ cells. FACSÒ histograms are 
gated on pentamer+ and pentamer- CD8+ cells. The dashed line in the histograms 
represents the upper limit of the staining with the isotypic control. ID, patient 
identification; MFI, mean fluorescence intensity; n, number of cases; PBL, peripheral 
blood lymphocytes.   
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The CD127 expression on pentamer+ cells in the CD127low group was 
almost three times lower (MFI, 13.90; IQR, 8.37) than in the CD127high group 
(MFI, 34.59; IQR, 10.02) (P < 0.001; Figs V.4 and V.11) and similar to the MFI 
observed with the isotype control staining (MFI, 5.60; IQR, 4.30) (P > 0.05). 
(Fig V.3). The pentamer+ cells were showing significant difference in CD127 
expression level, but the total CD8+ cells were showing similar CD127 
expression in respective groups, therefore, this difference was HCV antigen 




Figure. V.4: Box plots showing the directly ex vivo CD127 MFI on total CD8+ and 
pentamer+ cells in the CD127 expression level groups of the study. §Mann–Whitney 
U test. ¤Wilconxon test. MFI, mean fluorescence intensity; n, number of cases.  
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Therefore, CD127low-expressing HCV-specific CTLs associated with 
high HCV viraemia, while CD127high expression correlated with undetectable 
viral loads (P < 0.001). Similarly, the CD127 low expression level also 
associated with high liver damage, whereas high expression of CD127 in 
HCV-specific CTLs correlated with low serum ALT value. In fact, most 
populations with CD127high-expressing pentamer+ cells were sustained 
virologic responders, tested at least 6 months after finishing standard anti-
HCV treatment, while CD127low- expressing cells were mainly present in naive 
chronic hepatitis C infected cases. Thus, the CD127 expression level in HCV 
specific CTLs is clearly associated with the liver damage and viral replication 
in HCV patients.  
 
V.3 Reactivity of pentamer+ cells according to CD127 expression level: 
 
To test whether CD127 expression level could affect HCV-specific CTL 
reactivity after antigen encounter because of apoptosis activation, proliferation 
ability of HCV specific pentamer+ cells was analyzed after stimulation with 
HCV specific in vitro challenge with or without apoptosis blockade. Ten cases 
of each group were analyzed after HCV specific in vitro challenge by HCV 
specific peptide, in presence of either a pancaspase inhibitor (z-VAD-fmk) or 
!-galactosidase as control. Consequently, frequency of HCV specific CTLs 
according to the expression of CD127, directly ex vivo and after specific in 
vitro stimulation were compared to check the proliferation ability of those cells 




In directly ex vivo and in vitro stimulation, the peripheral frequency of 
HCV specific CTLs was analyzed and found significant differences. The 
peripheral frequency of pentamer+ cells out of the total CD8+ cells was very 
low directly ex vivo and similar in both groups; CD127low: 0.05% (IQR, 0.09) 
and CD127high: 0.04% (IQR, 0.05) (P > 0.05, Figs V.5 and V.7). However, the 
frequency of CD127high-expressing pentamer+ cells was higher than in CD127 
low expressing pentamer+ cells after stimulation with the specific peptides for 
10 days without z-VAD-fmk treatment. In CD127high expressing group, the 
median frequency of pentamer+ cells was 1.7% (IQR, 6.77), whereas only 
0.003% (IQR, 2.9) was found in CD127low group (P < 0.05, Figs V.6 and V.7). 
Furthermore, only 30% of the low CD127 expressing cases showed a positive 
proliferation as a cluster of pentamer+ cells, while in 80% of samples from 






Figure. V.5: Representative FACS dot plots and mean fluorescence intensity (MFI) 
histograms showing the Mcl-1 and Bim expression on peripheral CD8+/pentamer+ 
cells, directly ex vivo with regard to the CD127 expression level on those cells. The 
Figure on the top of the dot plots represents the frequency of pentamer+ cells out of 
the total CD8+ cells. The Figure in the upper right corner in the histogram plot 
represents the MFI for Bim and Mcl-1 staining. The continuous and dashed line in the 
dot plots and histograms represent the cut-off point for positive staining according to 





Figure. V.6: Representative FACS dot plots and mean fluorescence intensity (MFI) 
histograms showing the Mcl-1 and Bim expression on peripheral CD8+/pentamer+ 
cells, after specific in vitro challenge, with regard to the CD127 expression level on 
those cells. Peripheral blood lymphocytes were subjected to specific in vitro 
challenge in the presence of z-VAD-fmk and !-galactosidase as control. The Figure 
on the top of the dot plots represents the frequency of pentamer+ cells out of the total 
CD8+ cells. The Figure in the upper right corner in the histogram plot represents the 
MFI for Bim and Mcl-1 staining. The continuous and dashed line in the dot plots and 
histograms represent the cut-off point for positive staining according to the negative 
control. IC, isotypic control; ID, patient identification; N.D., not done because of lack 





Figure. V.7: Reactivity of CD8+/pentamer+ cells according to CD127 expression 
level: Box plots showing the frequency of CD8+/ pentamer+ cells directly ex vivo and 
after specific in vitro challenge in the presence of either z-VAD-fmk or !-
galactosidase as control in high and low CD127-expressing pentamer+ cells. 
*Wilconxon test. §Mann–Whitney U test. LOD, limit of detection; MFI, mean 
fluorescence intensity; n, number of cases; n.s., non-significant; O, outliers. 
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On the other hand, the pancaspase inhibitor works for inhibiting 
apoptosis and improved the proliferation ability after specific stimulation. In 
presence of pancaspase inhibitor –z-VAD-fmk in proliferation set up, 
CD127low-expressing pentamer+ cells improved in expansion ability after 
specific stimulation (1.39%; IQR, 13.2), with respect to the observed 
expansion without this pancaspase inhibitor (P < 0.05, Figs V.6 and V.9). The 
observed expansion with pancaspase inhibitor in CD127low expressing 
samples, reached a similar expansion level to the CD127high expressing 
pentamer+ cells (4.5%; IQR, 6.25) in absence of pancaspase inhibitor –z-
VAD-fmk (P > 0.05, Figs V.6 and V.9). Moreover, the percentage of 
experiments with pentamer+ cell proliferation augmented after z-VAD-fmk 
treatment up to 80% (P < 0.05) (Figs V.6 and V.9), in the CD127low group, 
showing a similar expansion frequency to the one observed in the CD127high 
group (P > 0.05) (Fig. V.9). Treatment of z-VAD-fmk did not only affect on 
CD127low group but also on CD127high group. The z-VAD-fmk treatment also 
non-significantly enhanced proliferation of CD127high expressing cells (P > 
0.05, Figs V.6 and V.9). Interestingly, CD127 expression has found to 
decrease in CD127high expressing pentamer+ cells (P < 0.001) and reached to 
a similar level (MFI, 8.05; IQR, 5.90) to the one observed directly ex vivo in 
the CD127 low group, after specific in vitro stimulation (Figs V.10 and V.11). 
 
 Therefore, proliferation of CD127low pentamer+ cell after specific in vitro 
challenge was impaired (P < 0.05), although this was corrected by z-VAD-fmk 
treatment (P < 0.05). Thus, the reactivity of HCV specific pentameric+ cells 
correlated with CD127 expression level.  
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V.4. Interferon-! production by pentamer+ cells according to CD127 
phenotype: 
 
The level of Interferon-! (IFN- !) production significantly correlates with 
the level of viral-specific CTL activity. The effectivity of viral specific cells is 
measured by the percentage of IFN- ! producing HCV specific CTLs. To 
explain, whether the CD127 expression level could affect on effectivity of 
HCV-specific cells, the IFN-! production on CD127 expressing CTLs was 
carried out. Directly ex vivo IFN- ! producing pentamer+ cells were analyzed 
in 11 cases (5 cases in CD127high and 6 cases in CD127low group). The 
frequency of IFN-! producing pentamer+ cells was directly proportional to the 
CD127 expression in pentamer+ cells. CD127low expressing pentamer+ cells 
were showing lower frequency of IFN-! producing pentamer+ cells (40%; IQR, 
32) than in the CD127high group (61%; IQR, 13.5) (P < 0.05, Fig. V.8). 
 
Therefore, the frequency of IFN- ! producing pentamer+ cells was 
lower in the CD127low than in the CD127high group. Thus, the correlation of 
percentage of frequency of IFN- ! production in HCV specific cells is directly 






Figure. V.8 (A) Representative FACS dot plots and mean fluorescence intensity 
(MFI) histograms showing directly ex vivo interferon-! (IFN-!) production on 
pentamer+ cells according to CD127 expression. (B) Box plots showing the 
percentage of IFN-producing pentamer+ cells, in relation to CD127 expression level. 
The Figure in the upper right corner in the histogram plot represents the MFI for IFN 
! staining. §Mann–Whitney U test; MFI, mean fluorescence intensity; ID, patient 
identification; n, number of cases. 
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V.5. Mcl-1 and Bim expression according to CD127 phenotype: 
 
 The observation of reactivity impairment on pentamer+ cells according 
to low CD127 level could be related to apoptosis induction. In intrinsic 
apoptosis pathway, the known Bcl-2 family proteins, Mcl-1 and Bim, are 
shown to be involved. To explain the different T cell reactivity according to 
CD127 level, anti-apoptotic molecule- Mcl-1 and pro-apoptotic molecule- Bim 
phenotypes were analyzed on pentamer+ cells. Bim and Mcl-1 were stained 
with Alexa-Flour 488 labeled antibody. Bim and Mcl-1 MFI on gated 
CD8+/Pentamer+ cells were calculated. A value, which is higher than the MFI 
mean plus 2 standard deviations obtained from the pool of pentamer+ cell 
staining with the isotypic Antibody control (Cut-off level: 90 unit of 





Figure. V.9: Bar plots showing the percentage of experiments with CD8+/pentamer+ 
cell proliferation after specific in vitro challenge in the presence of either z-VAD-fmk 
or !-galactosidase as control, with regard to CD127 expression level. Positive 
proliferation was considered when more than 0.2% of CD8+/pentamer+ cells in a clear 
cluster were observed after specific stimulation. *Wilconxon test. §Mann–Whitney U 






Figure. V.10:  Representative FACS dot plots and MFI histograms from CD127high-
expressing pentamer+ cells, with CD127 expression on CD8+/pentamer+ cells directly 
ex vivo and after specific in vitro challenge. MFI, mean fluorescence intensity; ID, 
patient identification.  
 
 The comparison of directly ex vivo Bim and Mcl-1 expression on 
peripheral pentamer+ cells according to CD127 level was analyzed. Directly 
ex vivo, Bim expression was similar on peripheral pentamer+ cells in both 
CD127 expressing pentamer+ cell groups. Particularly, Bim expression on 
pentamer+ cells was showing MFI about 79.19 (IQR, 117.60) in CD127low-
expressing cells and about 156.20 MFI (IQR, 136.01) was in case of 







Figure. V.11: Mcl-1 and Bim expression on CD8+/pentamer+ cells according to 
CD127 expression level and their relationship with CD8+/pentamer+ cell reactivity 
after antigen encounter: A) Box plots showing the MFI for CD127, Mcl-1 and Bim 
staining on peripheral CD8+/pentamer+ cells directly ex vivo and after specific in vitro 
challenge, blocking apoptosis, according to CD127 expression level. (B) Box plots 
describing the directly ex vivo Mcl-1/Bim expression on total CD8+ cells in the two 
groups of the study.  §Wilconxon test. *Mann–Whitney U test; MFI, mean 







 On the other hand, in case of Mcl-1, directly ex vivo Mcl-1 expression 
level was different between groups according to CD127 expression level. The 
Mcl-1 expression was directly proportional to the CD127 expression level. 
Directly ex vivo, Mcl-1 expression was significantly lower on CD127low 
pentamer+ (MFI, 172.80; IQR, 119.57) than on CD127high-expressing cells 




Figure. V.12: Scatter plots showing the correlation between CD127 expression on 
CD8+/pentamer+ cells and Mcl-1/ Bim expression on peripheral CD8+/pentamer+ 
cells. ‡ Spearman’s correlation coefficient; MFI, mean fluorescence intensity; n, 






 Thereafter, the correlation between CD127 expression level and Mcl-1 or 
Bim expression level on peripheral pentamer+ cells was analyzed. A positive 
significant correlation between CD127 expression level and Mcl-1 level on 
peripheral pentamer+ cells (r = 0.426, P < 0.05) was observed, while no 
significant correlation between CD127 and Bim expression was observed (P > 
0.05) (Figs V.12). Simultaneously, the Mcl-1 or Bim expression on total CD8+ 
cells was also analyzed. CD127 expression level was not inducing any 
difference in Mcl-1/ Bim expression on total CD8+ cells. In both study groups a 
similar expression for Mcl-1 or Bim on total CD8+ cells was observed directly 
ex vivo, which gave clear idea that Mcl-1 and Bim expression depending upon 
CD127 expression level was antigen specific (Figs V.11). 
 
 Anti-apoptotic molecule counteracts pro-apoptotic molecule and control 
apoptotic process. In addition, it is known that Mcl-1 expression could 
counteract Bim action. Therefore, bearing it in mind, the excess of Mcl-1 
expression over Bim level on pentamer+ cells was calculated by subtracting 
Mcl-1 Alexa-Fluor 488 MFI level to the MFI observed for Bim expression. This 
calculated variable showed a high significant positive correlation with CD127 
expression on pentamer+ cells (r = 0.648, P < 0.001, Fig. V.13). In fact, the 
difference between Mcl-1 and Bim expression was almost four times higher 
on CD127high-expressing pentamer+ cells (difference, 110.74; IQR, 267.57) 







Figure.V.13: Scatter plot showing the positive correlation between the Mcl-1/Bim 
expression subtraction and CD127 expression level on peripheral CD8+/pentamer+ 
cells. ‡ Spearman’s correlation coefficient. MFI, mean fluorescence intensity; n, 
number of cases. 
 
 According to proliferation ability, in presence of HCV-specific antigen, 
the excess of Mcl-1 expression regarding to Bim expression level, was 
analyzed in pentamer+ cells. The excess of Mcl-1 expression, regarding to 
Bim level, was higher in pentamer+ cells with proliferation ability after antigen 
encounter (difference, 239.57; IQR, 308.68) than in the cells without reactivity 
(difference, 52.71; IQR, 102.60) (P < 0.05, Figs V.14). Even this profile was 
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also showing a similar profile to the CD127 level, as far as expansion capacity 
was concerned. Thus, pentamer+ cells with proliferation ability expressed a 
higher CD127 level (MFI, 29.36; IQR, 22.85) and a higher Mcl-1/Bim 
expression difference than pentamer+ cells without expansion potential, 






Figure. V.14: Box plots describing the CD127 expression level and Mcl-1/Bim 
expression difference on peripheral CD8+/pentamer+ cells with regard to their 
reactivity after antigen encounter. * Mann–Whitney U test; MFI, mean fluorescence 
intensity; n, number of cases. 
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In presence of z-VAD-fmk and stimulating with HCV specific peptide, 
whether T cell receptor (TCR)/HLA-I- peptide engagement could influence 
Mcl-1/Bim imbalance was analyzed, according to CD127 expression level. 
Therefore, the Mcl-1/Bim/CD127 phenotype, after specific in vitro challenge in 
the presence of z-VAD-fmk, was also analyzed and compared between both 
CD127 expression groups. To study Bim and Mcl-1 expression after antigen 
encounter on CD127low-expressing pentamer+ cells, z-VAD-fmk was used to 
ensure the proliferation of these cells. After specific antigen stimulation, in 
CD127high-expressing pentamer+ cells CD127 expression was down-regulated 
(P < 0.01) to a similar level to the one observed on CD127low cell, directly ex 
vivo, in association with Mcl-1 down-regulation (MFI, 134.57; IQR, 106.04) (P 
< 0.05), which reached the level described on CD127low cells. However, in 
case on Bim expression, it remained unchanged (MFI, 121.04; IQR, 79.04) (P 
> 0.05) (Figs V.6 and V.11). On the other hand, in CD127low-expressing 
pentamer+ cells, CD127 expression was maintained at low levels after specific 
in vitro challenge (MFI, 11.28; IQR, 8.26) (P > 0.05), and Mcl-1 expression 
was not modified (MFI, 199.23; IQR, 177.95), but interestingly, Bim 
expression was significantly up-regulated (MFI, 191.08; IQR, 147.87) (P < 
0.05) to a significantly higher level than the one expressed by CD127high-
expressing pentamer+ cells (P < 0.05) (Fig V.14). These data suggest that 
Bim expression can be up regulated only after TCR triggering in cells with low 
CD127 expression. 
 
Therefore, the difference between Mcl-1 and Bim expression on 
pentamer+ cells directly ex vivo correlated positively with CD127 expression 
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level and with pentamer+ cell reactivity. To sum up, a low ex vivo Mcl-1 
expression and Bim up-regulation after antigen encounter are involved in 
CD127low HCV-specific CTL hyporeactivity during chronic infection, but it can 



















VI. Discussion  
 
 In HCV persistent infection, specific cytotoxic response is weak and 
unable to clear the virus [50]. Hepatitis C virus-specific CTLs are essential 
effector tools to control HCV infection, but the lack of a broad and strong 
CD8+ T-cell response has been linked to persistence of HCV infection [108, 
123]. In addition, sustained immunological viral pressure in chronic non-
cytopathic viral infection induces an anergic phase and a subsequent deletion 
on specific CTL [242], i.e. prone to apoptosis during persistent infection [121, 
243]. This phenomenon may be related to a high, long-term activation of 
these cells during persistently elevated viraemia, conducting to a exhausted 
CD8+ T cell response during chronic HCV infection [168, 244].  In fact, upon 
continued antigenic stimulation, CD8+ T cells lose their effector function and 
are selectively deleted, resulting in failure to achieve viral clearance, and this 
fact correlates with CD127 down-regulation and resulted in deletion of antigen 
specific naïve and memory T cells [245]. This could be a physiological 
strategy by the host to avoid immune-mediated injury during chronic infection. 
Therefore, in persistent HCV infection, peripheral HCV-specific CTLs could 
acquire an exhausted phenotype to avoid a harmful immune response. 
Subsequently, these cells cannot withstand further activation in the liver after 
antigen re-encounter, leading to selective T cell deletion. 
 
 The procedure of T cell death during chronic viral infection is determined 
by a carefully balanced and complex group of pro- and anti-apoptotic proteins 
of the Bcl-2 family, such as Bim and Mcl-1 [234]. Bim is clearly involved in 
intrahepatic-specific CTL apoptosis in animal models [172]. Bim is thought to 
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act principally by activating Bax, permitting mitochondrial release of 
cytochrome c, which activates caspases, ultimately leading to cell death [234]. 
Expression of Bim is up-regulated in human T cells in response to TCR 
triggering by the protein kinase C (PKC) and calcineurin pathways [199]. 
Nevertheless, there are other mechanisms involved in Bim up-regulation 
during chronic infection, such as the effect of certain cytokines. IL-7 
withdrawal could induce Bim-mediated apoptosis. In fact, in a persistent viral 
infection animal model, Bim-mediated apoptosis correlates with low IL-7 
receptor expression on specific T cells [200]. It has been proved that Bim is 
required for switching off CD8+ T cell response in the setting of a 
superantigenic stimulus [246] or an acute viral infection [247] in murine model. 
Furthermore, Bim has also recently been found to regulate CD8+ T cell 
responses during chronic LCMV infection in mice [213], which is more 
relevant to the situation of chronic HCV infection. Bim mediates apoptosis of 
CD127low effector T cells [200], which is the main responsible of CD127low 
expressing virus specfic CD8+ T cells apoptosis [248]. Transforming growth 
factor (TGF)-! is also involved in Bim-mediated apoptosis [219]. Therefore, all 
these data indicate that Bim action is not only modulated through TCR 
stimulation, but also by other regulatory mechanisms such as either IL-7 
withdrawal or TGF-! induction. Interestingly, persistent HCV infection is 
characterized by continuous TCR triggering and CD127 down-regulation on 
HCV-specific CTLs [235], which could favour, so far, Bim up-regulation. In our 
work, Bim was up-regulated on CD127low-expressing HCV-specific CTLs but 
not on CD127high cells after antigen encounter, suggesting that TCR triggering 
can only lead to Bim up-regulation in the absence of IL-7 stimulation on HCV-
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specific CTLs. Nevertheless, Bim level is not enough to lead to T cell 
apoptosis. T cell death also depends on the anti-apoptotic protein expression 
level, regulated by cytokines, such as IL-7. Regarding this, the Bim pro-
apoptotic effect is blocked by the action of the Bcl-2 family of anti-apoptotic 
proteins such as Mcl-1 and Bcl-2 [214, 237].  
 
 CD127 plays an essential role in mature lymphocyte survival by 
counteracting the induction of apoptosis after antigen encounter through 
regulation of some of the Bcl-2 proteins, enhancing IL-2 secretion and life 
span [236]. Therefore, HCV could modulate CD127 expression on HCV-
specific CTLs to impair the quality of the adaptive immune response by IL-7 
deprivation, as a survival strategy [166, 249]. Mcl-1, induced by IL-7, has 
been shown to counteract the pro-apoptotic effects of Bim to play an essential 
role in mature lymphocyte survival [220]. Interestingly, in an experimental 
model, IL-7 deprivation during stressing conditions leads to Mcl-1 down-
regulation on T cells, leading to T cell death that could be avoided by IL-7 
treatment [230]. In agreement with this experimental model, our ex vivo data 
show that during persistent HCV infection the predominant peripheral 
population of HCV-specific CTLs displays a CD127low/Mcl-1low phenotype that 
remains low after antigen encounter. All in all, these Mcl-1/Bim data could 
mean that during chronic HCV infection, experienced CD127low/ Mcl-1low-
expressing T cells attracted to the liver would up-regulate Bim expression 
after antigen encounter because of the absence of IL-7 stimulus, and 
subsequently Bim would be released freely to activate Bax, because of the 
low level of anti-apoptotic proteins such as Mcl-1. Consequently, CD127 level 
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would play a central role in HCV-specific CD8+ T cell apoptosis by regulation 
of Mcl-1 expression in vivo and by Bim modulation after antigen encounter. 
This theory could explain why CD127low HCV-specific CD8+ T cell reactivity 
from chronic hepatitis C patients is impaired, and theoretically this could be 
overcome by apoptosis blockade. To test this hypothesis, the correlation 
between CD127 phenotype, T cell reactivity and Bim/Mcl-1 phenotype on 
HCV-specific CTLs after apoptosis blockade was tested in this study. 
 
 In this work, directly ex vivo HCV-specific CTLs from a cohort of patients 
with different degrees of viral control were obtained. In patients with either low 
or undetectable viral load, a population of peripheral CD127high-expressing 
cells able to proliferate and to produce IFN-! after antigen encounter was 
observed. Theoretically, this population could control HCV traces or be ready 
for a rapid response in the case of re-infection [250, 251]. These cells were 
characterized by a higher Mcl-1 expression than the observed Bim level, 
which could be responsible for maintaining T cell reactivity, avoiding apoptosis 
activation after antigen encounter. Interestingly, these CD127-expressing cells 
from resolved patients down-regulated CD127 expression after specific in 
vitro challenge, linked to Mcl-1 down-regulation, without up-regulation of Bim 
expression, acquiring an in vitro phenotype after expansion similar to the one 
observed in directly ex vivo cells from chronic patients. Therefore, these cells 
could be prone to apoptosis after re-stimulation, mimicking the situation found 
in persistent infection. On the other hand, in cases with persistent high viral 
load, HCV-specific CTLs showed a CD127low phenotype that correlated with 
proliferation and IFN-! production impairment. This phenotype linked with a 
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directly ex vivo low Mcl-1 expression, similar to Bim levels that could allow 
apoptosis activation after Bim up-regulation. Actually, after specific in vitro 
TCR triggering, Bim up-regulation on CD127low-expressing HCV- specific 
CTLs was observed. This finding was previously shown by our group [174] 
and it did not occur on CD127high- expressing cells, as previously commented. 
In an experimental model, a similar observation was made showing that Bim 
was a critical mediator of apoptosis, induced by TCR re-stimulation, in the 
context of growth cytokine withdrawal [252]. Therefore, we could speculate 
that CD127 low expression on HCV-specific CTLs during persistent infection 
could favor Mcl-1 down-regulation on these cells, leading to apoptosis after 
antigen encounter, when Bim expression is up-regulated on HCV-specific 
CTLs, and Mcl-1 low level is unable to block Bim activity. In fact, the 
difference between Mcl-1 and Bim expression was significantly lower in 
CD127low-expressing HCV-specific CTLs than in CD127high cells, and this 
correlated with T cell reactivity. These findings were antigen specific, because 
no difference in Mcl-1/Bim expression on total CD8+ cells between the study 
groups was observed. Therefore, assuming that Mcl-1/Bim imbalance could 
be involved in the hyporeactivity of CD127low- expressing HCV-specific CTLs 
through apoptosis activation, CD127low HCV-specific CD8+ T cell reactivity 
rescue was attempted by interfering with caspase activity. Interestingly, 
CD127low HCV-specific CD8+ T cell treatment with a pan-caspase inhibitor 
restored T cell reactivity to a similar range to the one observed in CD127high 
HCV-specific CD8+ T cells from most HCV-resolved infection cases. These 
data suggested a link between apoptosis after TCR triggering and low CD127 
expression on experienced HCV-specific CTLs during persistent infection that 
 
 117 
could be related to Mcl-1/Bim imbalance as in chronic HBV infection [217]. 
Therefore, CD127- specific-CTL are prone to apoptosis due to the down-
regulation of the anti-apoptotic molecule Mcl-1 and the up-regulation of the 
apoptosis facilitator Bim, secondary to IL-7 deprivation [217, 220]. Bearing in 
mind these results, at least theoretically, therapeutic apoptosis blockade could 
help to restore the proliferation capacity of CD127low/Mcl-1low/Bimhigh HCV-
specific CD8+ T cells after antigen encounter in chronic hepatitis C patients. 
Moreover, CD127 expression correlates inversely with the expression of 
several negative co-stimulatory molecules, suggesting that anergy and 
apoptosis are processes closely related [253], indicating that probably it is 
necessary to act in both of them to obtain the HCV-specific CTL response 
restoration. Therefore, blocking intrinsic apoptosis pathway could be one of 
the necessary mechanisms to improve HCV-CTL reactivity as it has been 
shown in other persistent hepatotropic viral infection [217]. This strategy could 
be a useful tool to try to improve the response to standard of care in chronic 
HCV patients. So far, the common calceneurin inhibitor cyclosporine-A has 
been shown to prevent T cell deletion through blocking Bim up-regulation 
[199]. Considering the in vitro HCV-specific CTL restoration, using the 
pancaspase inhibitor z-VAD-fmk, a drug as cyclosporine-A with a similar 
effect, but commonly used in some human diseases, could be employed in 
combination with anti-viral treatments to enhance the immune adaptive 
response.  
 
 During chronic infection, a robust viral-specific cellular response is 
altered, showing a pro-apoptotic phenotype due to the deprivation of IL-7 
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secondary to the low expression of CD127. Recently, it has been investigated 
that TRAF1 is a signal adapter for positive co-stimulatory receptors whose 
level depends on the action of IL-7 and inhibits the expression of the pro-
apoptotic molecule Bim [254]. Therefore, in situations of deprivation of IL-7, 
action of TRAF1 could be impaired, favoring an imbalance between anti- and 
pro- apoptotic molecules. On the other hand, in an experimental model, IL-7 
deprivation during stressing conditions leads to Mcl-1 down-regulation on T 
cells, conducting to T cell death that could be avoided by IL-7 treatment [230]. 
Consequently, strategies directed to block the pro-apoptotic effect of IL-7 
deprivation should be designed to increase the effectiveness of CTL response 
restoration, by enhancing the TRAF1 and Mcl-1 expression level that could 
restore Bim/Mcl-1 balance. One of those strategies could be short-term use of 
FK506 could block the induction of the pro-apoptotic molecule Bim on CD127- 
cells [199]. This strategy could favor specific- CTL restoration during anti-viral 
treatments in combination with the standard of care. Another possible strategy 
to restore HCV-specific CTL reactivity during chronic infection could be the 
administration of IL-7, in order to increase the stimulation of the reduced 
number of IL-7R molecules on HCV-specific CTLs to modulate the balance 
between Bim and Mcl-1. In fact, in an animal model of cytotoxic T cell 
exhaustion, IL-7 treatment resulted in an increased T cell effector function and 
viral clearance [255]. 
 
In summary, this work suggests for the first time that CD127 phenotype 
modulates Bim and Mcl-1 expression on HCV-specific CTLs, and this affects 
T cell reactivity through apoptosis regulation. Specifically, during chronic 
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infection, Mcl-1/Bim imbalance could be involved in CD127low HCV- specific 
















1. CD127 expression level on peripheral HCV-specific CTLs 
correlates negatively with liver damage and viral control. Therefore, 
during chronic HCV infection CD127low-expresing HCV-specific CTLs 
are predominant. 
 
2. CD127 expression on HCV-specific cytotoxic T cells inversely 
correlates with their effector functions (proliferation ability and type-1 
cytokine secretion after antigen encounter). 
 
3. Low CD127 expression level up-regulates pro-apoptotic molecule-
Bim after antigen encounter and down-regulates anti-apoptotic 
molecule Mcl-1 in HCV specific CD8+ T cells during chronic HCV 
infection.  
 
4. The balance between pro- and anti-apoptotic molecules is critical 
for HCV specific CTL survival. The CD127 down-regulation modulates 
Bim and Mcl-1 balance on HCV-specific CTLs and this affect to T cell 
reactivity through apoptosis induction. 
 
5. Consequently, Mcl-1/Bim imbalance could be the reason for the 






1. El nivel de expresión de CD127 en los LTC VHC-específicos se 
correlaciona de forma negativa con el daño hepático y el control viral. 
Por tanto, los LTC VHC-específicos con baja expresión de CD127 son 
predominantes durante la infección crónica por VHC. 
 
2. La expresión de CD127 en los LTC VHC-específicos se 
correlaciona de forma inversa con las funciones efectoras de estas 
células (capacidad de proliferación y de secrecion de citoquinas tipo1). 
 
3. Un nivel bajo de expresión de CD127 en las células T CD8+ VHC-
específicas  durante la infección crónica por VHC provoca la sobre-
expresión de Bim tras el encuentro antigénico y la disminución de la 
expresión de Mcl-1. 
 
4. El equilibrio entre moléculas pro- y anti-apoptóticas es crítico para 
la supervivencia de los LTC VHC-específicos. La disminución de la 
expresión de CD127 en los LTC VHC-específicos modula el equilibrio 
entre Bim y Mcl-1 y esto afecta a la relatividad de estas células a 
través de la inducción de la apoptosis. 
 
5.     En consecuencia, el desequilibrio entre Mcl-1/Bim podría ser la razón 
de la eliminación de los LTC VHC-específicos aunque esto puede ser 
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SUMMARY. In persistent hepatitis C virus (HCV) infection,
HCV-specific cytotoxic T lymphocyte (CTL) reactivity is
impaired and this affects HCV control. Interleukin-7 receptor
(CD127) expressiononthese cells could regulateCTLreactivity
through Mcl-1/Bim balance modulation. Bim is a pro-apop-
totic molecule blocked by the action of Mcl-1. Mcl-1/Bim
expression and T cell reactivity on HCV-specific CTLs were
compared according to CD127 phenotype. Peripheral blood
lymphocytes (PBL) from HLA-A2+ HCV+ patients were ob-
tained.HCV-specific CTLswere visualized by stainingPBLwith
anti-CD8 and HLA-A2/peptide pentameric complexes (pent-
amer).Mcl-1/Bim/CD127phenotypeofHCV-specificCTLswas
tested by staining detectable CD8+/pentamer+ cells with anti-
Mcl-1/Bim/CD127 antibodies. HCV-specific CTL proliferation
ability after specific in vitro challengewas tested in thepresence
and absence of pancaspase inhibitor z-VAD-fmk. All stained
cells were analysed by flow cytometry. CD127low-expressing
HCV-specific CTLs associated with high HCV viraemia, while
CD127high correlated with undetectable viral loads
(P < 0.001). Directly ex vivo, pentamer+ cell frequency was
similar according to CD127 expression level. Nevertheless,
CD127low pentamer+ cell proliferation after specific in vitro
challenge was impaired (P < 0.05), although this was cor-
rected by z-VAD-fmk treatment (P < 0.05). Mcl-1 expression
was low directly ex vivo (P < 0.01), and Bimwas up-regulated
after antigen encounter (P < 0.05) of CD127low pentamer+
cells. The ex vivo difference betweenMcl-1 and Bim expression
on pentamer+ cells correlated positively with CD127 expres-
sion level (P < 0.001) and with pentamer+ cell reactivity
(P < 0.05). In summary, a low ex vivo Mcl-1 expression and
Bim up-regulation after antigen encounter are involved in
CD127low HCV-specific CTL hyporeactivity during chronic
infection, but it can be overcome by apoptosis blockade.
Keywords: Bim, CD127, HCV-specific CTL, Mcl-1, T cell reac-
tivity, z-VAD-fmk.
INTRODUCTION
Hepatitis C virus (HCV) infection progresses to a chronic
disease in most cases and is a major cause of hepatic cir-
rhosis and hepatocellular carcinoma [1]. HCV-specific cyto-
toxic T lymphocytes (CTLs) play an important role in HCV
control during acute infection [2]. Unfortunately, during
chronic infection, the reactivity of these cells is impaired
after antigen encounter, preventing their effector functions
[3] and allowing the development of persistent liver inflam-
mation [4]. After natural or treatment-induced HCV control,
a peripheral population of HCV-specific CTLs is maintained.
These cells are characterized by IL-7 receptor (CD127)
expression [5] and are able to control residual HCV traces
after clinical disease control [6] and to respond faster to a
new infection [7].
CD127 plays an essential role in mature lymphocyte
survival by counteracting the induction of apoptosis after
antigen encounter through regulation of some of the B cell
lymphoma 2 (Bcl-2) proteins, enhancing IL-2 secretion and
life span [8]. Therefore, HCV could modulate CD127
expression on HCV-specific CTLs to impair the quality of the
adaptive immune response by IL-7 deprivation, as a survival
strategy [5,9]. Passive T cell death, or death by cytokine
deprivation, is controlled by members of the Bcl-2 family,
such as Bim and Mcl-1. In experimental models, Bim carries
Abbreviations: ALT, alanine aminotransferase, Bcl-2, B cell lym-
phoma 2, CTL, cytotoxic T lymphocyte; HCV, hepatitis C virus; IFN,
c-interferon; IQR, interquartile range; MFI, mean fluorescence
intensity; PBL, peripheral blood lymphocytes; TGF, transforming
growth factor.
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out a pro-apoptotic role in intrahepatic T cells that is
counteracted by the Mcl-1 action [10,11]. Interestingly, a
role of Bim level on HCV-specific CTL reactivity, according to
CD127 expression, has been suggested recently by our group
but this pathway has not been described in depth [5]. In this
article, the correlation between CD127 expression on HCV-
specific CTLs and the Mcl-1/Bim phenotype and their effect
on T cell reactivity were analysed.
PATIENTS, MATERIAL AND METHODS
Patients
In this cross-sectional study, peripheral blood lymphocytes
(PBL) from 24 consecutive HLA-A2+ HCV+ genotype-1
subjects, previously known to have directly ex vivo HCV-
specific CTLs against one or two different HCV-NS3 immu-
nodominant epitopes, were obtained between January 2007
and August 2011 at Guadalajara University Hospital, Spain.
From these cases, 33 different HCV-specific CTL populations
were isolated; 20 of them specific against NS31406–1415 and
another 13 specific against NS31073–1081. These samples
were split into two groups according to CD127 expression
level on HCV-specific CTLs. The patients! clinical and viro-
logical features, regarding these two CD127 groups, are
shown in Table 1. Other causes of liver disease were
excluded. In all recruited patients, serum samples to test
HCV viral load and alanine aminotransferase (ALT) level and
heparinized blood samples to obtain PBL were taken. HCV
genotype data were obtained from the patients! clinical
records. The study protocol was approved by the Regional
Ethical Committee, and patients gave written informed
consent before enrolment.
Tissue typing
Screening for the HLA-A2 haplotype was performed by
staining PBL with fluorescein isothiocyanate (FITC)-conju-
gated anti-HLA-A2 monoclonal antibody (mAb; BD Biosci-
ence, Franklin Lakes, NJ, USA) and subsequent flow
cytometric analysis.
Virological assessment
Anti-HCV was determined by Ortho HCV version 3.0 ELISA
Test (Ortho Diagnostic System, Raritan, NJ, USA). HCV-RNA
load was assessed by a quantitative real-time-PCR assay
with a lower detection limit of 40 IU/mL (Cobas Amplicor
HCV Monitor 2.0; Roche, Indianapolis, IN, USA). HCV
genotype was tested by InnoLiPPA HCV II assay (Innogen-
tics Inc, Alpharetta, GA, USA).
Synthetic peptides and pentamers
A2-restricted peptides corresponding to the genotype-1
NS31406–1415 region (KLVALGINAV), NS31073–1081 region
(CINGVCWTV) and Phycoerithrin-conjugated (PE-conjugated)
HLA-A2 pentameric complexes (pentamer) loaded with the
same two NS3 peptides were purchased from ProImmune
(Oxford, UK).
CD8+/pentamer+ cell quantification
Peripheral blood lymphocytes were purified from heparinized
blood samples through a Ficoll-Hypaque gradient. To
quantify HCV-specific CD8+ cells, 0.5–1 · 106 PBL were
incubated for 10 min at 37 !C with 1 lg of PE-labelled
pentamers in RPMI 1640 plus 10% fetal calf serum (FCS).
Cells were washed in phosphate buffer saline plus 1% FCS
and then incubated at 4 !C for 20 min with saturating
concentrations of directly conjugated anti-CD8-Pe-Cy5 (Cy)
mAb (RD Systems, Minneapolis, MN, USA). Subsequently,
after washing, stained cells were analysed on a Becton
Dickinson FACS" using CELLQuest# software (BD Bios-
ciences, San Jose, CA, USA). HCV-specific CTL quantification
was expressed as the percentage of CD8+/pentamer+ cell out
of the total CD8+ cells. The lowest percentage at which
pentamer-binding CD8+ cells could be detected as a separate
cell population was 0.018% out of the total CD8+ cells.
CD127 phenotypic analysis on CD8+/pentamer+ cell
Peripheral blood lymphocytes were stained with PE-penta-
mers plus anti-CD8-Cy and FITC-conjugated anti-CD127
Table 1 Clinical and virological features of the HCV-specific




N = 19 P value*
Age (years old) 44 (4) 46 (15) NS
Sex (M/F) (%) 78/22 77/23 NS
Diagnosis (%)




24 (6) 29 (24) NS
ALT (IU/mL) 40 (31) 72 (82) <0.001
HCV viral load (IU/mL)
(log scale)
1.6 (0.8) 6.06 (0.96) <0.001




CHC, chronic hepatitis C; CTL, cytotoxic T lymphocyte;
F, female; HCV, hepatitis C virus; M, male; N, number of
samples; NS, nonsignificant; SVR, sustained virologic
response.
*Mann–Whitney U test.
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(Ebioscience, Hatfield, UK) mAbs as above. Subsequently,
stained cells were analysed by flow cytometry. Isotype-mat-
ched control mAbs were used to set the markers. CD127
phenotype was quantified on pentamer+ cells as the mean
fluorescence intensity (MFI). Based on our previous report [5],
CD8+/Pentamer+ cells were classified into two groups
according to the anti-CD127-FITC mAb MFI level (CD127high
group: MFI ‡ 20 units; CD127low group: MFI < 20 units).
Production of T cell lines
Peripheral blood lymphocytes were re-suspended at a con-
centration of 1 · 106/mL in complete medium plus 10%
FCS. Cells were stimulated with 1 lM of one of the two NS3-
specific peptides, NS31406–1415 and NS31073–1081, in a
96-well plate. Recombinant IL-2 (25 IU/mL) (RD Systems)
was added at the beginning and on day 2 of culture, and
cells were analysed after a total of 10 days of culture. PBL
were also cultured in the presence of either the pancaspase
inhibitor zVAD-fmk (50 lm) (BD Bioscience, San Jose, CA,
USA), or b-galactosidase (2 lg/mL) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) as control. Expansion was
considered positive when a pentamer-binding CD8+ cell
population, in a cluster shape, bigger than base line and
higher than 0.2% of the total CD8+ cells was observed after
specific stimulation for 10 days.
Intracellular Bim/Mcl-1 staining
Pentamer+/CD8+ T cells were surface-stained with PE-pen-
tamers and CD8-Cy mAb as above. After a further wash,
cells were subjected to intracellular staining using Cytofix-
Cytoperm (BD Bioscience) to permeabilize and fix cells
according to the manufacturer!s instructions, followed by
staining with Bim unconjugated rabbit anti-human poly-
clonal Ab (Cell Signaling, Boston, MA, USA), Mcl-1 uncon-
jugated rabbit anti-human mAb (Epitomics, Burlingame, CA,
USA) and its matched controls, plus the secondary mAb,
goat anti-rabbit IgG Alexa-Fluor 488 (Invitrogen, Grand
Island, NY, USA). Finally, cells were washed twice and
analysed by flow cytometry. Data were expressed as Alexa-
Fluor 488 MFI on gated pentamer+/CD8+ cells. The absolute
value of Alexa-Fluor 488 MFI for Mcl-1 and Bim staining
and the difference between these two values were compared
according to CD127 expression level, and correlated with
pentamer+/CD8+ cell reactivity. The cut-off for Mcl-1/Bim
positive staining was set according to the mean plus 2
standard deviations of the MFI observed with the matched
control stainings.
Intracellular c-interferon (IFN) staining
Peripheral blood lymphocytes were in vitro challenged with
NS31406–1415 peptide, for 5 h at 37 !C seeded at
1 · 106 cells/mL in RPMI 1640, plus 10% FCS, in the
presence of Brefeldin A (10 lg/mL; Sigma-Aldrich Inc, St.
Louis, MO, USA), during the last 4 h of incubation. Cells
were washed and surface-stained with PE-pentamers as
above. After a further wash, cells were subjected to intra-
cellular staining using Cytofix-Cytoperm (BD Bioscience) to
permeabilize and fix cells, followed by staining with FITC-
conjugated anti-IFN mAb and its isotype-matched control
(Pharmingen BD, San Jose, CA). Finally, cells were washed
twice and analysed by flow cytometry. c-IFN data are shown
as the percentage of c-IFN-producing pentamer+ cells out of
the total pentamer+ cells.
Statistical analysis
Continuous and categorical variables are summarized as
median plus interquartile range (IQR) and as frequency
distribution, respectively. Mann–Whitney U, Wilconxon and
Spearman tests were employed where appropriate. All the
tests were two-tailed and with a significance level of
P < 0.05.
RESULTS
Viral replication and liver damage according to CD127
expression on pentamer+ cells
Thirty-three different pentamer+ populations from 24 HLA-
A2+ HCV+ genotype-1 patients, with directly ex vivo
detectable pentamer+ cells, were recruited for this study. In
20 cases, NS31406–1415 pentamer
+ cells were observed,
while this was the case in 13 NS31073–1081 pentamer
+ cell
patients. All the phenotypic results, obtained with the two
different pentamers tested, were pooled into the same
variable for statistical analysis. Samples were split into two
groups according to CD127 expression level, as shown in
Patients, Material and Methods. Both CD127 groups were
similar with respect to patient!s age, disease evolution time
and sex distribution (Table 1). CD127high samples belonged
to patients with undetectable or low viral load, and low
ALT level, while CD127low HCV-specific CTLs associated
with high viral load and high ALT serum concentration
(P < 0.001) (Table 1 and Fig. 1). In fact, most patients
with CD127high-expressing pentamer+ cells were sustained
virologic responders, tested at least 6 months after finish-
ing standard anti-HCV treatment, while CD127low-
expressing cells were mainly present in naı̈ve chronic
hepatitis C patients (Table 1). The CD127 expression on
pentamer+ cells in the CD127low group was almost three
times lower (MFI, 13.90; IQR, 8.37) than in the CD127high
group (MFI, 34.59; IQR, 10.02) (P < 0.001; Figs 1 and 4)
and similar to the MFI observed with the isotypic control
staining (MFI, 5.60; IQR, 4.30) (P > 0.05). This difference
was antigen specific, because in both groups a similar
CD127 expression on total CD8+ cells was observed
(Fig. 1).
" 2012 Blackwell Publishing Ltd
Mcl-1/Bim and HCV-specific CTL reactivity 3
Reactivity of pentamer+ cells according to CD127
expression level
To test whether a low CD127 expression level could affect
HCV-specific CTL reactivity after antigen encounter because
of apoptosis activation, in ten cases of each group the pro-
liferation ability of pentamer+ cells after specific in vitro
challenge, in the presence of either a pancaspase inhibitor
(z-VAD-fmk) or b-galactosidase as control, was analysed.
Directly ex vivo, the peripheral frequency of pentamer+ cells
out of the total CD8+ cells was very low and similar in both
groups; CD127low: 0.05% (IQR, 0.09) and CD127high: 0.04%
(IQR, 0.05) (P > 0.05, Figs 2 and 3). Nevertheless, the fre-
quency of pentamer+ cells, after stimulation with the specific
peptides for 10 days without z-VAD-fmk treatment, was
higher in the CD127high than in the CD127low-expressing
pentamer+ cells. The median frequency of pentamer+ cells
was 1.7% (IQR, 6.77) in the CD127high group while it was
only 0.003% (IQR, 2.9) in CD127low group (P < 0.05,
Figs 2 and 3). Moreover, considering a positive proliferation
as a cluster of pentamer+ cells higher than 0.2% out of the
total CD8+ cells, only in 30% of the CD127low cases prolif-
eration was observed, while 80% of samples did proliferate in
the CD127high group (P < 0.05, Fig. 3). Nevertheless,
CD127low-expressing pentamer+ cells improved in prolifera-
tion ability after specific stimulation in the presence of
z-VAD-fmk treatment (1.39%; IQR, 13.2) with respect to the
observed expansion without this pancaspase inhibitor
(P < 0.05, Figs 2 and 3), reaching a similar expansion level
to the CD127high group (4.5%; IQR, 6.25) (P > 0.05, Figs 2
and 3). z-VAD-fmk treatment also raised nonsignificantly the
proliferation capacity of CD127high-expressing cells
(P > 0.05, Figs 2 and 3). Furthermore, in the CD127low
group, the percentage of experiments with pentamer+ cell
proliferation increased after z-VAD-fmk treatment up to 80%

























































































































































































Fig. 1 Liver damage and viral control according to CD127 expression on hepatitis C virus (HCV)-specific cytotoxic T cells. (a)
Box plots showing serum ALT (IU/mL) and viral load (IU/mL) levels according to the CD127 expression on HCV-specific
cytotoxic T cells (pentamer+/CD8+ cells). (B) Representative FACS! dot plots and MFI histograms of peripheral T cells stained
with labelled mAb against CD8 and CD127 and with pentameric HLA-A2/peptide PE-labelled complexes against NS31406 and
NS31073 HCV epitopes from cases with different degrees of liver damage and viral control. The figure on the upper left corner
of the FACS! dot plots for pentamer/CD8 staining shows the frequency of pentamer+ cells out of the total CD8+ cells. FACS!
histograms are gated on pentamer+ and pentamer- CD8+ cells. The dashed line in the histograms represents the upper limit of
the staining with the isotypic control. (c) Box plots showing the directly ex vivo CD127 MFI on total CD8+ and pentamer+ cells
in the two groups of the study. §Mann–Whitney U test. ¤Wilconxon test. ID, patient identification; MFI, mean fluorescence
intensity; n, number of cases; PBL, peripheral blood lymphocytes. *Outlier values.
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observed in the CD127high group (P > 0.05) (Fig. 3). Inter-
estingly, CD127 expression decreased significantly after
specific in vitro stimulation of CD127high-expressing pent-
amer+ cells (P < 0.001) to a similar level (MFI, 8.05; IQR,
5.90) to the one observed directly ex vivo in the CD127low
group (Figs 3 and 4).
c-Interferon production by pentamer+ cells according to
CD127 phenotype
Directly ex vivo c-IFN-producing pentamer+ cells were
analysed in 11 cases (5 CD127high and 6 CD127 low). The
frequency of c-IFN-producing pentamer+ cells was lower in
the CD127low (40%; IQR, 32) than in the CD127high group
(61%; IQR, 13.5) (P < 0.05, Fig. 3).
Mcl-1 and Bim expression according to CD127 phenotype
After the demonstration of impaired reactivity on CD127low
pentamer+ cells with regard to apoptosis induction, two Bcl-
2 family protein phenotypes, involved in the extrinsic
apoptosis pathway, were analysed on 28 populations of
pentamer+ cells to see whether those phenotypes could
explain the different T cell reactivity according to CD127
level. Bim and Mcl-1 MFI on gated CD8+ pentamer+ cells,








































































































































































































































































Fig. 2 Bim and Mcl-1 expression directly ex vivo and after specific stimulation on peripheral CD8+/pentameter+ cells according
to CD127 level. Representative FACS! dot plots and mean fluorescence intensity (MFI) histograms showing the Mcl-1 and Bim
expression on peripheral CD8+/pentamer+ cells, directly ex vivo and after specific in vitro challenge, with regard to the CD127
expression level on those cells. Peripheral blood lymphocytes were subjected to specific in vitro challenge in the presence of
z-VAD-fmk and b-galactosidase as control. The figure on the top of the dot plots represents the frequency of pentamer+ cells
out of the total CD8+ cells. The figure in the upper right corner in the histogram plot represents the MFI for Bim and
Mcl-1 staining. The continuous and dashed line in the dot plots and histograms represent the cut-off point for positive
staining according to the negative control. IC, isotypic control; ID, patient identification; N.D., not done because of lack of
pentamer+/CD8+ proliferation after specific stimulation.
" 2012 Blackwell Publishing Ltd
Mcl-1/Bim and HCV-specific CTL reactivity 5
molecules, were calculated. A value was considered positive
when it was higher than the MFI mean plus 2 standard
deviations obtained from the pool of pentamer+ cell staining
with the isotypic Ab control (Cut-off level: 90 unit of fluo-
rescence). Directly ex vivo, Bim expression on peripheral
pentamer+ cells was similar on CD127low pentamer+ (MFI,
79.19; IQR, 117.60) and on CD127high-expressing cells
(MFI, 156.20; IQR, 136.01) (P > 0.05, Figs 2 and 4). Nev-
ertheless, directly ex vivo Mcl-1 expression was significantly
lower on CD127low pentamer+ (MFI, 172.80; IQR, 119.57)
than on CD127high-expressing cells (MFI, 278.92; IQR,
266.65) (P < 0.01, Figs 2 and 4). These data translated into
a significant positive correlation between CD127 expression
and Mcl-1 level on peripheral pentamer+ cells (r = 0.426,
P < 0.05), while no significant correlation between CD127
and Bim expression was observed (P > 0.05) (Fig. 4). These
findings were antigen specific because in both study groups a
similar directly ex vivo Mcl-1/Bim expression on total CD8+
cells was observed (Fig. 4). Bearing in mind that Mcl-1 could













































































































































































































































































































Fig. 3 Reactivity of CD8+/pentamer+ cells according to CD127 expression level. (a) Box plots showing the frequency of CD8+/
pentamer+ cells directly ex vivo and after specific in vitro challenge in the presence of either z-VAD-fmk or b-galactosidase as
control in high and low CD127-expressing pentamer+ cells. (b) (b.1) Representative FACS! dot plots and mean fluorescence
intensity (MFI) histograms showing directly ex vivo c-interferon (IFN) production on pentamer+ cells according to CD127
expression. (b.2) Box plots showing the percentage of IFN-producing pentamer+ cells, in relation to CD127 expression level.
The figure in the upper right corner in the histogram plot represents the MFI for IFN staining. (c) Bar plots showing the
percentage of experiments with CD8+/pentamer+ cell proliferation after specific in vitro challenge in the presence of either
z-VAD-fmk or b-galactosidase as control, with regard to CD127 expression level. Positive proliferation was considered when
more than 0.2% of CD8+/pentamer+ cells in a clear cluster were observed after specific stimulation. (d) Representative FACS!
dot plots and MFI histograms from CD127high-expressing pentamer+ cells, with CD127 expression on CD8+/pentamer+ cells
directly ex vivo and after specific in vitro challenge. *Wilconxon test. §Mann–Whitney U test. LOD, limit of detection; MFI,
mean fluorescence intensity; n, number of cases; n.s., nonsignificant; O, outliers.
" 2012 Blackwell Publishing Ltd
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Bim level on pentamer+ cells was calculated by subtracting
Mcl-1 Alexa-Fluor 488 MFI level to the MFI observed for Bim
staining. This calculated variable showed a high significant
positive correlation with CD127 expression on pentamer+
cells (r = 0.648, P < 0.001, Fig. 4). In fact, the difference
between Mcl-1 and Bim expression was almost four times
higher on CD127high-expressing pentamer+ cells (difference,
110.74; IQR, 267.57) than on CD127low cells (difference,
32.50; IQR, 99.54) (P < 0.01). The excess of Mcl-1
expression, regarding Bim levels, was also higher in pent-
amer+ cells with proliferation ability after antigen encounter
(difference, 239.57; IQR, 308.68) than in cells without
reactivity (difference, 52.71; IQR, 102.60) (P < 0.05,
Fig. 4), showing a similar profile to the CD127 level, as far as
expansion capacity was concerned. Thus, pentamer+ cells
with proliferation ability expressed a higher CD127 level
(MFI, 29.36; IQR, 22.85) and a higher Mcl-1/Bim expression
difference than pentamer+ cells without expansion potential,
characterized by a low CD127 expression (MFI, 16.80; IQR,
22.85) (P < 0.05, Fig. 4).
To further analyse whether T cell receptor (TCR)/HLA-I-
peptide engagement could influence Mcl-1/Bim imbalance,
according to CD127 expression level, the Mcl-1/Bim/CD127
phenotype, after specific in vitro challenge in the presence of
z-VAD-fmk, was also tested and compared between both
CD127 expression groups. To study Bim and Mcl-1 expres-
sion after Ag encounter on CD127low-expressing pentamer+
cells, z-VAD-fmk was used to ensure the proliferation of these
cells. After CD127high-expressing pentamer+ cell specific




































































































































































































































































































Fig. 4 Mcl-1 and Bim expression on CD8+/pentamer+ cells according to CD127 expression level and their relationship with
CD8+/pentamer+ cell reactivity after antigen encounter. (a) (a.1) Box plots showing the MFI for CD127, Mcl-1 and Bim
staining on peripheral CD8+/pentamer+ cells directly ex vivo and after specific in vitro challenge, blocking apoptosis, according
to CD127 expression level. (a.2) Box plots describing the directly ex vivo Mcl-1/Bim expression on total CD8+ cells in the two
groups of the study. (b) Scatter plots showing the correlation between CD127 expression on CD8+/pentamer+ cells and Mcl-1/
Bim expression on peripheral CD8+/pentamer+ cells. (c) Scatter plot showing the positive correlation between the Mcl-1/Bim
expression subtraction and CD127 expression level on peripheral CD8+/pentamer+ cells. (d) Box plots describing the CD127
expression level and Mcl-1/Bim expression difference on peripheral CD8+/pentamer+ cells with regard to their reactivity after
antigen encounter. §Wilconxon test. *Mann–Whitney U test. !Spearman"s correlation coefficient. MFI, mean fluorescence
intensity; n, number of cases; n.s., nonsignificant; O, outliers.
! 2012 Blackwell Publishing Ltd
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(P < 0.01) to a similar level to the one observed on
CD127low cells, as previously commented, in association
with Mcl-1 down-regulation (MFI, 134.57; IQR, 106.04)
(P < 0.05), which reached the level described on CD127low
cells but without Bim expression change (MFI, 121.04; IQR,
79.04) (P > 0.05) (Figs 2 and 4). On the other hand, in
CD127low-expressing pentamer+ cells, CD127 expression
was maintained at low levels after specific in vitro challenge
(MFI, 11.28; IQR, 8.26) (P > 0.05), and Mcl-1 expression
was not modified (MFI, 199.23; IQR, 177.95), but interest-
ingly, Bim expression was significantly up-regulated (MFI,
191.08; IQR, 147.87) (P < 0.05) to a significantly higher
level than the one expressed by CD127high-expressing pent-
amer+ cells (P < 0.05) (Figs 2 and 4). These data suggest
that Bim expression can be up-regulated only after TCR
triggering in cells with low CD127 expression.
DISCUSSION
Hepatitis C virus-specific CTLs are essential effector tools to
control HCV infection, but they are anergic and prone to
apoptosis during persistent infection [5,12]. This phenome-
non may be related to a high activation of these cells during
persistently elevated viraemia during chronic HCV infection
[13,14]. In fact, upon continued antigenic stimulation,
CD8+ T cells lose their effector function and are selectively
deleted, resulting in failure to achieve viral clearance, and
this fact correlates with CD127 down-regulation [15]. This
could be a physiological strategy by the host to avoid
immune-mediated injury during chronic infection. There-
fore, in persistent HCV infection, peripheral HCV-specific
CTLs could acquire an exhausted phenotype to avoid a
harmful immune response. Subsequently, these cells cannot
withstand further activation in the liver after antigen
re-encounter, leading to selective T cell deletion.
The procedure of T cell death during chronic viral infec-
tion is determined by a carefully balanced and complex
group of pro- and anti-apoptotic proteins of the Bcl-2 family,
such as Bim and Mcl-1 [10]. Bim is clearly involved in int-
rahepatic-specific CTL apoptosis in animal models [16]. Bim
is thought to act principally by activating Bax, permitting
mitochondrial release of cytochrome c, which activates
caspases, ultimately leading to cell death [10]. Expression of
Bim is up-regulated in human T cells in response to TCR
triggering by the protein kinase C (PKC) and calcineurin
pathways [17]. Nevertheless, there are other mechanisms
involved in Bim up-regulation during chronic infection, such
as the effect of certain cytokines. IL-7 withdrawal could in-
duce Bim-mediated apoptosis. In fact, in a persistent viral
infection animal model, Bim-mediated apoptosis correlates
with low IL-7 receptor expression on specific T cells [18].
Transforming growth factor (TGF)-b is also involved in Bim-
mediated apoptosis [19]. Therefore, all these data indicate
that Bim action is not only modulated through TCR stimu-
lation, but also by other regulatory mechanisms such as
either IL-7 withdrawal or TGF-b induction. Interestingly,
persistent HCV infection is characterized by continuous TCR
triggering and CD127 down-regulation on HCV-specific
CTLs [12], which could favour, so far, Bim up-regulation. In
our work, Bim was up-regulated on CD127low-expressing
HCV-specific CTLs but not on CD127high cells after antigen
encounter, suggesting that TCR triggering can only lead to
Bim up-regulation in the absence of IL-7 stimulation on
HCV-specific CTLs. Nevertheless, Bim level is not enough to
lead to T cell apoptosis. T cell death also depends on the anti-
apoptotic protein expression level, regulated by cytokines,
such as IL-7. Regarding this, the Bim pro-apoptotic effect is
blocked by the action of the Bcl-2 family of anti-apoptotic
proteins such as Mcl-1 and Bcl-2 [20,21]. Interestingly, in
an experimental model, IL-7 deprivation during stressing
conditions leads to Mcl-1 down-regulation on T cells, leading
to T cell death that could be avoided by IL-7 treatment [22].
In agreement with this experimental model, our ex vivo data
show that during persistent HCV infection the predominant
peripheral population of HCV-specific CTLs displays a
CD127low/Mcl-1low phenotype that remains low after anti-
gen encounter. All in all, these Mcl-1/Bim data could mean
that during chronic HCV infection, experienced CD127low/
Mcl-1low-expressing T cells attracted to the liver would
up-regulate Bim expression after antigen encounter because
of the absence of IL-7 stimulus, and subsequently Bim would
be released freely to activate Bax, because of the low level of
anti-apoptotic proteins such as Mcl-1. Consequently, CD127
level would play a central role in HCV-specific CD8+ T cell
apoptosis by regulation of Mcl-1 expression in vivo and by
Bim modulation after antigen encounter. This theory could
explain why CD127low HCV-specific CD8+ T cell reactivity
from chronic hepatitis C patients is impaired, and theoreti-
cally this could be overcome by apoptosis blockade. To test
this hypothesis, the correlation between CD127 phenotype,
T cell reactivity and Bim/Mcl-1 phenotype on HCV-specific
CTLs after apoptosis blockade was tested in this study.
In this work, directly ex vivo HCV-specific CTLs from a
cohort of patients with different degrees of viral control were
obtained. In patients with either low or undetectable viral
load, a population of peripheral CD127high-expressing cells
able to proliferate and to produce c-IFN after antigen
encounter was observed. Theoretically, this population could
control HCV traces or be ready for a rapid response in the
case of re-infection [6,7]. These cells were characterized by a
higher Mcl-1 expression than the observed Bim level, which
could be responsible for maintaining T cell reactivity,
avoiding apoptosis activation after antigen encounter.
Interestingly, these CD127-expressing cells from resolver
patients down-regulated CD127 expression after specific
in vitro challenge, linked to Mcl-1 down-regulation, without
Bim expression up-regulation, acquiring an in vitro pheno-
type after expansion similar to the one observed in directly
ex vivo cells from chronic patients. Therefore, these cells
could be prone to apoptosis after re-stimulation, mimicking
! 2012 Blackwell Publishing Ltd
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the situation found in persistent infection. On the other
hand, in cases with persistent high viral load, HCV-specific
CTLs showed a CD127low phenotype that correlated with
proliferation and c-IFN production impairment. This phe-
notype linked with a directly ex vivo low Mcl-1 expression,
similar to Bim levels that could allow apoptosis activation
after Bim up-regulation. Actually, after specific in vitro TCR
triggering, Bim up-regulation on CD127low-expressing HCV-
specific CTLs was observed. This finding was previously
shown by our group [5], and it did not occur on CD127high-
expressing cells, as previously commented. In an experi-
mental model, a similar observation was made showing that
Bim was a critical mediator of apoptosis, induced by TCR re-
stimulation, in the context of growth cytokine withdrawal
[23]. Therefore, we could speculate that CD127 low
expression on HCV-specific CTLs during persistent infection
could favour Mcl-1 down-regulation on these cells, leading
to apoptosis after antigen encounter, when Bim expression is
up-regulated on HCV-specific CTLs, and Mcl-1 low level is
unable to block Bim activity. In fact, the difference between
Mcl-1 and Bim expression was significantly lower in
CD127low-expressing HCV-specific CTLs than in CD127high
cells, and this correlated with T cell reactivity. These findings
were antigen specific, because no difference in Mcl-1/Bim
expression on total CD8+ cells between the study groups was
observed. Therefore, assuming that Mcl-1/Bim imbalance
could be involved in the hyporeactivity of CD127low-
expressing HCV-specific CTLs through apoptosis activation,
CD127low HCV-specific CD8+ T cell reactivity rescue was
attempted by interfering with caspase activity. Interestingly,
CD127low HCV-specific CD8+ T cell treatment with a pan-
caspase inhibitor restored T cell reactivity to a similar range
to the one observed in CD127high HCV-specific CD8+ T cells
from most HCV-resolved infection cases. These data sug-
gested a link between apoptosis after TCR triggering and low
CD127 expression on experienced HCV-specific CTLs during
persistent infection that could be related to Mcl-1/Bim
imbalance.
Bearing in mind these results, at least theoretically, ther-
apeutic apoptosis blockade could help to restore the prolif-
eration capacity of CD127low/Mcl-1low/Bimhigh HCV-specific
CD8+ T cells after antigen encounter in chronic hepatitis C
patients. This strategy could be a useful tool to try to
improve the response to standard of care in chronic HCV
patients. So far, the common calceneurin inhibitor cyclo-
sporine-A has been shown to prevent T cell deletion through
blocking Bim up-regulation [17]. Considering the in vitro
HCV-specific CTL restoration, using the pancaspase inhibitor
z-VAD-fmk, a drug as cyclosporine-A with a similar effect,
but commonly used in some human diseases, could be em-
ployed in combination with anti-viral treatments to enhance
the immune adaptive response. Another possible strategy to
restore HCV-specific CTL reactivity during chronic infection
could be the administration of IL-7, in order to increase the
stimulation of the reduced number of IL-7R molecules on
HCV-specific CTLs to modulate the balance between Bim and
Mcl-1. In fact, in an animal model of cytotoxic T cell
exhaustion, IL-7 treatment resulted in an increased T cell
effector function and viral clearance [24].
In summary, this work suggests for the first time that
CD127 phenotype modulates Bim and Mcl-1 expression on
HCV-specific CTLs, and this affects T cell reactivity through
apoptosis regulation. Specifically, during chronic infection,
Mcl-1/Bim imbalance could be involved in CD127low HCV-
specific CTL hyporeactivity, but it could be overcome by
pancaspase inhibition.
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a b s t r a c t
PD-1 molecule promotes anergy and IL-7 receptor (CD127) induces an anti-apoptotic effect on T cells.
Correlation between PD-1/CD127 phenotype and hepatitis C virus (HCV)-specific CD8+ cell reactivity in
resolved infection (RI) after treatment and persistent HCV-infection (PI) was analysed. Directly ex vivo,
PD-1 and CD127 expression on HCV-specific CD8+ cells displayed a positive and negative correlation,
respectively with viraemia. Proliferation after stimulation on PD-1!/CD127+ cells from RI cases was pre-
served, while it was impaired on PD-1+/CD127! cells from PI patients. PD1+/CD127+ population was
observed in PI, and these maintained expansion ability but they did not target the virus. Frequency of
PI cases with HCV-specific CD8+ cell proliferation increased after anti-PD-L1 and anti-apoptotic treat-
ment. Bim expression on HCV-specific CD8+ cells from PI patients was enhanced. In conclusion, during
chronic HCV infection non-reactive HCV-specific CD8+ cells targeting the virus are PD-1+/CD127!/Bim+
and, blocking apoptosis and PD-1/PD-L1 pathway on them enhances in vitro reactivity.
! 2011 Elsevier Inc. All rights reserved.
1. Introduction
Hepatitis C virus (HCV) infection is often associated with persis-
tent viraemia and progressive liver disease [1]. HCV-specific cyto-
toxic T lymphocytes (CTL) play a major role in spontaneous
infection resolution. Nevertheless, during chronic infection these
cells lack adequate effector functions and fail to control HCV [2].
Appropriate activation of experienced virus-specific CTL de-
pends on the engagement between T cell receptor (TCR) and
HLA-I/epitope complex [3] plus interaction between positive co-
stimulatory molecules and their ligands [4]. These cells after
developing their effector action, express negative co-stimulatory
molecules, such as programmed death-1 (PD-1), to switch-off their
activity [5]. Engagement of PD-1 and its ligand (PD-L1) delivers a
negative signal avoiding proliferation and interleukin (IL)-2 pro-
duction [6]. On the other hand, IL-7 receptor (CD127) plays an
essential role in mature lymphocyte survival by counteracting
the induction of apoptosis after antigen encounter through
myeloid cell leukemia sequence-1 (Mcl-1) expression and Bcl2-
interacting mediator (Bim) down-regulation, enhancing IL-2 secre-
tion and life span [7].
HCV infection could modulate these two molecules to impair
HCV-specific CTL reactivity through induction of either a virus-
associated tolerogenic-like state or apoptosis. PD-1+/CD127! phe-
notype associated with anergic features and apoptosis in chronic
hepatitis C has been shown [8–10]. Nevertheless, HCV-specific
CTL reactivity after antigen encounter in a proportion of HCV per-
sistent infection cases are also maintained [11,12]. In this study the
effect of PD-1/CD127 phenotype on HCV-specific CTL reactivity
after antigen recognition according to viral control was analysed
and the effect of modulating these molecules was tested.
2. Patients and methods
2.1. Patients
In this cross-sectional study ninety-four consecutive HLA-A2+
subjects with genotype-1 HCV infection were recruited between
January-2007 and August-2010 at Guadalajara University Hospital
and ‘‘Fundación Jiménez Díaz’’ Hospital, Spain. These patients were
divided into two groups according to their serum HCV-RNA and
0008-8749/$ - see front matter ! 2011 Elsevier Inc. All rights reserved.
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alanine transaminase (ALT) levels at the time of investigation; 76
patients with ALT > 40 IU/mL and HCV-RNA > 1000 IU/mL [hereaf-
ter indicated as persistent infection (PI)] (12 relapsers, 10 non-
responders after anti-HCV treatment and 54 naïve) and 18 subjects
with ALT < 40 IU/mL and HCV-RNA < 40 IU/mL, persistently main-
tained after developing sustained virologic response (SVR) subse-
quent to anti-HCV treatment [hereafter indicated as resolved
infection (RI)] (Table 1). Other causes of chronic liver disease were
excluded. 10 HLA-A2! HCV infected patients were taken as con-
trols. In all recruited patients a serum and heparinised blood sam-
ples were taken. In treated patients, samples were taken 24 weeks
after stopping treatment and in naïve patients at enrollment. All
treated patients received treatment with pegylated interferon
alfa-2b (1.5 ug/kg/week) and ribavirin (800–1400 mg/day) for
48 weeks following the standard stopping rules [13]. In nineteen
PI patients and pre-treatment in all RI cases a liver biopsy was also
performed. The study protocol was approved by the Regional Eth-
ical Committee and patients gave written informed consent before
enrolment.
2.2. Tissue typing
Screening for the HLA-A2 haplotype was performed by staining
PBMC with FITC-conjugated anti-HLA-A2 mAb (Incstar, Stillwater,
MN) and flow cytometric analysis.
2.3. Virological assessment
Anti-HCV was determined by Ortho HCV Version 3.0 ELISA Test
(Ortho Diagnostic System, Raritan, NJ). HCV-RNA load was assessed
by a quantitative real-time-PCR assay with a lower detection limit
of 40 IU/mL (Cobas Amplicor HCV Monitor 2.0 Roche, Indianapolis,
IN). HCV genotype was tested by InnoLiPPA HCV II assay (Innogen-
tics Inc., Alpharetta, GA).
2.4. Synthetic peptides and pentamers
A2-restricted peptides corresponding to the genotype-1
NS31406–1415 region (KLVALGINAV), NS31073–1081 region (CIN-
GVCWTV) and PE-conjugated HLA-A2 pentameric complexes (pen-
tamer) loaded with the same two NS3 peptides and with
cytomegalovirus (CMV) pp65495–504 (NLVPMVATV) peptide were
purchased from ProImmune (Oxford, UK).
2.5. CD8+/pentamer+ cell quantification
Peripheral blood (PBMC) and intrahepatic mononuclear cells
(IHMC) were purified from heparinised blood samples and biopsies
according to method described previously [14]. To quantify HCV-
specific CD8+ cells, 0.5–1 " 106 PBMC or a variable number of
IHMC were incubated for 10 min at 37 !C with 1 lg of PE-labelled
pentamers in RPMI 1640 plus 10% FCS. Cells were washed in PBS
and then incubated at 4 !C for 20 min with saturating concentra-
tions of directly conjugated anti-CD8-Pe-Cy5 (Cy) mAb, (Sigma–
Aldrich Inc., St. Louis, MO). Subsequently, stained cells were
analysed after washing on a Becton Dickinson FACS" using CELL-
Quest™ software. The cut-off for pentamer assay was determined
by staining intrahepatic and peripheral blood mononuclear cells
from 10 HLA-A2! PI patients. Using the mean plus 2 standard devi-
ations as the cut-off point, the lowest percentage at which penta-
mer-binding CD8+ cells could be detected as a separate cell
population was 0.018% out of total CD8+ cells.
2.6. PD-1/CD127 phenotypic analysis on CD8+/pentamer+ cell
In patients with proven pentamer+ cells, phenotypic analysis
was performed. PBMC and IHMC were triple stained with PE-
pentamers plus anti-CD8-Cy mAb as above and either FITC-conju-
gated anti-CD127 (Pharmingen BD, San Jose, CA) or anti-PD-1
(eBiosicience Inc., San Diego, CA) mAbs. Subsequently, stained cells
were analysed by flow-cytometry. Isotype-matched control mAbs
were used to set the markers for the different stainings. Different
phenotypes were quantified on pentamer+ cells as the mean fluo-
rescence intensity (MFI) for each staining, and compared between
the study groups. Phenotypes were performed directly ex vivo in
circulating and liver-infiltrating pentamer+ cells and after specific
in vitro challenge in the peripheral compartment. Depending on
the MFI, PD-1 and CD127 phenotypes were marked as: low (!),
intermediate (+) and high (++).
2.7. Production of T cell lines
PBMC were re-suspended at a concentration of 1 " 106/ml in
RPMI 1640 plus 10% FCS. Cells were stimulated with 1 lM of one
of these two NS3 specific peptides, NS31406–1415 and NS31073–1081,
in a 96-well plate. Recombinant IL-2 (25 IU/ml) was added on
day 2 of culture, and cells were analysed after a total of 10 days
of culture. After specific in vitro expansion, pentamer+ cell pheno-
type was again analysed as above. T cells from selected RI and PI
patients were also cultured in presence or absence of either anti-
PD-L1 blocking mAb (2 lg/mL) (Santa Cruz Biotechnology, Santa
Cruz, CA) or the pancaspase inhibitor zVAD-fmk (50 lM) (BD Bio-
science, San Jose, CA), using in both cases b-galactosidase (2 lg/
mL) (Santa Cruz Biotechnology, Santa Cruz, CA) as control. Expan-
sion was considered positive when a pentamer-binding CD8+ cell
population bigger than base line and higher than 0.04% out of total
CD8+ cells was observed after specific stimulation.
2.8. HCV-epitope sequencing
In PI patients with directly ex vivo NS31406–1415 or NS31073–1081-
pentamer binding CD8+ cells, epitope was sequenced in order to
test whether PD-1/CD127 phenotype could be affected by HCV se-
quence variation. Patients’ plasma were collected by centrifugation
in plasma preparation tubes and frozen immediately at !80 !C. To-
tal HCV-RNA was isolated using QIAamp Viral RNA Kit (Qiagen,
Germany) and, reverse transcribed. Subsequently, nested-PCR
Table 1






N! of patients (n) 18 76
SVR (n/%) 18 (100%) –
Relapser (n/%) – 12 (16%) –
Non responder (n/%) – 10 (13%) –
Naïve (n/%) – 54 (71%) –
HLA-A2 (%) 100 100 –
Age (years) 41 ± 7 47 ± 9.16 NS
Male sex (%) 70 68 NS
Evolution time (years) 24 ± 9 31 ± 12 NS
ALT (IU/L) 42.1 ± 19.2 92.8 ± 54.5 <0.001
Viral load (IU/mL) <40 2.12 ± 3.7 " 106 <0.001




1.82 ± 0.67! 1.97 ± 0.6 NS
Portal
activity
2.11 ± 0.56! 2.21 ± 0.6 NS
Fibrosis 1.14 ± 0.45! 1.8 ± 0.7 NS
Data are presented as either percentage or mean ± standard deviation. NS: non-
significant. SVR: sustained virologic response. ⁄Liver histology is described
according to Scheuer index. !Liver histology data just before anti-HCV treatment.
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amplification was carried out, using the NS3 primers described in
Table 2. A single band of the expected size was obtained. Final
PCR products were purified using GeneClean kit (Bio101, La Jolla,
CA) and, subsequently sequenced in an ABI PRISM! 377 DNA se-
quencer (Applied Biosystems Inc., Foster City, CA).
2.9. Intracellular Bim staining
Directly ex vivo and after specific in vitro challenge in presence
of zVAD-fmk, HCV-specific CD8+ T cells from selected RI and PI
cases were surface stained with PE-pentamers and CD8-Cy mAb
as above. After a further wash, cells were subjected to intracellular
staining using Cytofix-Cytoperm (BD Bioscience, San Jose, CA) to
permeabilise and fix cells according to the manufacturer’s instruc-
tions, followed by staining with Bim unconjugated Ab (Cell Signal-
ing Technology, Beverly, MA) plus goat anti-rabbit IgG2 Alexa 488
(Invitrogen, Carlsbad, CA) and its isotype-matched control (Pharm-
ingen BD, San Jose, CA). Finally, cells were washed twice and ana-
lysed by flow cytometry and expressed as MFI Bim-Alexa 488 on
CD8+/pentamer+ cells.
2.10. Statistical analysis
Categorical data are presented as either percentage or 95% con-
fidence interval for percentage (CIP) whereas continuous variables
are summarised as median plus interquartile range (IQR) or
mean ± standard deviation. Wilcoxon, Mann–Whitney-U and Pear-
son tests were employed where appropriate. Significance was
established at p < 0.05. Statistical analysis of frequency, phenotype
and proliferation of pentamer+ cells was performed pooling the re-
sults for the different epitopes tested in a single variable. For cor-
relation tests, HCV viral load and PD-1 MFI were log transformed
in order to make these variables follow a normal distribution.
3. Results
3.1. PD-1/CD127 expression on intrahepatic and circulating CD8+/
pentamer+ cells
Mononuclear cells from PI patients’ liver biopsies and periphe-
ral blood samples were studied. A portion of these cells were di-
rectly ex vivo double stained with anti-CD8-Cy mAbs and with
PE-pentamers to test the presence of HCV-specific CD8+ cells
against the two NS3 immunodominant epitopes studied. In 74%
and 89% of liver biopsies from PI patients, intrahepatic pentamer+
cells against NS31406–1415 and NS31073–1081 epitopes, respectively
were observed with a mean global percentage of 78% (22 out of
28 tests; 95% CIP: 60–91%), while only in 14–28% of PI patients,
according to the pentamer tested, there were cells in peripheral
blood also, with a mean percentage of 23% (23 out of 115 tests;
95% CIP: 12–25%) (Table 3). Therefore, an intrahepatic sequestra-
tion of pentamer-binding CD8+ cells was shown (p < 0.001; Table 3)
with a median intrahepatic frequency of 0.35% (IQR: 3.7) penta-
mer+ cells out of total liver-infiltrating CD8+ cells, while median
frequency of peripheral pentamer-binding CD8+ cells was 0.046%
out of total CD8+ cells (IQR 0.07), in the cases with detectable cells.
In patients with RI, the frequency of cases with detectable penta-
mer+ cells in peripheral blood was also very low, between 20%
and 22%, depending on the NS3 epitope tested, with a mean per-
centage of 21% (7 out of 33; 95% CIP: 7–35%), which was similar
to the one observed in PI (p = NS; Table 3). The median frequency
of peripheral pentamer-binding CD8+ cells in RI patients with
detectable cells was also low (0.056%; IQR: 0.05) and similar to
the frequency found in PI cases (p = NS; Table 3). In patients with
directly ex vivo detectable pentamer+ cells, mononuclear cells were
triple stained with PE-pentamers and anti-CD8-Cy mAb plus either
anti-PD1-FITC or anti-CD127-FITC mAbs. The PD-1 FITC MFI on
intrahepatic pentamer-binding cells was higher (++) (105; IQR:
94) than the MFI observed in peripheral blood (+) (34; IQR: 25)
for PI cases (p = 0.04; Fig. 1A and B). PD-1 FITC MFI on peripheral
HCV-pentamer+ cells from RI patients was much lower (!) (8;
IQR: 5) than the MFI observed in PI (p < 0.001; Fig. 1A and B) and
similar to the intensity observed for peripheral CMV-pentamer+
cells from PI patients. On the other hand, CD127-FITC MFI on intra-
hepatic pentamer+ cells was lower (!) (5.1; IQR: 1.2) than in the
peripheral compartment (+) (13; IQR: 9) in PI (p = 0.03; Fig. 1A
and B), while CD127 expression on peripheral HCV-pentamer+ cells
from RI patients was much higher (++) (32; IQR 15) than in PI
(p < 0.001; Fig. 1A and B) and similar to the expression on periph-
eral CMV-pentamer+ cells from PI subjects. In the group of PI pa-
tients, these data translated into a significant positive and
negative correlation between HCV viral load and PD-1 (r = 0.443;
p = 0.03) and CD127 expression (r = !0.456; p = 0.038) on periphe-
ral pentamer+ cells respectively (Fig. 2).
3.2. Proliferation ability of CD8+/pentamer+ cells after antigen
encounter
The capacity for circulating pentamer+/CD8+ cells to expand
after exposure to viral antigens according to viral control in en-
rolled patients was investigated. A different clonal expansion po-
tential between PI and RI subjects was observed. Specifically, in
22% (5 out of 22) and 39% (21 out of 53) of PI, and in 82% (9 out
of 11) and 72% (13 out of 18) of RI cases an expansion after
NS31073–1081 and NS31406–1415 stimulation, respectively was shown
(p < 0.001 and p = 0.018, respectively; Fig. 3A). The proportion of
experiments with expansion, taking together the results for both
epitopes, was higher in RI (22 out of 29; 76%: 95% CIP [59–92%])
than in PI (26 out of 75; 34%: 95% CIP [23–45%]) (p < 0.001;
Fig. 3A and B). PD-1/CD127 phenotype was different between PI
and RI patients after standard proliferation. PD-1 FITC MFI on pen-
tamer+ cells from PI cases was significantly higher (+) (32.3; IQR
32.3) than in RI subjects (!) (8.3; IQR 8.1) (p = 0.001; Fig. 3C). Inter-
estingly, CD127 expression on pentamer+ cells from RI patients
was low (8.1; IQR 6.4) (!) after in vitro challenge, as would be ex-
pected for effector cells after antigen encounter (p = 0.03; Fig. 3C).
Nevertheless, pentamer+ cells from PI cases with expansion ability
without any extra-treatment displayed an intermediate CD127-
FITC MFI (+) (17.6; IQR 17.25) after proliferation which was higher
than in expanded cells from RI subjects (!) (p = 0.022; Fig. 3C).
Table 2
HCV primers for amplification and sequencing.
Sense Antisense
NS31406–1415 (KLVALGINAV) First PCR (50-ACGTACTCCACCTACGGCAA-30) (50-AAGGTAGGGTCAAGGCTGAA-30)
Second PCR (50-CATCCCAACATCGAGGAGGT-30) (50-TTGCAGTCTATCACCGAGTC-30)
NS31073–1081 (CINGVCWTV) First PCR (50-GGCYTGCCCGTCTCYGCCCG -30) (50-CGGCGCACSGGAATGACATCG -30)
Second PCR (50-CGGCSTACKCCCARCAGACGMGAGGCC-30) (50-CCTCGTGACCARGTAAAGGTCC-30)
PCR conditions were as follows: 1 cycle (95 "C 5 min); 35 cycles (95 "C 45 s, 42 "C 45 s, 72 "C 45 s) and 1 cycle (72 "C 10 min).
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3.3. Pentamer-binding CD8+ cell populations according to CD127
expression in PI
In those cases with directly ex vivo detectable pentamer-binding
CD8+ cells, PD-1/CD127 phenotype and expansion ability were
correlated. The analysis of all the performed experiments together
showed that independently of HCV control and PD-1 level, CD127
expression correlated positively with pentamer-binding cell
expansion capacity. In fact, 83% of CD127-expressing pentamer+
cells expanded while only 16% of CD127- did expand (Fig. 4A and B;
p = 0.001). PD-1 expression also associated with an impaired
expansion ability but only in the CD127- cell subset (Fig. 4A and
B; p = 0.034). After this preliminary study, the experiments were
analysed according to viral control. All RI cases with detectable
HCV-pentamer binding CD8+ cells displayed a PD-1!/CD127+ phe-
notype (Fig. 4A), while in PI, two different CD127-expressing pop-
Table 3
Number of patients tested directly ex vivo for the presence of pentamer+ cells against two different NS3-HCV immunodominant epitopes, and frequency of these cells in patients
with detectable pentamer+ cells.
All epitopes NS31406–1415 NS31073–1081 p-value
PI IH N0 of cases tested (n) 28 19 9
Cases with detectable pentamer + cells (n; %) 22 (78%) 14 (74%) 8 (89%)
Frequency of Pent + cells out of total CD8 + cells (%)! 0.36 (IQR 3.7) 0.21 (IQR 3.9) 2.1 (IQR 3.8)
PB N0 of cases tested (n) 115 76 39
Cases with detectable pentamer + cells (n;%) 23(20%) 11(14%) 11(28%)
Frequency of Pent + cells out of total CD8 + cells (%)! 0.046 (IQR 0.07) 0.048 (IQR 0.04) 0.07 (IQR 0.09)
RI PB N0 of cases tested (n) 33 18 15
Cases with detectable pentamer + cells (n;%) 7(22%) 4(22%) 3(20%)
Frequency of Pent + cells out of total CD8 + cells (%)! 0.056 (IQR 0.05) 0.064 (IQR 0.08) 0.054 (IQR NA)
PI: persistent HCV infection. RI: resolved HCV infection. IH: intrahepatic. PB: peripheral blood. ⁄Pearson Chi-square test. NA: non applicable due to sample size. Pent:
pentamer. !Median frequency of pentamer+ cells in patients with detectable pentamer+ cells. The lower limit of detection with pentamer staining technique was 0.018%



































































































Fig. 1. Directly ex vivo analysis of PD-1/CD127 phenotype on pentamer-binding CD8+ cells in HCV infection according to viral control. (A) Box-plots summarising the PD-1/
CD127 MFI on CD8+/Pentamer+ cells against the different epitopes tested in resolved and persistent HCV patients. Int: intermediate. NS: non significant. O: outlier. ⁄: extreme
value. ⁄Mann–Whitney U test. ¤Wilcoxon test. !Number of cases studied for every epitope. (B) FACS! dot-plots of peripheral and intrahepatic lymphocytes stained with CD8-
Cy mAb, Pentamer-PE and either PD-1!FITC or CD127-FITC mAbs, and FACS! histograms for PD1-FITC and CD127-FITC mAbs intensity of fluorescence gated on CD8+/
Pentamer+ cells. The plots and histograms are representative from one patient with persistent infection and one subject with resolved infection. Upper left figures in each dot-
plot represent the percentage of positive Pentamer+ cells out of total CD8+ cells. (!) Low, (+) intermediate and (++) high fluorescence.
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ulations with different expansion potential were observed
(Fig. 4A). In PI, pentamer+/CD8+ cells maintaining expansion ability
after antigen encounter expressed a higher CD127 expression (MFI
23.03; IQR 16) than cells without proliferation capacity (MFI 6.04;
IQR 3.9) (Fig. 4C and D; p = 0.045). Nevertheless, independently of
the pentamer-binding cell proliferative potential, PD-1 expression
was high and similar (Fig. 4C and D; p = NS). In eight out of these 13
PI patients with directly ex vivo pentamer-binding CD8+ cells, we
were able to sequence HCV-epitopes. The presence of epitope
mutations at TCR interaction sites was associated with a higher
CD127 expression (Fig. 5A and B; p = 0.048), lower PD-1 expression
(Fig. 5A and B; p = 0.034), and a different proliferation ability,
although the last one did not reach statistical significance
(Fig. 5C; p = 0.112), probably due to the small sample size.
3.4. Effect of apoptosis and PD-1/PD-L1 pathway blocking on
pentamer-binding CD8+ cell reactivity
The effect of PD-1/PD-L1 interaction blocking on T cell prolifer-
ation was tested by paired incubation with either anti-PD-L1 mAb
or b-galactosidase as control, during T cell HCV-specific in vitro
challenge in selected RI and PI patients. In PI patients, anti-PD-L1
mAb treatment increased significantly from 29% (8 out of 27;
95% CIP [11–48%]) up to 52% (14 out of 27; 95% CIP [31–72%])
the percentage of experiments with specific CTL proliferation after
NS31073-1081 or NS31406-1415 stimulation (p = 0.023; Fig. 6A and B).
However, this treatment did not increase the frequency of cases
with expansion on RI patients (13 out of 18: 72%; 95% CIP
[49–95%]) (p = NS; Fig. 6A and B), probably due to the low PD-1
expression on these cases. Finally, we tested the effect of blocking
apoptosis by pancaspase inhibitor zVAD-fmk on pentamer+ cell
proliferation in PI and RI cases. This treatment was performed to
counteract the presumable pro-apoptotic effect of IL-7 deprivation
on CD127- pentamer+ cells from PI cases. PBMC were in vitro chal-
lenged with either NS31406–1415 or NS31073–1081 in presence of
zVAD-fmk or b-galactosidase as control. Blocking apoptosis in-
creased the frequency of experiments with positive proliferation
in PI from 23% (3 out of 13; 95% CIP [0–49%]) up to 54% (7 out of
13; 95% CIP [22–85%]) (p = 0.018; Fig. 6C and D). Nevertheless,
anti-apoptotic treatment did not affect the proliferation ability of
pentamer-binding CD8+ cells after specific in vitro challenge in RI
cases (8 out of 11: 72%; 95%CIP [41–100%]) (p = NS; Fig. 6C and
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Fig. 2. Correlation between PD-1/CD127 phenotype and viral load in PI patients. Scatter-plot showing the correlation between PD-1/CD127 expression on pentamer binding
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Fig. 3. Pentamer-binding CD8+ cells expansion ability after specific in vitro challenge according to viral control. (A). Bar-plots showing the frequency of experiments with
pentamer-binding cell expansion after specific in vitro challenge in PI and RI. Whiskers represent 2! standard error of the percentage. ⁄Mann–Whitney-U test. (B). FACS! dot-
plots of peripheral mononuclear cells stained with PE-labelled Pentamers and CD8-Cy mAb directly ex vivo and after specific stimulation from representative PI and RI
patients. Upper left figures in each dot-plot represent the percentage of positive Pentamer+ cells out of total CD8+ cells. (C) Box-plots showing the PD-1 and CD127 FITC-MFI
on pentamer binding CD8+ cells and total CD8+ cells, as internal control, after specific in vitro challenge in PI and RI. Representative FACS! fluorescence histograms of PD-1
and CD127 FITC on total CD8+ and pentamer-binding CD8+ cells from one RI and one PI patient are shown. ⁄Mann–Whitney U test. Int: intermediate.
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D). Directly ex vivo and after specific in vitro expansion in presence
of zVAD-fmk treatment, Bim expression on pentamer-binding
CD8+ cells from PI and RI patients was also tested. Directly
ex vivo, Bim expression was higher on PI patients (MFI 166; IQR:
151) than in RI cases (MFI 118; IQR: 93), although this difference
was not statistically significant, probably due to the sample size.
However, pentamer-binding CD8+ cells from PI cases after specific
in vitro expansion in presence of zVAD-fmk displayed a signifi-
cantly higher Bim expression (MFI 221; IQR: 331) than RI patients
(MFI 77; IQR: 32) (Fig. 6D and E; p < 0.001).
4. Discussion
In persistent HCV infection, specific cytotoxic response is weak
and unable to clear the virus [2]. Sustained immunological viral
pressure in chronic non-cytopathic viral infection could induce
an anergic phase and a subsequent deletion on specific CTL
[15,16]. In this process, the expression of the negative co-stimula-
tory molecule PD-1 [17] and down-regulation of the anti-apoptotic
IL-7 receptor [18] could take part. In this study the effect of these
two molecules on HCV-specific CTL reactivity according to viral
control was analysed (See Table 4).
In the majority of PI patients studied in this work, intrahepatic
HCV-specific CD8+ cells were demonstrated and circulating cells
were also detectable in a few patients. These data suggested that
there did not occur a specific CTL deletion in most chronic patients
despite of the intrahepatic apoptotic process previously described
[10], but that these cells were sequestered in the liver and below
the detection threshold in the peripheral compartment. These cells
were characterised by a PD-1/CD127 phenotype associated with
anergy and apoptosis [9,10], which could conduct them to die in
the liver during chronic infection. Therefore, there probably is a
continuous recruitment of newly generated HCV-specific CD8+
cells to maintain the intrahepatic population of specific CTL as it
has recently been described in LCMV infection [19]. As a result,
the fact that these cells in chronic infection are not completely de-
leted but dysfunctional is important information, because it could
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Fig. 4. Association between directly ex vivo PD-1/CD127 phenotype and pentamer-binding cell reactivity after antigen encounter. (A) Three-dimensional scatter plot showing
the PD-1 and CD127 FITC MFI on peripheral pentamer-binding cells according to viral control and expansion ability. (B) Bar-plots showing the percentage of experiments with
proliferation according to PD-1/CD127 phenotype on CD8+/Pentamer+ cells. The three different PD-1/CD127 subsets are compared between them (small arrows) and also PD-
1 and CD127 phenotypes are compared independently (big arrows). !Man-Whitney U test. (C) Box-plots showing the PD-1 and CD127 FITC-MFI on pentamer-binding cells
according to proliferation ability in patients with PI. ⁄Mann–Whitney U test. O: outlier. Inter: intermediate. NS: non significant. (D) Representative FACS! dot-plots and
fluorescence histograms of peripheral pentamer-binding cells stained with PD-1- FITC and CD127-FITC mAbs from two PI patients with different expansion ability after
specific in vitro challenge. Upper left figures in each dot-plot represent the percentage of positive pentamer+ cells out of total CD8+ cells. (!) Low, (+) intermediate and (++)
high fluorescence.
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encourage us to search for mechanisms to restore their function in
order to clear the HCV infection.
To asses the role of PD-1 and CD127 molecules on HCV-specific
CTL reactivity, we analysed deeper the effect of these molecules on
peripheral T cell expansion ability. Interestingly, in chronic infec-
tion PD-1/CD127 phenotype on circulating pentamer+ cells corre-
lated with level of viraemia. HCV-specific CTL submitted to high
viral load displayed an anergic PD-1+/CD127- phenotype, probably
due to persistent ineffective CTL triggering as it has been shown in
other viral infections [16]. The higher the viral load in chronic
patients, the more intense the PD-1+/CD127! phenotype is on
HCV-specific CTL. The correlation between PD-1 expression and
HCV viral load has been described previously [20], but this is the
first report showing a negative correlation between CD127 expres-
sion and HCV viraemia. Moreover, a gradient for PD-1/CD127
expression between peripheral and intrahepatic compartment in
PI was also observed. Consequently, the level of persistent HCV
antigenemia was able to regulate the expression of these two
molecules on HCV-specific CD8+ cells, being this modulation more
intense in the HCV replication site where the antigenemia is higher
[21]. Clearly this could be a HCV evolutionary mechanism to
escape from immune control.
In the complete cohort of patients enrolled in the study, high
specific-CTL reactivity in RI after anti-HCV treatment was ob-
served, suggesting that these cells could be important to obtain a
SVR. Whether it is necessary to restore the HCV-specific CTL re-
sponse to obtain a SVR after treatment is not known yet but our
cross-sectional data, and some previous work suggest that this
could be required [22]. On the other hand, in chronic infection an
impaired reactivity of HCV-specific CD8+ cells after antigen
encounter was demonstrated, and this was related with the
PD-1!/CD127+ phenotype. Nevertheless, some PI cases kept spon-
taneous HCV-specific CD8+ cell proliferation after specific in vitro
challenge. In order to test whether these cells displayed a different
PD-1/CD127 phenotype, in patients with directly ex vivo detectable
HCV-specific CD8+ cells, PD-1/CD127 phenotype and expansion
ability were correlated. Directly ex vivo reactive HCV-specific CTL
during PI displayed an unexpected high CD127 and low PD-1
expression. These cells may be able to escape sensitization to apop-
tosis after antigen encounter by maximizing rescue signals from IL-
7 such as the anti-apoptotic protein Mcl-1 [23]. This phenotype
may be a reflection of the recently primed status of the detectable
HCV-specific CD8+ T cells; such continuous recruitment of newly
generated T cells to the ongoing response has been previously de-
scribed in some viral persistent infections [19]. Nevertheless, our
HCV-epitope sequencing data suggest that this fact could also be
due to absence of immunological pressure, produced by viral var-
iation on the targeted epitope, in agreement with recent previous
works [12,24,25]. In this last case, PD-1/CD127 phenotype in PI
could be a tool to discover CTL escape mutations. Interestingly,
PD-1 expression was slightly increased in CD127+ PI patients with
respect to the level that should be expected due to the absence of
viral pressure. This detail could be due to a non-TCR dependent PD-
1 up-regulation induced by HCV infection, as it has been previously
suggested by the effect of HCV-core protein [26]. These reactive
cells from PI patients, non-targeting the virus, maintain a higher
CD127 expression after expansion than cells from RI patients,
probably suggesting that CD127+ cells from RI and PI patients be-
long to different T cell subsets with distinct degree of differentia-
tion. The status of CD8+ T cells is influenced by the history of
antigen stimulation [27,28], therefore in the case of HCV escape
mutations the long absence of antigen stimulation could provoke
a naïve-early phenotype in peripheral HCV-specific CTL while in
RI, these cells would present and early-intermediate phenotype
ready to transform into effector-memory cells after antigen
encounter. On the other hand, non-reactive HCV-specific CTL tar-


























ID Genotype Epitope Sequence PD-1 MFI CD127 MFI Exp 
144 1a NS31073-1081 Wild type 38 4 Neg 
270 1b NS31073-1081 Wild type 31 7 Neg 
42 1a NS31406-1415 Wild type 39 ND Neg 
184 1b NS31073-1081 Wild type 31 8 Pos 
292 1b NS31073-1081 Wild type ND 7 Pos 
270 1b NS31406-1415 L1410M, I1412V 19 12 Pos 
300 1a NS31406-1415 L1410M, I1412V 26 27 Pos 






























































Fig. 5. PD-1/CD127 phenotype on pentamer-binding cells according to epitope sequence. (A) Table showing the PD-1 and CD127 FITC-MFI, the HCV-epitope sequence and the
proliferation ability after antigen encounter in eight PI patients with directly ex vivo detectable pentamer+ cells. Exp: expansion. (B) Box-plots displaying the PD-1 and CD127
FITC-MFI on peripheral pentamer-binding cells according to the presence or absence of wild-type HCV-epitope. ⁄Mann–Whitney U test. (C) Bar-plot showing the percentage
of experiments with proliferation of pentamer-binding CD8+ cells after specific in vitro challenge according to the HCV-epitope sequence. ⁄Mann–Whitney U test.
J.R. Larrubia et al. / Cellular Immunology 269 (2011) 104–114 111
geting the virus expressed a directly ex vivo CD127-/PD-1+ pheno-
type, as was expected. Therefore, therapeutic strategies focused on
restoring HCV-specific CTL response should be directed against
non-reactive CD127-/PD-1+ cells, which are the ones able to recog-
nise the current infecting virus and potentially able to control the
infection.
In the second part of our study, we tried to modify HCV-specific
CTL reactivity through manipulation of PD-1 and CD127 pathways.
To attempt to restore in vitro HCV-specific CTL reactivity in chronic
patients, PD-1/PD-L1 pathway and IL-7 deprivation induced apop-
tosis were blocked. PD-1/PD-L1 interaction conducts to anergy by
blocking the TCR signalling stream [6]. In fact, blocking this inter-
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Fig. 6. Pentamer-binding cell proliferation ability restoration after blocking apoptosis and PD-1/PD-L1 pathway. (A) Plots showing the frequency of CD8+/Pentamer+ cells
after specific in vitro challenge in presence of anti-PD-L1 mAb or b-galactosidase (b-gal) as control in PI and RI patients. ⁄Wilcoxon test. NS: non significant. (B) Representative
FACS! dot-plots of PBMC stained with PE-pentamer and CD8-Cy after in vitro stimulation in presence of b-gal or anti-PD-L1 mAb, and PD-1 FITC fluorescence intensity
histograms of gated pentamer-binding cells after expansion from one RI and one PI case. Dash-line represents the upper limit of FITC staining for the isotype control. (C). Plots
showing the frequency of CD8+/Pentamer+ cells after specific in vitro challenge in presence of z-VAD-fmk or b-gal as control in PI and RI patients. ⁄Wilcoxon test. (D)
Representative FACS! dot-plots of PBMC stained with PE-pentamer and CD8-Cy after in vitro stimulation in presence of b-gal or z-VAD-fmk, and Bim Alexa-488 fluorescence
intensity histograms of gated pentamer-binding cells after expansion from one RI and one PI case. Dash-line represents the upper limit of Alexa-488 staining for the isotype
control. (E) Box-plots showing the Bim Alexa-488 MFI in pentamer-binding cells directly ex vivo and after specific in vitro expansion in presence of z-VAD-fmk in RI and PI
patients. ⁄Mann–Whitney U test.
Table 4
Summary of the phenotypic and functional features of HCV-specific CD8+ cells according to HCV control.
PD-1 ex vivo CD127 ex vivo Epitope mutation Expansion! Expansion (aPD-L1)§ Expansion (zVAD-fmk)¤
Persistent infection
PBMC⁄ (++) (!) Absent Impaired Increase Increase
(+) (+) Present Non-impaired
IHMC (++) (!)
Resolved infection
PBMC (!) (++) Non-imparied No change No change
⁄In persistent infection two different peripheral HCV-specific CD8 + populations according to PD-1/CD127 phenotype were shown. (-) Low expression; (+) Intermediate
expression; (++) High expression. Expansion: proliferation after specific in vitro challenge !without any treatment, §in presence of anti-PD-L1 mAb, and after treatment with
¤z-VAD-fmk. Ag: antigen. PBMC: peripheral blood mononuclear cells. IHMC: intrahepatic mononuclear cells.
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crease of PI cases with HCV-specific CD8+ cell expansion after anti-
gen encounter as it has been previously observed by others [20,29].
Interestingly, not all dysfunctional T cells were rescued by block-
ade of the PD-1/PD-L1 pathway, suggesting that it is probably nec-
essary to modulate other additional mechanisms in order to
restore CTL reactivity, some of which have already been described
[24,30,31]. Interestingly, a previous report shows that CD127
expression correlates inversely with the expression of several neg-
ative co-stimulatory molecules such as PD-1, suggesting that an-
ergy and apoptosis are processes closely related [24] and,
indicating that probably it is necessary to act in both pathways
to obtain the HCV-specific CTL response restoration. Therefore,
blocking intrinsic apoptosis pathway could be one of the necessary
mechanisms to improve HCV-CTL reactivity as it has been shown
in other persistent hepatotropic viral infection [23]. In chronic
HBV infection, CD127- specific-CTL are prone to apoptosis due to
the down-regulation of the antiapoptotic molecule Mcl-1 and the
up-regulation of the apoptosis facilitator Bim, secondary to IL-7
deprivation [7,23]. In our study, by first time to our knowledge,
HCV-specific CTL reactivity was significantly restored in chronic
HCV infection through an anti-apototic in vitro treatment, using
the irreversible pancaspase inhibitor zVAD-fmk. Interestingly,
these cells displayed a high Bim expression, suggesting a similar
apoptotic mechanism to the one described in chronic HBV infec-
tion [23]. Cytokine withdrawal on T cells results in activation of
the mitochondrial apoptosis pathway, regulated by Bcl-2 protein
family members. Bim pro-apoptotic activity is counteracted by
the binding to Mcl-1[32], but in the case of Bim up-regulation this
association would fail and apoptosis could be induced. As a result,
our data could suggest that IL-7 deprived CD127- HCV-specific CTL
up-regulate Bim expression during chronic infection, and this
could explain the low T cell reactivity after antigen encounter
due to apoptosis induction.
Consequently, strategies directed to block the pro-apoptotic ef-
fect of IL-7 deprivation should be designed to increase the effec-
tiveness of CTL response restoration, in addition to blocking
other negative co-stimulatory molecules. Short-term use of cyclo-
sporine-A or FK506 could block the induction of the pro-apoptotic
molecule Bim on CD127- cells [33]. This strategy could favour HCV-
CTL restoration during anti-HCV treatment in combination with
the standard of care.
5. Conclusions
In summary, we postulate that in persistent HCV infection,
there are two different populations of peripheral HCV-specific
CTL; PD-1+/CD127! subset without expansion ability and prone
to apoptosis and other one PD-1+/CD127+, characterised by main-
taining proliferation capacity, although not targeting the current
infecting virus. When HCV-specific CTL reach the liver, they ac-
quire a PD-1++/CD127- phenotype, which could predispose them
to apoptosis and anergy. Therefore, strategies designed to block
Bim-mediated apoptotic mechanisms on CD127- cells plus block-
ing of the PD-1/PD-L1 pathway could restore functionality of
HCV-specific CD8+ cells targeting the virus. To restore the function-
ality of these cells could be important to obtain a SVR, since reac-
tive PD1-/CD127+ HCV-specific CTL are found in most of sustained
responders.
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Abstract
-
lution of hepatic infection. However, during chronic 
hepatitis infection these cells lack their effector func-
tions and fail to control the virus. Hepatitis B virus and 
hepatitis C virus have developed several mechanisms 
to generate immune tolerance. One of these strategies 
The immunotolerogenic liver has unique property to 
retain and activate naïve T cell to avoid the over reac-
tivation of immune response against antigens which 
is exploited by hepatotropic viruses to persist. The 
-
sic (passive) apoptotic mechanism. The pro-apoptotic 
molecule Bcl-2 interacting mediator (Bim) has at-
tracted increasing attention as a pivotal involvement in 
apoptosis, as a regulator of tissue homeostasis and an 
enhancer for the viral persistence. Here, we reviewed 
our current knowledge on the evidence showing criti-
pathways and helps in the immune tolerance. 
© 2013 Baishideng. All rights reserved.
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Hepatotropic, non-cytopathic viruses such as hepatitis 
B virus (HBV) and hepatitis C virus (HCV) behave as 
intracellular parasites. The activation of  cellular immune 
T cells in the lymph nodes is very important to control 
viral infection. However, the unique ability of  the liver to 
-
ance, by-passing normal activation in the lymph nodes. 
The continuous triggering of  antigen presenting cells 
(APCs) in the sinusoids by the antigen-rich blood leads to 
peripheral tolerance to protect the liver tissue. This physi-
ological feature can be used by hepatotropic viruses as a 
persistence mechanism. The depletion of  liver activated 
-
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nisms for immune tolerance in liver specific pathogens 
pro-apoptotic molecule, Bcl-2 interacting mediator (Bim) 
after intrahepatic T cell activation by hepatocytes[1], in 
chronic HBV and HCV infection[2,3]. Therefore, this 
review provides glimpse of  the recent advances to un-
derstand the cellular and molecular mechanism involved 
on “T cell death” during viral hepatitis as a viral escape 
-
tolerant status on the host.
!"#$%&'()$*"*"+
HBV and HCV viruses are two hepatotropic non-
cytopathic, human blood-born viruses. HBV is a small, 
to persist in the host. HCV is an enveloped virus with 
more than 350 million for HBV and 170 million people 
-
fected adults in HBV succeed in establishing a chronic in-
fection, with the potential for developing severe liver dis-
eases such as cirrhosis and hepatocellular carcinoma .
Highly productive and replicative viruses such as 
HBV and HCV are associated with ineffective antiviral 
immunity during persistent viral infections. The complex 
ineffective immunity involves the functional deterioration 
of  antiviral T cell responses and contraction of  the size 
cells are continuously challenged by high levels of  viral 
antigens that eventually result in limiting the antiviral T 
cell response and ultimately leading to T cell exhaustion. 
in cytokine production, proliferation and survival[6], to 
end with physical deletion of  specific antiviral T-cell 
populations[7]. 
Meticulously, cytotoxic T lymphocytes (CTLs) play 
a vital role in viral eradication  and in the pathogenesis 
of  hepatitis[9-11]
T-cell immune response emerges to be important for 
control of  viral infection . Appropriate, polyclonal, 
complete viral clearance, in which long-lasting protec-
responses are usually not strong enough to eradicate the 
virus, hence contributing to persistent infection[15,16].
HBV and HCV are hepatotropic viruses that repli-
cate in the liver. This organ features a unique immune 
tissue, where the deletion of  antiviral T cell populations 




Liver situates at a hemodynamic convergence, receiving 
the splanchnic stream, which means an intense contact 
with exogenous antigens. This fact leads to the develop-
ment of  tolerance mechanisms to avoid inappropriate 
immune system activation, but it also allows antigen 
presentation by resident cells. Therefore, the liver is pro-
gressively more being recognized as an immune organ[17]. 
Liver sinusoids, hepatic arteries and portal venous carry 
blood containing digested nutrients and micro antigens 
from intestine, and as a primary metabolic organ, the 
liver produces multiple neo-antigens. All these molecules 
-
tabolized by different hepatic resident cells. The liver has 
acquired specialized mechanisms of  immune tolerance to 
avoid the over reactivation of  immune response against 
hepatotropic viruses exploit these immunotolerogenic 
T cells ineffectively, in contrast to other lymphoid tis-
sues. This fact may allow pathogens to escape from T 
cell mediated immunity and establish a persistent hepatic 
infection due to immune tolerance induction. This immu-
notolerant state can be reached by the development of  T 
Uniqueness of the liver
The unique character of  the hepatic tissue to tolerate 
liver allograft across major histocompatibility complex 
(MHC) mismatch in the pig without immunosupression 
[17]. Later studies con-
firmed that this occurred because of  the induction of  
immunological tolerance in the liver
theory” suggested that the exclusive ability of  the liver 
to get rid of  activated T cells, programmed to undergo 
apoptosis, was the root of  the hepatic tolerance effect[19]. 
This theory proposed two functions of  the liver as a T 
cell graveyard: (1) passive killer of  the liver cells after their 
(TCR) triggering by cognate antigen on TCR transgenic 
T cells leads to activation and accumulation of  those cells 
in the liver and undergoes depletion of  mature T cells[20].
The theory was again proved by Mehal et al[21] by in-
dicating that the normal liver is a “sink” for activated T 
cells. The liver was perfused by T cells showing retention 
of  activated, but neither resting nor apoptotic T cells[21]. 
Liver as a graveyard for activated T cells theory forced to 
believe that all the immune response in the liver would be 
silent; in spite of  this, the presence of  an effective virus 
-
tions[22,23] -
moval of  activated T cells by the liver cannot be excluded, 
as evidenced by the ability of  liver allograft to rescue re-
jecting skin grafts[21], in which lately tolerising capacity of  
cases, the limited capacity of  the liver to induce tolerance 
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could be due to large number of  activated T cells .
Naïve T cells activation in the liver
The site of  T cell activation is a determinant of  the out-
come of  an immune response in the liver[22]. Tolerance 
will occur when T cells are activated in the liver. On the 
other hand, an effective immune response will be gener-
ated, when T cells are activated in the lymph nodes. This 
model put forward the theory that tolerance during viral 
hepatitis could be the result of  early deletion of  antigen-
[22]. 
Usually, naïve T cells are activated in secondary lymphoid 
organs with consequent up regulation of  adhesion mol-
ecules and integrins expression, which can bind to endo-
thelial layer of  the target organ and ultimately direct T 
cells to the parenchyma[25]. Moreover, T cells are not able 
to interact with parenchymal cells easily and thus they are 
the situation in the liver is slightly different. Fenestrated 
endothelial layer in the liver makes available interac-
tions between naïve T cells and liver cells[26]
showed by MHC class Ⅰ-restricted, hepatitis B surface 
into wide-spread antigen expressing transgenic mouse 
model, leading to retention of  those cells  within the liv-
er[26]. Moreover, it has been shown that primary antigen-
of  lymphoid tissues[27].
Liver APCs in tolerance
Retention, activation and tolerance of  naïve T cells in 
the liver is the result of  the action of  resident liver cells, 
including liver sinusoidal endothelial cells (LSEC), Kuffer 
cells (HSC) and hepatocytes. Their collective function in 
induction of  inflammatory response and tolerance has 
been illustrated in the Figure 1.
Endocytosis specialist-LSEC can express MHC 
class Ⅰ and Ⅱ -
ecules. These features enable those cells to behave as 
. However, LSEC primed 
rather than Th1 cells[29]
-
vated T cell apoptosis[21]. Furthermore, the cross presenta-
tolerance rather than immunity, demonstrating that LSEC-
induced tolerance is an active and dynamic process[30]. 
Bone marrow derived and largest group of  liver resi-
dent macrophages-KC mediate host resistance to infec-
factor- ) pro-inflammatory cytokines released 
by KC[31] are involved in the inflammatory activities, 
-
leased by KC[29,32] down-regulate the production of  pro-
-
antigen-specific T cell activation can be inhibited by 
KCs[29]
activated T cell death[21]. 
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Figure 1  Collective illustration 
-
-
ecules or receptors. LSEC: Liver 
sinusoidal endothelial cells; KC: 
Kuffer cells; DC: Dendritic cells; 
HSC: Hepatic stellate cells; TNF: 
Tumor necrosis factor; IL: Inter-
leukin; mDC: Myeloid dendratic 
cell; pDC: Plasmacytoid dendritic 
cell; PD-L1: Programmed death 
ligand-1; Bim: BCL-2 interact-
ing mediator; Tim-3: T cell im-
munoglobulin mucin-3; CTLA-4: 
Cytotoxic T-lymphocyte antigen 4; 
TGF: Transforming growth factor; 
NO: Nitric oxide. 
Larrubia JR et al . T cell death and viral hepatitis
1880 March 28, 2013|Volume 19|Issue 12|WJG|www.wjgnet.com
triumph of  certain pathogens such as HBV and HCV. 
Till date, there are two main mechanisms by which HBV 
and HCV could successfully escape from CTL action: es-
cape mutant generation, and immunosuppressive effects 
exertion (effector T cell exhaustion and T cell death by 
apoptosis) . Among these mechanisms involved in 
viral hepatitis persistence, new advances on the role of  T 
cell death induction have been obtained recently and our 
review in the apoptosis role, paying special attention to 
the last new insights in this issue will be discussed in the 
following pages. 
!"#"$#%&%
A normal cellular process involving physiologically rel-
evant cell death and deletion of  unwanted cells is called 
apoptosis. Apoptosis is essential for cell selection, tissue 
homeostasis, morphogenesis, and host defense in multi-
cellular organisms. A cell that undergoes apoptosis dies 
neatly, without damaging its neighbors. The apoptotic 
signals give rise to activate various proteins and follow a 
specific classical caspase chain reaction set activation[51]. 
Quickly and neatly dismantlement process includes mem-
brane blebbing with shrinking of  the cytoplasm and con-
densation of  the nucleus. Phagocytic cells begin to pick 
up the apoptotic bodies, preventing the release of  cellular 
[52] (Figure 2). 
Apoptosis occurs by two mechanisms: active and passive 
-
mination of  immune response by passive apoptotic mech-
anism (intrinsic pathway). On the other hand, the ligation 
triggered apoptosis lead to active mechanism of  apoptosis 
a family of  cysteine proteases, called caspases. These mol-
ecules are synthesized in the cell as inactive precursors, or 
pro-caspases for self-protection against accidental death, 
which are usually activated after receiving proper trigger 
by cleavage (Figure 3). Structurally, pro-caspases contain 
and around central veins, which exert tolerogenic proper-
ties due to “immature” phenotype. The production of  
 T cell 
tolerance by inhibiting proliferation and cytokine produc-
tion of  liver infiltrating effector T cells[33]




sponse[36], but also a tolerogenic role , which is the result 
of  induction of  T cell death  by intrinsic mechanism of  
immune inhibition. The HSCs regulate immune modula-
tion by inducible B7-H1 expression, an inhibitor molecule 
of  B7 family, resulting in T cell apoptosis induction. 
Hepatocytes are also capable of  activating naïve 
cells may occur through LSEC fenestrations . However, 
-
vival, leading to an impaired T cell activation[39] -
tion, hepatocyte-activated T cells in vitro acquired activity 
and secrete cytokines but both levels are not constant and 
T cells consequently appeared to die by passive mecha-
nisms -
interaction with MHC Ⅱ-expressing hepatocytes, which 
viral clearance , which conclude in the tolerance during 
by hepatocytes undergo premature death , whereas 
acquired effector functions in the liver. 
The site of  primary T cell activation could also induce 
, which leads 
degradation by lysosomal proteolytic enzymes. This dis-
tinct form of  emperipolesis has been termed as “suicidal 
emperipolesis” (SE) . Benseler et al  suggested that SE 
is a significant mechanism by which death of  activated 
few hours before T cells are able to divide and expand. 
reinforced by break of  tolerance in immune-mediated 
liver damage by treatment of  wortmannin , inhibitor 
of  phosphoinositide 3-kinases that blocks emperipolesis. 
to rapidly delete T cells.
T cell stimulation in the liver encourages tolerance by 
using mechanisms such as, immune divergence , genera-
tion of  regulatory T cells , T cell anergy  and T cell 
death[1]. Undeniably, hepatic tolerance can explain the el-
evated frequency of  viral persistence during hepatotropic 
virus infections[1]. Although there are evidences showing 
that most infectious microorganisms are promptly re-
moved from the liver, a favorable situation for evading 
immune responses occurs in some viruses, leading to the 
Apoptosis
Cell shrinking and 
chromatin condensation
Membrane blebbing 
Nuclear collapse and 
continued blebbing 
Apoptotic body formation  
Lysis of apoptotic bodies 
Normal cells 
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and a small subunit. After activation, the active caspase 
enzyme is formed by heterodimerization of  small and 
large subunits . Moreover, active caspase molecules are 
ready to cleave target proteins such as structural or signal-
ing proteins and other effector caspases, preventing other 
proteins cleavage randomly[52]. 
Extrinsic pathway 
The extrinsic pathway initiates from outside the cell 
through triggering the activation of  transmembrane 
gene superfamily. Members of  this receptor family bind 
to extrinsic ligands known as pro-apoptotic ligands[53] and 
transduce intracellular signals that ultimately result in the 
destruction of  the cell . To date the most well char-
, 
Apo3L and Apo2L and corresponding receptors are 
[55-57]. 
The signal transduction of  active cell death process in-
volves several caspases. Activated caspases have an effect 
on several cellular functions as part of  the process that 
results in the death of  the cells[53].
The signal transduction of  mitochondrial-indepen-
dent active cell death process involves binding of  a pro-
apoptotic ligand (such as FasL) with its receptors (Fas) on 
the surface of  a target cell. The cytosolic tail of  receptors 
contains a death domain, which when activated, binds 
cleavage  that finally initiates the proteolytic caspase 
the caspase cascade via two different pathways, leading to 
the pro-apoptotic molecule Bid and go ahead for apopto-
sis via the disruption of  mitochondrial membrane and cy-
tochrome C release[59]
1 and type 2 Fas induced apoptosis fate is decided by the 
ratio between proteolytically activated effector caspases, 
X-chromosome linked inhibitor of  apoptosis protein 
and proto-typical effector caspase substrate inhibitor of  
-
trahepatic lymphocytes contribute to bystander killing via 
Fas-FasL interaction[60], which support the fact that the 
liver facilitates liver-trapped activated T cell apoptosis[61].
Intrinsic pathway 
The intrinsic or mitochondrial pathway is initiated within 
the cell, involving non-receptor-mediated intracellular sig-
nals and inducing activities in the mitochondria that initi-
or other types of  severe cell stress causes the induction 
signal for the intrinsic pathway. This passive death process 
pivots on the balance of  activity between pro- and anti-
apoptotic signals of  the B cell lymphoma 2 (Bcl-2) family 
proteins[62]. This balance is maintained by regulation of  
the permeability of  the mitochondrial membrane and 
by the pro- or anti-apoptotic signal that will be released 
inside the cell[63]. Following mitochondrial permeabiliza-
tion, the intrinsic pathway divides into two pathways: 
Apoptosis protease-activating factor-1 (Apaf-1) dependent 
pathway, release of  cytochrome c from mitochondria, 
by triggering the pro-apoptotic Bcl-2 family member , 
and ATP activate monomer inactive Apaf-1 proteins by 
a conformational change, leading to form a heptamer of  
Apaf-1 molecules called apoptosome[65]. Apoptosome al-
lows activation of  pro-caspase 9, which consequently trig-
gers the caspase cascade[66]. On the other hand, in Apaf-1 
independent pathway, permeabilization of  mitochondrial 
effector caspases by provoking inhibitors of  apoptosis 
proteins[67] and triggers caspase cascade  (Figure 5).


































 A: Mitochondria-independent extrinsic pathway: 
Fas-FasL ligation strikes to recruit pro-caspase 8 activation and induction of 
caspase cascade by caspase 3 leading to apoptosis; B: Mitochondria-depen-
dent extrinsic pathway: Fas-FasL ligation trigger to activate the pro-caspase 8, 
which cleave Bid (pro-apoptotic Bcl-2 family molecule) to form truncated Bid 
(tBid). Then, mitochondrial dependent cell death begins with tBid.
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tains the apoptotic activity[69]. The Bcl-2 family members 
regulate mostly neglect or intrinsic pathway. This family is 
subdivided into three groups of  proteins on the basis of  
their functions and the number of  Bcl-2 homology (BH) 
motifs included in their primary structure; first group: 
“anti-apoptotic multidomain” members, such as Bcl-
apoptotic process. Other two groups of  “pro-apoptotic 
multidomain” members, which are Bax-like proteins and 
“BH3-only” proteins[70]. Bax-like proteins possess threee 
BH domain (BH1 to BH3), including Bax, Bak, and Bok, 
which are referred as death effector members. BH3-only 
members contain BH3 domain, including Bim, Bad, Bik, 
-
ment is thought to confer anchorage to mitochondrial 
membranes, which is also possessed by most multi-BH 
members and several BH3-only proteins. 
Three models (Figure 6) have been postulated by 
which the BH3 family promotes passive cell death in 
which Bax and Bak bind directly or indirectly with cell 
death sensitizer (e.g., Bad, Bik) and activators of  cell death 
(e.g., Bim, tBid). The direct activation model proposes 
that sensitizer BH3-only proteins displace the activator 
BH3-only proteins from the anti-apoptotic proteins to 
promote apoptosis. Anti-apoptotic proteins inhibit the 
activator BH3-only proteins but not Bax and Bak to sup-
are sequestered by anti-apoptotic proteins for cell survival 
and constitutively active in cells. BH3-only proteins play 
the sensitizer role and inhibit their respective anti-apop-
totic proteins to promote apoptosis. The third model, 
called embedded together model, highlights the interac-
tions occurring in and on membranes, which were not 
embedded together model, Bcl-2 family proteins insert 
into and change their conformations according to their 
functions in membrane[71]. The predominantly studied 
messenger death molecule, Bcl-2 interacting protein (Bim) 
will be focused further.
!"#
Bim/Bod is a pro-apoptotic protein belonging to the 
BH3-only group of  Bcl-2 family members and is being 
called the “ghost” molecule or “suicide” molecule, which 
enables cells to expire gracefully. Two independent stud-
ies discovered Bim as a Bcl-2 binding protein and Mcl1-
[72,73]. Bim induces apoptosis by 
binding to and antagonizing anti-apoptotic members of  
the Bcl-2 family. The Bim interactions have been ob-
served with Bcl-2 family members, such as Bcl-2, Bcl-xL, 
Mcl-1, Bcl-w, etc[72,73].
Bim is a well-known pivotal initiator of  apoptosis in 
thymocyte-negative selection . Bim has 19 Bim isoforms 
including three major isoforms, which have distinct sizes 
and pro-apoptotic activities in the mammals, caused by 
alternative splicing: BimEL (extra long), BimL (long) and 
BimS (small)[73]. The shortest form, BimS, is the most 
potent and is generally only transiently expressed dur-
ing apoptosis[73]. The other two isoforms are sequestered 
to the dynein motor complex, and apoptotic activity 
of  these longer isoforms is regulated by phosphoryla-
tion[75,76], which is triggered by environmental stress, 
resulting in its dissociation from the dynein complex and 
increasing apoptotic activity. 
Expression of  Bim is up regulated in human T cells in 
response to TCR-triggering by protein kinase C and calci-
neurin pathways[77] -
nisms involved in Bim up-regulation during chronic in-
a persistent viral infection animal model, Bim-mediated 
. 
The regulation of  Bim expression at transcriptional 
level in growth factor deprivation and in endoplasmic re-
ticulum stress has observed by the class O fork-head box 
transcription factor (FOX03A) and transcriptional factor 
CEPB-  respectively . Post-transcriptional phos-
phorylation of  Bim can also regulate its function. Phos-
phorylated Bim is targeted for proteasomal degradation 
and avoid its interaction with Bax, thus maintaining cell 
existence













 Death stimulation up regulates Bcl-2 interacting 
mediator leading to the separation from Bcl-2, favoring the activation of Bax, 
Bak, which form pores in the mitochondrial membrane leading to release of 
cytochrome c. Cytochrome c with Apaf-1 and procaspase 9 participate in the 
formation of apoptosome, which activate caspase 9. Caspase-9 activates cas-
pase 3 after cleavage of pro-caspase-3. That caspase-3 triggers to induction of 
caspase cascade and cell death. Apaf-1: Apoptosis protease-activating factor-1. 
Bim: Bcl-2 interacting mediator.
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effects of  TRAF1 and TRAF1-dependent Bim down-
. TRAF1 
during the chronic human immunodeficiency virus and 
lymphocytic chorio-meningitis virus (LCMV) infection .
Bim plays a vital role in the immune system, in bone 
biology and in tumor-genesis by inducing apoptosis . 
Bim in T cells, B cells, neurons and many other cell types 
can trigger apoptosis . Gene targeting in mice for the 
important region for apoptosis, BH3 region, uncovered 
the important physiological role in Bim
-
mus, spleen were high in number . The role of  Bim in 
apoptosis has been revealed in Bim-/- thymocytes, which 
were more resistant to apoptosis after different apoptotic 
treatment such as ionomycin, taxol,  irradiation .
!"#$%&'(&#)$*+#$"!&$&)",,-&./&.*0
The liver is having a property that might explain its role 
in inducing tolerance due to its recognition as an alterna-
-
low 
low phenotype, which was associated with increased 
expression of  the Bim and caspase-3, demonstrating 
that these cells are programmed to apoptosis following 
intrahepatic activation. Strikingly, Bim deficient T cells 
survived following intrahepatic activation[1]. Therefore, 
hepatocytes in vivo could explain the death penalty role 
of  Bim in chronic hepatotropic viral infection[1]. The dis-
tinct phenotype can be due to the lack of  co-stimulatory 
molecule expression on hepatocytes ; however the treat-
hepatocyte-activated cells from death .
Lymphocyte fate deciding pathways synergize to kill 
activated T cells in chronic herpes simplex viral immune 
responses, whereas death of  activated T cells in acute im-
mune responses relies only on the mitochondrial pathway 
involved only Bim with no contribution by Fas, which 
showed critical overlapping roles for Fas and Bim in T 




ability during chronic LCMV infection in mice
study, in Bim mutated mice, Bim mutation almost com-
has a critical role in maintaining naive and memory T 
cells in LCMV infection[90]
shown that a defect in apoptosis dramatically not only 
-
lymph nodes following acute LCMV infection, compared 
to the parental genotypes or wild type mice[91]. There-
fore, the loss of  both Bim and Fas caused the increase 
in memory T cells in acute LCMV infection[91]. The Bim 
role has been demonstrated in the development of  LC-
MV-induced, T cell-mediated hepatitis by controlling the 
apoptosis of  both T cells and hepatocytes[92].
Bim attrition of  virus specific CTLs during HBV 
Models of intrinsic cell death
Bim Bcl-2 Bad  Bcl-2 Release Bim
Inactive Bax or Bak 
Active Bax or Bak 
Active Bax or Bak 
Bim Bcl-2Active Bax 
or Bak 
Bcl-2
A. Direct activation model
B. Displacement model
C. Embedded together model
Release Bim
Inactive Bax or Bak 






















Direct activation model postulates Bcl-2 inter-
acting mediator (Bim) is required for activating 
Bax and Bak. Anti-apoptotic proteins inhibit 
BH3-only proteins to suppress apoptosis, but 
not Bax or Bak. Replacement of Bim to sen-
sitizer BH3-proteins from the anti-apoptotic 
proteins occurs to promote apoptosis; B: The 
displacement model proposes that anti-apop-
totic proteins for cell survival must sequester 
constitutively active Bax and Bak in cells. 
Bim inhibits their respective anti-apoptotic 
proteins by playing sensitizer role to promote 
apoptosis; C: Embedded together model 
highlights the active role of the membrane, 
and displacement model. Bcl-2 family proteins 
insert into and change their conformations 
that dictate their functions at the membrane. 
Sensitizer BH3-only proteins relocate the acti-
vator BH3-only proteins and Bax/Bak from the 
anti-apoptotic proteins to endorse apoptosis. 
Activator BH3-only proteins recruit Bax to 
the membrane to induce mitochondrial outer 
membrane permeabilization and apoptosis. 
These reversible interactions are directed 
by equilibrium constants that are depended 
on the concentrations and interactions of the 
proteins with each other and with membranes.
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[3,93]. The gene expres-
-
cording to viral control. Bim was one of  the up-regulated 
chronic HBV infection. Blocking Bim-mediated apop-
function[3].  Furthermore, the elevated apoptosis has been 
observed not only with Bim tolerogenic phenotype, but 
[93] or T 
cell-intrinsic transforming growth factor- . 
-
tial to control HCV infection. However, in HCV chronic 
-
ated attrition, and remaining cells are functionally ex-
induction of  apoptosis after antigen encounter through 
myeloid cell leukemia sequence-1 (Mcl-1) expression and 
Bim down-regulation[95] after the cognate antigen recogni-
tion by TCR. Similarly, our group has shown in previous 
-
sion in persistent infection respect to resolved infection 
patients[2], suggesting a similar apoptotic mechanism to 
the one described in chronic HBV infection. 
The procedure of  T cell death during chronic viral in-
fection is determined by a carefully balanced and complex 
group of  pro- and anti-apoptotic proteins of  the Bcl-2 
family, such as Bim and Mcl-1[96]
persistent hepatotropic viral infection is characterized by 
on viral-specific CTLs[97], which could favor Bim up-
involved in intrahepatic specific-CTL apoptosis in ani-
mal models[1]. Furthermore, Bim pro-apoptotic effect is 
blocked by the action of  Bcl-2 family anti-apoptotic pro-
teins such as Mcl-1 and Bcl-2 , clearly pointing out that 
T cell death also depends on the anti-apoptotic protein 
expression. Bearing in mind all these facts, recently our 
-
letion during persistent hepatotropic viral infection (Figure 
Bim and Mcl-1 expression on virus-specific CTLs, lead-
ing to Mcl-1/Bim imbalance during persistent infection, 
which impairs T cell reactivity and suggesting that restora-
tion of  T cell function could occur by correcting the levels 
of  Mcl-1 and Bim expression.
low -
127high cells after antigen encounter, suggesting that TCR 
triggering can only lead to Bim up-regulation in absence 
Bim level is not enough to lead to T cell apoptosis. Our 
data also showed the Mcl-1/Bim ratio could decide the 
fate of  the activated T cells by sequestration of  experi-
low/Mcl-1low-expressing T cells to the liver 
and subsequent Bim up-regulation after antigen encoun-
[99]. Finally, Bim 
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tive; CTLs: Cytotoxic T lymphocytes; (+): Possible 
molecules induced by viral infection; (-): Possible 
molecules down-regulated by viral infection; BIM: 
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 Misbalance of Mcl-1/Bcl-2 in-
T lymphocytes. TCR: T cell receptor; Mcl-1: Myeloid cell leukemia sequence-1.
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would be released freely to activate Bax, due to the low 
level of  the anti-apototic protein Mcl-1 during chronic 
-
sis by regulation of  Mcl-1 expression in vivo and by Bim 
modulation after antigen encounter, which is checked by 
T cell reactivity restoration and Mcl-1/Bim phenotype on 
low
9), that suggested a link between apoptosis after TCR 
specific CTLs during persistent infection that could be 
related to Mcl-1/Bim imbalance. 
cell reactivity through apoptosis regulation. Specifically, 
during chronic infection, Mcl-1/Bim imbalance could be 
low
could be overcome by blocking apoptosis.
For control of  hepatotropic viral infection is essential 
-
ever, during chronic infection this response is altered, 
showing a pro-apoptotic phenotype due to the depriva-
Recently, it has been investigated that TRAF1 is a signal 
adapter for positive co-stimulatory receptors whose level 
of  the pro-apoptotic molecule Bim . Therefore, in situ-
impaired, favoring an imbalance between anti- and pro-
apoptotic molecules. On the other hand, in an experimen-
leads to Mcl-1 down-regulation on T cells, conducting to 
[100]. 
Consequently, strategies directed to block the pro-apop-
increase the effectiveness of  CTL response restoration, 
by enhancing the TRAF1 and Mcl-1 expression level that 
could restore Bim/Mcl-1 balance. On of  those strategies 
Directly ex vivo
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 The different plots show the Bcl-2 interacting mediator (Bim) 
and myeloid cell leukemia sequence-1 (Mcl-1) expression directly ex vivo
plot represents the MFI for Bim and Mcl-1 staining. The continuous and dashed line in the dot-plots and histograms represents the cut-off point to consider a staining 
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could be short-term use of  cyclosporine-A or FK506 
could block the induction of  the pro-apoptotic molecule 
- cells[77]
CTL restoration during anti-viral treatments in combina-
tion with the standard of  care. Another possible strategy 
-
in order to increase the stimulation of  the reduced num-
-
effector function, and viral clearance[101].
!"#!$%&'"#
likely to represent the deregulation of  the Bim pro-apop-
totic pathway. The balance between pro- and anti-apop-
totic molecules is critical for cell survival. The unavail-
ability of  appropriate survival marker modulates Bim and 
Mcl-1 expression on virus hepatitis-specific CTLs and 
this affect to T cell reactivity through apoptosis regula-
persistent infection. Consequently, Mcl-1/Bim imbalance 
could be the reason for the deletion of  virus hepatitis-
of  apoptosis. The interruption of  this tolerizing mecha-
nism may provide a new strategy to restore the balance 
between apoptotic molecules in order to achieve viral 
chronic viral hepatitis. 
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